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1.1 The retina  
The eye is the organ that enables visual perception. The human eye is composed of an 
optical portion and a neural component. The optical part comprises of the lens and the 
cornea, which enables the image to focus upon the neural component called the retina. The 
retina is a specialized part of the central nervous system, which transforms the visual 
image into an electrical signal [1-5]. The retina is made up of a supporting layer called the 
retinal pigment epithelium (RPE) and a neural layer of specialized cells. The RPE is 
composed of a single cell layer that separates the neural retina from the choroidal vessels, 
and in addition it supports and nourishes the cells in the neural retina [6]. The neural retina 
is a complex layered structure of neuronal cells interconnected by synapses (Figure 1A). 
Rods and cones, collectively called photoreceptors, are the light-sensitive cells that convert 
incoming light into neural impulses. Both cone and rod photoreceptors consist of an outer 
segment (OS), which is connected by the connecting cilium to the inner segment (IS), the 
nuclear body, and the synaptic terminus. The OS consists of stacks of membranous discs 
that contain the photopigment required for photoreception [7, 8], whereas the IS is the site 
of protein synthesis and metabolic processes. 
The rods are cylindrical elongated structures, which mediate vision in dim light [9]. 
Rods have a low spatial resolution but are highly sensitive as they are able to capture even 
a single photon of light [8, 9]. The cones function in ambient light and are responsible for 
color vision and the perception of fine details. In humans, there are three distinct types of 
cone photoreceptor proteins that either respond to short-wave length (426 nm) or blue 
light, to middle-wave length (530 nm) or green light, or to long-wave length (560 nm) or 
red light. The human retina contains about 3 million cones and 100 million rods. Although 
the human retina has more rods than cones, sharpness in vision relies upon the use of cone 
photoreceptors. The most cone-rich region of the retina is known as the fovea, located in 
the central region of the retina called the macula. The fovea is the area that enables high 
visual acuity in humans [2, 9-11]. 
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1.2 Molecular mechanisms of vision 
The light sensitive molecule in the OS of the rod photoreceptor is rhodopsin, which 
constitutes 95% of the total disc proteins. Rhodopsin is composed of the opsin protein and 
the chromophore 11-cis-retinal [12, 13]. Opsin is synthesized in the rod IS, glycosylated in 
the ribosomes of the rough endoplasmic reticulum, further modified in the Golgi complex 
and transported to the OS by post-Golgi vesicles through the connecting cilium, and 
subsequently inserted into the disc membranes. The connecting cilium is a microtubule 
structure that forms a bridge between the IS and OS, where kinesin II and dynein motor 
proteins together with many other proteins, mediate the transport of proteins to and from 
the OS, respectively [14].  
 
Figure 1. Structure of the eye and the retina. (A) Diagram of the eye; an enlarged diagram 
of the fovea is shown in the box. The retina forms the inner lining of the posterior part of 
the eye. (B) Diagram of the organization of retinal cells. A, amacrine cell; B, bipolar cell; 
C, cone photoreceptor cell; G, ganglion cell; H, horizontal cell; M, Müller cell; R, rod 
photoreceptor cell. From Sung et al. 2010 [9]. 
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When a photon of light strikes rhodopsin, the isomerization of 11-cis-retinal to all-trans-
retinal initiates a cascade of events called the phototransduction cascade [9]. The photo-
activated rhodopsin catalyzes the conversion of inactive GDP-bound transducin to its 
active GTP-bound conformation. The active transducin in turn activates membrane-
associated phosphodiesterase (PDE) that then hydrolyzes cyclic guanosine monophosphate 
(cGMP), which is bound to cyclic nucleotide gated channels (CNG). These channels are 
responsible for the influx of cations (Na+, Mg2+, Ca2+) across the photoreceptor plasma 
membrane under dark conditions. This influx is responsible for the depolarization of the 
photoreceptor interior in the dark, where the resting membrane potential is -40mV. The 
level of cGMP declines inside the cytoplasm as a result of PDE hydrolysis, which causes 
closure of cation channels and blockage of cation influx (Figure 2). The inside of the 
photoreceptor as a result becomes more negatively charged i.e. hyperpolarized (from -
40mV to-70mV). The change in the membrane potential inhibits release of the 
neurotransmitter glutamate to the connected bipolar cells and stimulates the adjacent 
neurons in response to light [8, 9, 14]. In the recovery phase, photoisomerization takes 
place in the OS, which converts 11-trans-retinal into all-trans-retinol. All-trans-retinol is 
then transported through the interphotoreceptor matrix to the RPE where it is recycled back 
into 11-cis-retinal by a series of enzymatic steps, collectively called the retinoid cycle, 
before it re-enters the rod OS [9, 14] (Figure 2).  
 
1.3 Clinical characteristics of inherited retinal diseases 
Retinal dystrophies are characterized by degeneration of the photoreceptors and/or the RPE 
cells, and are classified according to the type of cells that are primarily affected. The 
distinction between some retinal dystrophies can be very subtle, due to substantial clinical 
and genetic overlap. Inherited retinal dystrophies can either present as non-syndromic 
forms restricted to the eye, or can present as a feature of a syndrome accompanied by 
disorders of other organs such as the heart, kidney, and ear. Usher syndrome (USH) is one 
of the most common syndromic forms of retinal dystrophy accompanied by hearing loss. 
Bardet-Biedl syndrome (BBS) is characterized by retinal dystrophy, obesity, polydactyly 
and mental retardation. 
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Figure 2. Schematic representation of three key pathways involved in rod-mediated vision. 
The retinoid cycle that takes place in the rod outer segment (OS) and the retinal pigment 
epithelium (RPE), converts 11-trans-retinal into 11-cis-retinal. Phototransduction occurs 
entirely in the OS, and involves translation of a light signal into a neural signal. Ciliary 
transport is required to direct structural and functional components synthesized in the rod 
inner segment (IS) to the OS. Key steps and major molecular players functioning in these 
processes are indicated (from den Hollander et al. 2010) [14]. 
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The clinical diagnosis is based on various ophthalmological tests such as visual acuity 
(VA) measurements, visual field (VF) assessment, ophthalmoscopy, and 
electroretinography (ERG). VA is an estimate of visual perception and represents the 
ability to resolve fine details. VA roughly quantifies the angle of resolution of the visual 
system based on the eye's ability to resolve and recognize letters of varying sizes and 
shapes (optotypes), presented on VA test charts [15]. The most widely used chart type is 
the Snellen chart, as the measurements obtained with this procedure are more consistent 
and less variable [15, 16]. The Snellen chart uses 11 different rows of optotypes or letters, 
and on each row the optotype width decreases exponentially while moving from the top to 
the bottom (from line 20/200 to line 20/13). Goldmann perimetry can be used to assess the 
VF loss that corresponds to the area of retinal degeneration. Ophthalmoscopy is used to 
examine the appearance of the fundus, which involves the assessment of the optic disc, the 
retinal vasculature, and characteristic pigmentations [17]. As retinal dystrophies can 
present with a great clinical variability corresponding to different fundus appearances, 
ophthalmoscopy is frequently used in daily clinical practice.  
ERG is the recording of the electrical activity in the retina in response to light 
stimuli [17, 18]. In this test the photoreceptor cells are first either dark-adapted (scotopic 
ERG) or adapted to a specific level of light (photopic ERG). The retina is then stimulated 
with a brief flash of light, and using an extraocular contact lens electrode, the electrical 
responses are measured as waves or components of different amplitudes [18-21]. The 
scotopic ERG measures rod responses, whereas the photopic ERG measures the response 
of cones [18]. The a-wave represents the electrical responses generated directly by 
photoreceptors, as a result of photobleaching. The b-wave with the largest amplitude 
represents the recovery phase of phototransduction, and is derived from the potassium 
influx within the photoreceptors and surrounding Müller cells and bipolar cells. The 
amplitude of the a-wave is a direct measure of photoreceptor health, while that of the b-
wave reflects synaptic function and hence the physiology of the inner retina [21, 22]. ERG 
is the gold standard for the differential diagnosis and classification of retinal diseases. ERG 
is especially useful in cases with early-onset or atypical presentation when the fundus 
appears normal [23].  
The clinical utility of fundoscopy and ERG in the diagnosis of retinal diseases is 
unquestionable, but considering the overlap between the clinical subtypes, additional 
clinical tests are needed to clarify the disease status. A common ophthalmic procedure is to 
measure fundus autofluorescence (FAF). The fluorescence predominately originates from 
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lipofuscin in the RPE [24]. The fundus spectrophotometer is used to measure FAF, which 
records the difference between the excitation and emission spectra of autofluorescence 
from small retinal areas of the fundus [25]. Increased FAF is indicative of impaired RPE 
function, as a result of accumulation of waste material from metabolic activities. On the 
other hand decreased or absent FAF may indicate RPE atrophy and loss of photoreceptor 
cell layers, which leads to a deposition of other fluorophores that contribute to FAF [24, 
25]. As in most retinal dystrophies, degeneration of either the RPE or the photoreceptors is 
eventually evident, and FAF imaging can provide additional clinical insight, which is 
helpful in establishing diagnosis and genotype-phenotype correlations [25]. 
Another revolutionary development in the field of ophthalmic imaging is the use of 
non-invasive optical coherence tomography (OCT) in the clinic. The most advanced 
version of OCT, called spectral-domain optical coherence tomography (SD-OCT), enables 
visualization of the retinal cell layers [26, 27]. SD-OCT can resolve the external limiting 
membrane (ELM), and the photoreceptor IS and OS junctions. The integrity of these 
junctions provides clues about the health or disease status of the photoreceptors [26, 28]. 
The thickness of the OS of the photoreceptor cell layer can be quantified and hence the 
degeneration of the photoreceptors can be measured by gradual thinning of the OS [28]. 
The rate of OS thinning also provides a direct measure of the retinal disease progression 
[28]. More recently automated analysis in 3 dimensions have been made possible, which 
allow segmentation of different retinal cell layers so each cell layer can now be analyzed 
separately [27-30].  
 
Retinitis pigmentosa (RP) 
The term retinitis pigmentosa (RP) was first coined by F.C. Donders in 1857 to describe 
what he believed was an inflammatory disorder characterized by night blindness and 
retinal pigmentary deposits [31, 32]. R. Liebreich in 1861 recognized a high percentage of 
RP patients with first degree relatives having the disease and thus described the condition 
as hereditary rather than being inflammatory [33-35].  
RP is a progressive retinal disease in which the degeneration of rod photoreceptor 
cells precedes that of cone photoreceptor cells. RP is the most common inherited 
progressive retinal degenerative disease characterized by pigmentary deposits, called bone 
spicules, predominantly in the peripheral retina. The prevalence of RP is approximately 
one in 4,000 individuals [14, 36, 37]. In RP, night blindness (nyctalopia) is the most 
common symptom in the early stages. Patient experience a bilateral symmetric loss of the 
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mid-peripheral visual field, which gradually increases both centrally and peripherally [38, 
39]. In the mid-stage night blindness is obvious in addition to the further loss of the 
peripheral visual field, which results in tunnel vision [23]. With progression, cone 
photoreceptor cells are also affected and day vision and central visual acuity are 
compromised as well [17]. The mean rate of visual field (VF) loss in RP is estimated 
between 4.6%-13.5% (mean 9%) per year [17]. Although the age of onset varies among RP 
cases, typical symptoms in autosomal recessive forms of RP (arRP) usually appear early in 
life (mean age of onset 10.7 years of age), progressing to legal blindness by middle age 
(40-50 years of age) and, in some cases total vision loss follows later in life (>60 years of 
age) [1, 23, 40]. Compared to arRP, autosomal dominant RP (adRP) represents a milder 
form of the disease (mean age of onset 23 years of age) [40]. Disease progression in adRP 
cases is generally slow, and patients may retain part of their VA even at 70-80 years of age 
[41-43]. The mean annual exponential rate of VF and VA loss in adRP patients, is 
estimated to be 2.6% and 1.4%, respectively [41]. Early age of onset (5-10 years of age) 
and rapid progression of X-linked RP (xlRP) renders it a severe form of all RP. Most 
patients with xlRP lose their VA at the age of 30-40 years of life [42, 44, 45]. The mean 
annual exponential rate of VF and VA loss in xlRP patients with RPGR mutations, is 
estimated to be 4.7% and 4%, respectively. Compared to VF and VA loss in an adRP 
patient with RHO mutations (i.e. 2.9% and 1.6%, respectively), it is evident that the 
corresponding rate of vision loss is significantly higher in xlRP patients than in adRP [42].  
Ophthalmoscopic examinations of the fundus of individuals with advanced stages of RP 
reveal changes that typically involve attenuation of the retinal arterioles, perivascular and 
midperipheral dark ‘bone-spicule’ pigmentation, and a waxy pallor of the optic disc [17]. 
Pigments originate from the gradual destruction of the RPE cells in the retina, which 
migrate from the RPE into the degenerating retina, and often are located along the retinal 
vessels [14, 17, 46]. As the scotopic ERG measures rod responses, a reduced scotopic ERG 
at an early stage indicates a rod-cone pattern of the disease as seen in RP [18]. In the 
middle stages of RP the scotopic ERG is unrecordable and photopic (cone) responses are 
reduced [20, 39]. 
 
Retinitis punctata albescens (RPA) 
Retinitis punctata albescens (RPA) is a rare subtype of RP characterized by progressive 
night blindness and presence of numerous whitish-yellow dots throughout the retina [45, 
47]. The peripheral VF and the VA decrease with time, but the course of RPA is relatively 
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slow with preservation of useful vision beyond the fifth decade [47, 48]. The scotopic ERG 
responses are diminished or non-recordable, while photopic responses are normal or mildly 
decreased [47]. 
 
Fundus albipunctatus (FA) 
Fundus albipunctatus (FA) closely resembles RPA, as nyctalopia and the presence of tiny, 
yellowish-white dots throughout the retina are common features [47]. However, FA is 
classified as a form of congenital stationary night blindness (CSNB) due to the quiescent 
course of the disease. The clinical course of FA is characterized by a decrease in VA and a 
constriction of the peripheral VF. The differential diagnosis is mainly based on the ERG, 
where relatively normal scotopic responses after prolonged dark adaptation (>3 hours) are 
indicative of FA, while the scotopic responses after normal dark adaptation (<1 hour) are 
reduced or absent [21, 47, 49, 50].  
 
Congenital stationary night blindness (CSNB) 
Congenital stationary night blindness (CSNB) is a non-progressive retinal dystrophy 
starting in early childhood, mainly characterized by nyctalopia. Ocular symptoms are 
variable, but often pigmentary changes and vascular attenuation are not evident even at 
later stages of the disease [21, 51]. Refractive errors such as myopia and nystagmus are 
often associated with the disease [21, 22, 52]. In CSNB, rod-specific scotopic ERG 
responses are diminished or completely absent, while photopic responses are normal or 
nearly normal. The CSNB phenotype is divided into two types based on the presence or 
absence of a scotopic b-wave amplitude [53, 54]. In CSNB type 1 (CSNB1), also known as 
complete CSNB, both scotopic (rod) a-wave and b-wave responses are not recordable [53]. 
In CSNB type 2 (CSNB2), commonly known as incomplete CSNB, the scotopic (rod) a-
wave is present, but the amplitude of the rod b-wave is either absent or significantly 
reduced [21, 22, 52]. The absence of the scotopic b-wave reflects synaptic dysfunction, and 
indicates altered electrophysiology of the inner neural retina, whereas the rod 
photoreceptor cells are intact and functional [22]. In general, the scotopic ERG is severely 
affected in CSNB but the photopic responses remain normal for a prolonged period of 
time.  
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Oguchi disease  
Oguchi disease is a form of recessive CSNB, characterized by a delayed dark adaptation, 
and a distinct fundus coloration. Night vision problems range from mild to severe, while 
VF are less frequently observed [21]. The fundus of patients typically appear to be gray or 
golden in color, which returns to normal coloration after prolonged dark adaptation. A 
brief exposure to light quickly changes the normal fundus coloration back to a gray or 
golden color. The fundus color change is one of the typical diagnostic features of Oguchi 
disease, and is called the Mizuo-Nakamura phenomenon [21, 55, 56]. Patients with Oguchi 
disease have characteristic dark-adapted ERG curves where scotopic responses reach 
normal amplitudes after a prolonged period (1-2 hours) of dark adaptation [21]. The 
normal scotopic ERG response is very brief, and is not observed if illuminated shortly by a 
second light flash, until after another prolonged period of dark adaptation [21].    
 
Cone-rod dystrophy (CRD) 
Cone-rod dystrophy (CRD) is characterized by substantial loss of the cone-mediated 
central VF early in life, while night and peripheral vision are preserved [14, 57-60]. The 
estimated prevalence of CRD is one in 40,000 individuals [57, 58, 60]. Other associated 
features are photophobia and a variable degree of color vision abnormalities 
(dyschromatopsia) [57, 59, 60]. Later on, progressive loss of peripheral vision is observed 
and night vision is compromised. CRD quickly progresses to legal blindness, usually at a 
younger age than in patients with RP [58]. A typical CRD fundus presents with early 
maculopathy, and at later stages vascular attenuation and pigmentary changes can occur. 
Pigmentary deposits are predominantly localized to the macular region, while retinal 
vessels are usually normal or moderately attenuated [14, 60]. At advanced stages of CRD, 
night vision is compromised and VA further decreases [57, 58, 60]. 
 
Cone dystrophy (CD) 
Cone dystrophy (CD) is a progressive cone disorder, characterized by a reduced VA, color 
vision impairment and a variable degree of photophobia and nystagmus [61, 62]. With an 
estimated prevalence of one in 35,000, CD also represents a rare form of progressive 
retinal dystrophy. CRD and CD are differentiated based on the absence of rod involvement 
in CD, although mild rod dysfunction may develop at an advanced stage. In CRD early 
involvement of rod photoreceptors is evident shortly after the cones degenerate [62-64]. In 
CD, the fundus changes are hardly visible at early stages, but at an advanced stage macular 
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degeneration is observed, and complete loss of VA occurs before the fourth decade of life 
[59].  
In CRD and CD, the photopic ERG is predominantly disturbed, in contrast to RP which is 
characterized by a reduced scotopic ERG [61]. In progressive forms of CRD photopic 
responses are severely altered as compared to scotopic responses [57].  
 
Achromatopsia (ACHM) 
Achromatopsia is a rare congenital stationary cone disorder, which affects one in 30,000 
individuals. Achromatopsia is characterized by a variable degree of colour blindness, low 
visual acuity, nystagmus and photophobia. Fundus examination usually reveals no apparent 
retinal abnormalities but infrequently central or mid-peripheral RPE abnormalities are 
present. Photopic ERG responses are unrecordable which represent complete absence of 
cone function, while rod specific scotopic responses are entirely normal [59, 60, 61, 62]. 
 
Leber congenital amaurosis (LCA) 
Leber congenital amaurosis (LCA) manifests early in life and is sometimes referred to as 
an early-onset form of RP. The worldwide incidence of LCA is one in 30,000 individuals. 
LCA is a congenital panretinal dystrophy, often involving severe loss of central and 
peripheral vision early in life [39, 52, 60, 65, 66]. Patients with LCA usually present with 
wandering nystagmus, as patients are unable to fix their eyes on an object [67, 68]. Fundus 
examination in LCA patients can range from an essentially normal retinal appearance with 
mild retinal vessel attenuation, to severe pigmentation and retinal vessel attenuation 
resembling RP [14, 67, 68]. The absence of both rod- and cone-derived electrical responses 
on ERG in the first year of life are indicative of LCA [14, 67, 68]. 
It is important to mention here that at the end stage of progressive retinal 
dystrophies such as RP, CRD and LCA, the ERG responses are unrecordable because of 
complete loss of rod and cone photoreceptors [20]. It is evident that at this stage, the 
distinction between RP, CRD and LCA cannot be made, thus the diagnosis relies on the 
clinical history of the disease [60]. The diagnosis of RP is made in patients who experience 
night vision problems first, and CRD is mostly diagnosed in individuals who first 
experience vision problems during the day-time [60]. 
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Table 1. Typical clinical features and diagnostic criteria for various retinal dystrophies 
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 RP  early/late  early   late severe, late attenuated pallor  peripheral bone spicules -  -  + ↓ + ↓ rapid 
RPA  early/late  early  later mild, later attenuated pallor  whitish yellow dots  -  -  + ↓ + ↓ slow 
CSNB1 congenital  early  -  -  normal  normal  no  -  -  +  +  no  
CSNB2 congenital  early  -  -  normal  normal  no  +  - ↓ +  +  no  
FA  congenital  early  -  -  normal  normal  whitish yellow dots  -  -  +  +  no  
Oguchi congenital  early  -  -  normal  normal  dark or golden hue  + ↓ + ↓ +  +  no  
LCA  congenital  early  early severe, early attenuated pallor  wide spread or macular -  -  -  -  rapid 
CRD  early/late  late  early severe, early attenuated pallor  macular  + ↓ + ↓ -  -  rapid 
CD  early/late  later  early severe, late normal  normal, pallor  macular  +  +  -  -  slow 
ACHM  early/late  no  early no, mild  normal  normal, pallor  no, macular  +  +  -  -  no  
Note: These symptoms apply to typical cases, at initial stage of presentation. At later stages of the disease the features 
frequently overlap. ACHM, achromatopsia; CD, cone dystrophy; CRD, cone-rod dystrophy; CSNB1, congenital stationary 
night blindness type 1; CSNB2, congenital stationary night blindness type 2; ERG, electroretinography; FA, fundus 
albipunctatus; LCA, Leber congenital amaurosis; RP, retinitis pigmentosa; RPA, retinitis punctata albescens. +, present; -, 
absent; ↓, decreased. 
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1.4 Molecular genetics of retinal diseases  
Retinal diseases exhibit all modes of inheritance and are characterized by genetic 
heterogeneity. Most forms of RP are monogenic with classical inheritance patterns 
including autosomal dominant (15%-20%), autosomal recessive (20%-30%), and X-linked 
(10%-15%) [14, 23, 39, 45, 66, 69, 70]. In the remaining 40% to 55% of RP cases the 
segregation pattern cannot be established due to the absence of family history. Such cases 
are termed isolated or simplex RP [23]. 
Some RP cases exhibit more complex inheritance patterns that include digenic-
diallelic inheritance [71, 72], and uniparental disomy [73-75]. Digenic-diallelic RP has 
been described for ROM1 and PRPH2 (RDS), in which affected family members carry a 
heterozygous mutation in each of these genes, while heterozygous carriers of only one of 
these mutations remain unaffected [66, 71, 72]. In uniparental disomy an individual carries 
two chromosomes of a given chromosome pair from one parent and no copy from the other 
parent [73, 74]. This can cause disease if the chromosome carries a mutation conferring a 
recessive disease. Subsequently the patient is homozygous for the mutation, which is 
inherited from an asymptomatic heterozygous parent [74].  
CRD can be inherited in an autosomal dominant, an autosomal recessive or X-
linked fashion [60]. For CSNB autosomal recessive inheritance and X-linked forms have 
been described. LCA in the majority of cases is inherited as an autosomal recessive 
disease, although some dominant cases have been described [67, 68]. 
Autosomal recessive inheritance is the most prevalent among inherited retinal 
dystrophies, accounting for 50-60% of familial RP and >95% of LCA [14, 39]. It has been 
proposed that consanguinity greatly influences the disease etiology, and thus in populations 
with a high rate of consanguineous marriages, recessively inherited diseases are expected 
to be even more prevalent [76, 77]. In Pakistan, where about 60% of the marriages are 
consanguineous and about 80% of those are between first cousins, the incidence of 
recessively inherited anomalies is expected to be high [76, 78]. The data presented in this 
thesis on non-syndromic retinal dystrophy families from Pakistan indicates that indeed 
recessive inheritance predominates, as it accounts for 97% of all cases.  
Retinal dystrophies are genetically very heterogeneous in nature as a large number 
of genes have been identified for each mode of inheritance. Currently more than 170 
retinal dystrophy genes have been identified. For RP, 56 genes and 8 loci are known, 14 
different genes are associated with CSNB (Figure 3), 20 genes have been identified so far 
for LCA, while 25 genes and 4 loci have been implicated in CD and CRD (RetNet; 
F B
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https://sph.uth.tmc.edu/retnet). RPA is caused by mutations in LRAT and RLBP1, both 
encoding components of the visual cycle [48, 79, 80]. FAP is caused by mutations in 
RDH5, encoding 11-cis-retinol dehydrogenase, the enzyme that is responsible for recycling 
11-cis-retinol to 11-cis-retinal [81, 82]. Most genes associated with RD encode proteins 
that are either structural or functional components of three major pathways; the retinoid 
cycle, the phototransduction cascade, and ciliary transport [14] (Figure 2). 
Genetic heterogeneity is most profound in autosomal recessive retinal dystrophies 
[14]. ArRP shows extreme levels of genetic heterogeneity as 36 genes and three loci have 
been shown to be associated with the disease, while for arLCA, 17 genes have been 
identified (RetNet; https://sph.uth.tmc.edu/retnet). Despite such a large number of genes 
known to be associated with autosomal recessive forms of retinal dystrophies, four years 
ago when the studies for this thesis started, it was estimated that mutations in these genes 
would explain the genetic defect in 50% of arRP, 70% of arLCA, 40% of arCRD and 10% 
of CD [14, 75], which indicated that many retinal dystrophy genes still remained to be 
identified. 
 
1.5 Disease gene identification techniques 
 
Linkage analysis & homozygosity mapping 
Genetic linkage mapping is used to locate the region of the genome, that contains the 
genetic defect causative of the phenotype or disease in question. Linkage analysis relies on 
the use of genetic markers, which are polymorphic DNA sequences. These markers have a 
fixed sub-chromosomal location and serve as landmarks which aid in tracing the 
inheritance of chromosomal fragments. Every genetic marker is made up of at least two 
genotypes or alleles, which are inherited in a Mendelian fashion, and thus every individual 
inherits one allele from each parent. The loci are considered to be linked to the disease if 
subsets of the markers (a block of alleles or a haplotype) at a specific genomic location are 
passed on together from parents to offspring more often than expected by chance in a 
pedigree. Linkage studies require the availability of families with multiple affected sibs, in 
which the disease of interest segregates. In addition to affected sibs, other family members 
(both unaffected and affected) are required not only to determine the inheritance pattern, 
but also to determine the order (phase) of alleles in which they are inherited from parents 
to offspring [83, 84]. 
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Figure 3. Clinical subtypes of rod and rod-cone diseases, based on progression and 
inheritance patterns. The genes known to be associated with different diseases are 
indicated below each category (RetNet; https://sph.uth.tmc.edu/retnet, last accessed 
February 14, 2013). The gene symbols in bold represent the genes in which different types 
of mutations can cause more than one phenotype. 
 
For recessive diseases, consanguineous families with multiple affected sibs are an excellent 
resource to identify the genetic defects using homozygosity-based linkage mapping. The 
approach is based on the assumption that patients not only inherit the same mutation from 
both parents but also homozygous stretches of DNA surrounding the mutation [85]. In a 
single affected individual born of a first-cousin marriage, ~10% of the genome is 
homozygous, which in the majority of the cases contains the causative mutation. In 
consanguineous families with two or three affected siblings, the shared homozygous 
regions cover 2.5 and 0.6% of the genome, respectively [85, 86]. This illustrates the power 
of consanguineous families with multiple affected sibs to identify the underlying genetic 
defect. Homozygosity based approaches are very successful in mapping disease genes not 
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only in patients from consanguineous marriages, frequently encountered in countries such 
as Pakistan [87], India [77, 88], and Saudi Arabia [89], but also in non-consanguineous 
families found in The Netherlands [90, 91], Indonesia [92], Japan [93], and other 
populations [94]. 
Different types of genetic polymorphisms exist, which can be utilized as genetic 
markers. Microsatellite markers have been the most widely used markers in the past [93]. 
Microsatellite or short tandem repeats are short (1–6 bp) repetitive sequences of 
nucleotides, most often di, tri, or tetra repeats in the genome, with variation in the repeat 
numbers between different individuals [95, 96]. The main advantage of microsatellite 
markers is that they are highly polymorphic, as they can have many possible alleles and 
can be assayed easily using PCR [83]. 
Single nucleotide polymorphisms (SNPs) are the most abundant variations in the 
human genome, with a total of approximately 3 million SNPs [97]. Theoretically, a SNP 
can have up to four alleles, but more than two rarely exist, so they are far from being as 
polymorphic as microsatellites. The main advantage is their abundance (one SNP every 
200-300 basepairs), their even distribution in the genome and their stability over time [83, 
98]. High-resolution SNP microarrays are commercially available which can be used for 
rapid and efficient genotyping across the whole genome. The genotype data are analyzed 
using various software programs to determine the region linked to the disease [99, 100]. 
 
Next generation sequencing 
Automated Sanger sequencing has dominated the field of molecular genetics for the past 
two decades. Sanger sequencing is now recognized as “first generation” technology since 
newer technologies are emerging, which are collectively called “next generation 
sequencing” (NGS). One of the major advantages of these new sequencing techniques is 
their ability to produce large amounts of sequence data much faster (higher throughput) 
and at reduced costs, as compared to the Sanger method [101, 102]. There are more than 
20 different NGS platforms available from different companies, and although these 
technologies differ in methodology, they all involve basic steps that include target 
selection, enrichment, sequencing, imaging, alignment to the reference genome and 
assembly. Different target enrichment strategies exist that can enrich a specific 
target/chromosomal fragment (targeted NGS), the exons of all human genes (whole exome 
sequencing; WES) or even the entire genome (whole genome sequencing; WGS) [101, 
103]. 
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1.6 Outline and aim of this thesis 
The aim of this thesis was to identify the genetic causes of autosomal recessive non-
syndromic retinal dystrophies in the Pakistani population. Genome-wide high-density SNP 
genotyping was performed for selected members of each family. Homozygosity-based 
linkage analysis was performed to identify the genetic loci associated with the disease. 
Sanger sequencing and/or NGS was performed to pinpoint the genetic variants responsible 
for the disease. 
 
Chapter 2 describes the results of mutation screening of genes previously implicated in 
RP and LCA in eight families. Most of the identified mutations (6/8) have previously been 
described in patients from diverse ethnic backgrounds. 
Chapter 3 presents the first report of homozygous missense mutations in EYS, as 
previously only splice site, nonsense and frameshift mutations have been reported to cause 
RP. Strikingly, both mutations, which were found in persons with a diverse ethnic 
background, affect amino acids located at homologous positions in two different laminin A 
G-like domains of EYS. 
Chapter 4 describes, for the first time, the involvement of a splicing factor in autosomal 
recessive RP. A homozygous missense mutation in SNRNP200 is reported in a 
consanguineous RP family from Pakistan. Previously, only autosomal dominant mutations 
in SNRNP200 have been associated with RP. 
Chapter 5 reports a novel association of CLRN1 mutations with non-syndromic RP. 
Previously, CLRN1 mutations have only been associated with Usher syndrome, in which 
retinal degeneration is accompanied by hearing loss and vestibular dysfunction. Two 
families are described with CLRN1 missense mutations, which result in a misfolded protein 
that is retained in the endoplasmic reticulum.  
Chapter 6 describes two novel RDH5 mutations in persons from two unrelated 
consanguineous Pakistani families with fundus albipunctatus. 
Chapter 7 reports on seventeen different consanguineous Pakistani RD families, in eight 
of which the causal genetic defects have been identified. In nine families involvement of 
novel genetic loci is suspected. In addition, this chapter provides a comprehensive 
overview of all published genetic causes of retinal dystrophies in Pakistan. 
Chapter 8 comprises of a general discussion on different aspects concerning the diagnosis 
and treatment of retinal dystrophies.  
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ABSTRACT 
Purpose: To identify the gene mutations responsible for autosomal recessive retinitis 
pigmentosa (arRP) in Pakistani families. 
Method: A cohort of consanguineous families with typical RP phenotype in patients was 
screened by homozygosity mapping using microsatellite markers that mapped close to 21 
known arRP genes and 5 arRP loci. Mutation analysis was performed by direct sequencing 
of the candidate gene.  
Result: In two families, RP21 and RP53, homozygosity mapping suggested RHO, the gene 
encoding rhodopsin, as a candidate disease gene on chromosome 3q21. In 6 out of 7 
affected members from the two families, direct sequencing of RHO identified a 
homozygous c.448G>A mutation resulting in the p.(Glu150Lys) amino acid change. This 
variant was first reported in PMK197, an Indian arRP family. Single nucleotide 
polymorphism (SNP) analysis in RP21, RP53, and PMK197 showed a common disease-
associated haplotype in the three families.  
Conclusions: In two consanguineous Pakistani families with typical arRP phenotype in the 
patients, we have identified a disease-causing mutation p.(Glu150Lys) in the RHO gene. 
SNP analysis suggests that the previously reported Indian family (PMK197) and the two 
Pakistani families studied here share the RHO p.(Glu150Lys) mutation due to a common 
ancestry. 
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INTRODUCTION 
Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous group of 
ophthalmic diseases which are characterized by night blindness and gradual loss of 
peripheral vision due to a progressive degeneration of the photoreceptor cells in the retina. 
RP is a major cause of inherited blindness in adulthood with a worldwide prevalence of 1 
in 3500-4000 individuals [1-4]. The diagnosis of individuals affected by RP is typically 
based on fundus examination and the electroretinogram (ERG). In affected individuals, the 
fundus shows a waxy pallor of the optic discs, retinal vessel attenuation, and peripheral 
pigmentary alterations with bone spicule deposits. The ERG typically shows a 
photoreceptor dysfunction with the rod-derived responses being more affected than the 
cone-derived ones [5]. In addition to clinical heterogeneity of RP, there is a significant 
genetic heterogeneity of the disease, with different modes of inheritance [6-8]. To date 
more than 40 different RP-associated genes have been identified 
(http://www.sph.uth.tmc.edu/RetNet). These genes encode proteins that are involved either 
in the phototransduction cascade, retinoid metabolism, cell-cell interaction or 
photoreceptor development. Some of these proteins are transcription or splicing factors, 
whereas others are intracellular transport molecules. 
Rhodopsin is an abundant rod photoreceptor-specific transmembrane protein, which 
upon photoexcitation initiates the phototransduction cascade. Heterozygous mutations of 
the corresponding gene (RHO; MIM 180380) account for approximately 30% of all 
autosomal dominant RP (adRP) cases in the USA and the UK, whereas the relative 
frequency and prevalence of RHO mutations is uncertain in the Asian population [11,12]. 
Up to now there are more than 100 adRP-causing mutations but only two autosomal 
recessive RP-associated mutations have been reported in the coding sequence of RHO 
[http://www.sph.uth.tmc.edu/RetNet, 13, 14, 15]. The first arRP case, a French-Canadian 
female patient, carried an apparently homozygous null mutation in exon 4 [14], whereas in 
the second case, in a consanguineous Indian family, a homozygous c.448G>A; 
p.(Glu150Lys) mutation in exon 2 has been reported [15]. Here we report the identification 
of the p.(Glu150Lys) RHO mutation in affected individuals from two Pakistani families 
with arRP.  
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METHODS 
Family collection: A total of 29 arRP families representative of autosomal recessive form 
of the disease were collected from different areas of northern and central Pakistan. 
Pedigree analysis and clinical ophthalmic examination: After an initial linkage analysis, 
described below, two consanguineous Pakistani families were ascertained, RP21 was from 
Dera Ghazi Khan (central Pakistan), and family RP53, which was identified later during 
control panel screening for RHO mutation, was from Abbottabad (northern Pakistan). 
Affected individuals had typical RP symptoms with early onset of night blindness. Medical 
and family histories of the participants were then obtained with the help of a questionnaire 
and the pedigree structure was drawn (Figure 1). Clinical examination and characterization 
of the affected and unaffected individuals was done by an experienced ophthalmologist. 
For this purpose, individuals IV-1 and IV-7 of RP21 and V-1 and V-3 of RP53 were then 
selected for further detailed investigations including fundoscopy of the retina and 
electroretinographic (ERG) studies. 
Ethics committee approval: This study adhered to the tenets of the Declaration of 
Helsinki. The consent of both families was taken for this study that was approved by the 
Shifa College of Medicine/Shifa International Hospital Ethics Committee/Institutional 
Review Board after an extensive review of the protocol. 
Sample collection and DNA isolation: Peripheral blood samples of each individual for 
which haplotypes are depicted in Figure 1, except RP21-III-6, were collected using 
vacutainer tubes containing Acid Citrate Dextrose (ACD) (Becton Dickinson product no 
364606, New Jersey, USA, http://www.bd.com/). Blood samples of 100 random unrelated 
healthy control individuals were also collected for determination of allele frequency in the 
general Pakistani population. Genomic DNA was isolated using an organic extraction 
method [17, 18]. 
Linkage mapping and haplotype analysis of arRP genes: In order to find the causative 
gene in the arRP families, homozygosity mapping using polymorphic microsatellite 
markers for the known arRP loci was carried out. Microsatellite markers mapped by the 
Cooperative Human Linkage Center (CHLC) were obtained from Invitrogen, Inc. (USA). 
Cytogenetic locations of these markers as well as the length of the amplified products were 
obtained from the Human Genome Database (www.gdb.org) and the Marshfield Medical 
Center database (www.marshmed.org.gov/genetics/). Table 1 lists the arRP genes and loci 
with the flanking markers used for homozygosity mapping. Each microsatellite marker was 
amplified in a 25 μl volume consisting of the following: 0.5 mM dNTPs, 1X Taq Buffer 
Chapter  2A 
 
38 
 
(10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1% Triton X-100, 0.01% (w/v) gelatin), 1.5 mM 
MgCl2, 0.3 μM of each forward and reverse primer, 2.5U Taq polymerase and 50 ng 
genomic DNA. The thermal cycling conditions were as follows: initial denaturation of 
90°C for 2 min, followed by 40 cycles of 90°C for 1 min, 55°C for 1 min, 72°C for 1 min 
and a final extension at 72°C for 7 min. Genotypes were defined following polymerase 
chain reaction (PCR) and 8% polyacrylamide gel electrophoresis. Images of the gels were 
visualized by UV transillumination after staining with ethidium bromide, captured with a 
digital camera and documented using the software BioCap MW Version 11.01 software 
from Vilber Lourmat (France). Haplotypes were constructed based upon the allelic patterns 
of microsatellites. 
 
Table 1. Microsatellite marker alleles flanking genes or loci associated with arRP in 
selected individuals of families RP21 and RP53 
RP21 RP53 
Genes & loci Markers cM Parent Parent Affected Affected Parent Parent Affected Affected
III-12 III-13 IV-9 IV-10 III-6 IV-1 V-3 III-12 
ABCA4 D1S406 125.5 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
D1S1587 126.2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
CRB1 D1S2816 211.1 1,1 1,1 1,1 1,1 1,1 1,1 1,1 1,1 
D1S1660 212.4 1,2 1,1 2,1 2,1 1,2 1,2 1,2 1,2 
USH2A D1S474 233.9 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
D1S2827 234.5 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
RPE65 D1S2806 100.4 1,2 1,3 2,1 2,1 1,1 1,1 1,1 1,1 
D1S219 101.5 1,2 1,2 2,1 2,1 2,1 1,3 1,1 2,1 
RP32 D1S2808 131.9 1,2 1,1 2,1 1,1 1,2 3,1 1,1 1,2 
D1S2896 134.2 1,1 2,1 1,1 1,1 1,1 1,1 1,1 1,1 
D1S485 136.9 1,2 1,2 2,1 1,2 1,2 1,2 1,2 1,2 
SAG D2S2348 242.2 2,1 1,2 1,2 1,1 1,1 1,2 1,2 1,2 
D2S2205 243 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
CERKL D2S2261 185.1 2,2 1,1 1,2 1,2 1,2 1,2 1,2 1,1 
D2S1391 186.2 1,2 1,1 1,2 1,1 1,1 1,2 1,2 1,2 
MERTK D2S1888 121.6 1,1 1,1 1,1 1,1 1,1 1,1 1,1 1,1 
D2S1892 122.1 1,2 1,3 1,3 1,3 1,2 1,1 1,2 1,2 
RP28 D2S2225 82.8 1,1 1,1 1,1 1,1 1,1 1,2 1,2 1,1 
D2S1337 85 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
RHO D3S3607 143.9 1,1 1,2 1,1 1,1 1,2 1,2 1,1 1,1 
D3S2322 146.6 1,2 1,2 1,1 1,1 1,2 1,2 1,1 1,2 
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D3S1587 146.6 1,3 1,2 1,1 1,1 1,2 1,2 1,1 1,2 
LRAT D4S1586 147 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
D4S2962 152.9 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
CNGA1 D4S1627 60.1 1,2 1,1 1,1 1,1 1,2 1,3 1,3 1,2 
D4S3255 61.4 2,2 2,2 2,2 2,2 1,2 1,2 1,1 1,1 
PDE6B D4S3360 0 1,1 1,1 1,1 1,1 1,1 1,1 1,1 1,1 
D4S2936 1.4 1,3 1,3 1,3 1,3 1,2 1,2 1,2 1,2 
RP29 D4S621 175.6 1,1 1,1 1,1 1,1 1,1 1,1 1,1 1,1 
D4S415 181.3 1,1 1,1 1,1 1,1 1,1 1,2 1,1 1,2 
PROM1 D4S403 25.9 1,1 1,1 1,1 1,1 1,2 1,2 1,1 1,2 
D4S3048 29.1 1,2 1,3 1,3 1,3 1,3 1,1 1,3 1,2 
PDE6A D5S812 150.3 1,1 1,1 1,1 1,1 1,3 1,2 1,2 1,2 
D5S2013 152.6 1,2 1,1 1,1 1,1 1,2 1,2 1,2 1,2 
TULP1 D6S265 44.4 1,2 1,2 1,2 2,1 1,2 1,3 1,2 1,3 
D6S1645 48.3 1,2 1,1 1,1 2,1 1,2 1,2 1,2 1,2 
RP25 D6S257 79.9 1,2 1,2 2,1 2,1 1,2 1,2 2,1 1,2 
D6S1644 96.1 1,2 1,1 2,1 2,1 1,1 1,2 1,1 1,2 
RP1 D8S509 69.4 1,2 1,1 1,1 2,1 1,2 1,2 1,2 1,2 
D8S1828 71 1,1 1,3 1,3 1,1 1,1 1,3 1,3 1,2 
RGR D10S219 100.9 1,2 1,1 1,1 1,2 1,2 1,1 2,1 1,2 
D10S523 103.4 1,1 1,2 1,2 2,1 1,1 1,3 1,3 1,2 
NRL D14S50 12.5 1,2 1,3 1,2 1,1 1,2 1,2 2,1 1,1 
D14S283 14 1,1 1,2 1,1 1,1 1,1 1,2 1,1 1,1 
RLBP1 D15S116 85.6 1,2 1,2 1,1 2,1 1,2 1,2 1,2 1,2 
D15S996 86.8 1,2 1,3 2,1 2,1 1,2 1,1 1,1 1,2 
NR2E3 D15S650 70.7 1,1 1,1 1,1 1,1 1,2 1,1 1,1 1,1 
D15S204 71.8 1,2 1,3 1,3 1,3 1,2 1,2 1,1 1,2 
CNGB1 D16S3057 77.1 1,2 1,2 1,2 1,2 1,2 1,3 1,2 1,2 
D16S670 78.7 1,1 1,1 1,1 1,1 1,2 1,2 1,2 1,2 
RP22 D16S403 43.8 1,3 1,2 3,1 1,2 1,1 1,2 1,2 1,2 
D16S287 48.6 1,1 1,1 1,1 1,1 1,2 1,2 1,2 1,3 
PRCD D17S1848 95.9 1,1 1,2 1,2 1,1 1,2 1,2 1,1 1,2 
D17S1839 102.5 1,2 1,2 1,1 2,1 1,2 1,2 1,2 1,2 
 
After suggestive linkage was observed, additional flanking markers were selected from the 
above mentioned databases and haplotypes were constructed for two generations in both 
the pedigrees. The LOD score analysis of all the genotyped individual for family RP21 
(excluding RP21-III-6 for whom the haplotype was logically deduced) for the markers was 
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performed with the easyLinkage software package version 5.02 
(http://genetik.charite.de/hoffmann/easyLINKAGE/index.html) [19]. 
 
Sequence analysis of RHO: The sequencing primers for RHO were designed for the 
upstream promoter sequence and the 5 coding exons with Primer3 software 
(http://frodo.wi.mit.edu/) (Table 2). All exons of the RHO gene were bidirectionally 
sequenced with an automated DNA sequencer. 
 
Table 2. Amplification and sequencing primers for RHO 
Forward primer (5'→3') Reverse Primer (5'→3') 
Promoter 1 CTAGCGTTCAAGACCCATTAC ACTCAGGATCCAGGAAAAGG 
Promoter 1 GGACTGGATGACTCCAGAGG CCAAGAATGCTGCGAAGG 
Exon 1 CTGCAGCGGGGATTAATATG GGACAGGAGAAGGGAGAAGG 
Exon 2 GTTGCCTTCCTAGCTACCCTCT GCCAGGAGACATACAAGGTCAG 
Exon 3 CAGCCATGCAGACGTTTATG GTCCAGACCATGGCTCCTC 
Exon 4 ACGGCTCTGAGGGTCCAG AGGAATCTGCATTTCTCACACA 
Exon 5a GAATCGTGAGGGGCAGAAG AAAGATGAGTTGGGAGGAGGA 
Exon 5b GGGACATCCACCAAGACCTA AAAATGTTCACTATCAGGAGGTGAT
Exon 5c GGGCCTCACTTTCTTCTCCT ATAGGCCACATTGGGAAGG 
Exon 5d AACCTTGGGGCAGGTTTTTA CTTGTCTGGCAAGGGAAACT 
Exon 5e TCTCGAAGAGCTTAGAAACAAAGA CCCAGCCAAGGTCAGTTTTA 
 
Statistical analysis: Genotype frequencies of cases and controls were compared in order to 
determine the association/correlation, and chi-square (χ2) tests were performed at 95% 
confidence interval in order to calculate the difference between the observed and the 
expected frequencies of the variant. 
Founder effect detection: In order to determine the status of any founder effect in the 
Pakistani families RP21 & RP53 and the Indian family PMK197, microsatellite and SNP 
analysis were carried out in all the three families. Informative SNPs surrounding the RHO 
gene were selected using the UCSC genome browser (http://genome.ucsc.edu/) and 
haplotypes were constructed for all the three families. 
 
RESULTS 
In family RP21, there are four generations with five affected individuals in the fourth 
generation (Figure 1A) suggesting that RP has an autosomal recessive inheritance pattern 
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(Figure 1). The onset of RP in this family was in the first decade, with typical symptoms of 
the disease including night blindness and progressive visual field loss. Fundus examination 
of the affected members of the family revealed typical features of RP, including optic disc 
pallor, attenuation of the retinal vessels, atrophy of the peripheral retinal pigment 
epithelium (RPE), and formation of bone spicule pigmentation. In addition, affected 
individuals had macular edema in the posterior pole and small white dots in the mid-
periphery at the level of the RPE (Figure 2). The ERG showed unrecordable rod and cone 
responses with undetectable 30 Hz flicker ERG (data not shown). In contrast, in unaffected 
individuals the fundus was completely normal and the rod response and the mixed rod-
cone response had normal amplitudes and implicit times, with normal oscillatory potentials 
(data not shown). Single flash photopic ERG and photopic 30-Hz flicker responses were 
also normal, thus the ERG pattern being unremarkable in these individuals. 
Homozygosity mapping by microsatellite marker analysis for family RP21 
excluded all reported loci for arRP but RHO (Table 1), for which homozygosity was seen 
in all 5 affected individuals for all flanking markers. The flanking markers of the RHO 
locus used in our study were those described previously by Young et al. [20]. Refinement 
of the marker analysis (Figure 1A) resulted in a 6.8 Mb (4.8 cM) critical interval flanked 
by D3S1589 and D3S2322 with a maximum LOD-score, for all the genotyped individuals 
only, of 2.6 for marker D3S3606 at a theta value of 0.00. 
Direct sequencing of RHO resulted in identification of c.448G>A, a previously reported 
mutation in exon 2, resulting in the replacement of a lysine residue for a glutamic acid 
p.(Glu150Lys) [15]. All affected individuals in this family were found to be homozygous 
for this change whereas all unaffected individuals were found to be heterozygous for this 
mutation (Figures 1 and 3). 
To determine the frequency of the c.448G>A mutation in the general Pakistani 
population, exon 2 was sequenced in 100 random control samples, which resulted in a 
frequency of 0.005 of the disease allele in the general population. During this screening of 
the unrelated healthy control panel, one individual (V-1, Figure 1B) was identified as a 
heterozygous carrier of this mutation. Upon further investigation it was found that a person 
with RP was also present in this family. Detailed clinical examination of this family 
(RP53) confirmed the presence of RP, with onset of night blindness in the second decade 
of life in the two affected individuals. Blood samples of selected family members were 
then obtained and homozygosity mapping was conducted for the RHO locus (Figure 1B). 
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Figure 1. Pedigrees and 3q21 marker haplotypes spanning the RHO gene in autosomal 
recessive RP families RP21 (A) and RP53 (B).  A. Family RP21 consists of four 
generations. White circles represent unaffected females, filled circles affected females, 
white squares unaffected males, and filled squares affected males. Deceased individuals 
are shown with a slanting line across the symbol. Also shown are the marker loci and their 
positions in a 18.5-Mb interval, which were used for fine mapping of the disease locus. 
Marker allele sizes were not accurately determined and therefore we only give two-allele 
designations. Arrowheads designate cross-overs that define the 6.8-Mb minimal critical 
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region between D3S1589 and D3S2322. B. Family RP53 consists of five generations. 
Patient V-3 in one branch of the family is homozygous for marker alleles flanking RHO. 
The disease in affected individual III-12 could be RHO unrelated suggesting locus 
heterogeneity in the different branches of the family. Haplotypes were established for all 
individuals for which marker alleles are depicted, except for RP21-III-6, the haplotypes of 
whome were deduced (indicated with brackets around the haplotypes). 
 
 
Figure 2. Fundus photograph of an individual affected with RP. The fundus appearance of 
individual RP21-IV-1 is characteristic of advanced RP, with optic disc pallor, attenuation 
of the retinal vessels, peripheral pigment epithelial atrophy, and bone spicule pigmentation. 
The posterior pole shows macular edema, and small white dots are present in the mid-
periphery at the level of RPE. 
 
 
Figure 3. Sequence analysis of RHO in family RP21. A. Sequence trace of part of exon 2 
of an affected individual (IV-1) showing the homozygous mutant sequence c.448G>A. B. 
Sequencing results of IV-7 showing the heterozygous c.448G>A sequence. C. Sequence 
trace of an unaffected individual with the homozygous wild-type c.448G. 
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Homozygosity mapping and sequencing resulted in identification of 11 heterozygotes 
including the affected individual III-12, while only one female, V-3, was homozygous for 
the c.448G>A mutation. Sequencing of the remaining exons and upstream regulatory 
regions of RHO in III-12 did not reveal any additional RHO mutations. 
In addition to the 100 control samples, exon 2 of the RHO gene was also sequenced using 
the DNA samples of 28 probands from a Pakistani RP cohort in order to determine the 
prevalence of the c.448G>A mutation. None of the affected individuals were found to 
carry this mutation. The chi-square (χ2) analysis resulted in a significant association of the 
homozygous mutant allele A (p<0.05) with the disease when calculated for all the 
individuals of both the families and also when compared with the control samples (Table 
3A & B, respectively). 
 
Table 3. Chi square analysis 
A Unaffected family members Patients P (χ2) 
GG/GA 20 1 
<0.05 (22.04) 
AA 0 6 
B Controls + Unaffected family members Patients P (χ2) 
GG/GA 119 1 
<0.05 (107.10) 
AA 0 6 
Chi square analysis for families RP21 and RP53 showing association of  
alleles AA with the disease. 
 
Founder effect analysis of the c.448G>A mutation in the two Pakistani families (RP21, 
RP53) and the Indian family (PMK197) [15] revealed that all affected members share the 
same homozygous haplotype consisting of three highly informative SNPs surrounding the 
RHO gene mutation (Figure 4), therefore suggesting a common ancestry between the three 
families. 
 
DISCUSSION 
Two apparently unrelated, ethnically diverse Pakistani arRP families from different 
geographical regions of Pakistan, RP21 from the Punjab province and RP53 from the 
North West Frontier Province, were identified and analyzed by homozygosity mapping 
using highly informative microsatellite markers flanking the known arRP genes and loci. 
Initially, one of the families (RP21) showed homozygosity for the RHO (RP4) locus at 
3q22.1, in all affected individuals of the family. 
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Figure 4. Haplotype analysis for SNPs in close proximity to the RHO mutation. 
Frequencies [26] of the combined homozygous variants based on individual allele 
frequencies in the studied population are: rs789231 (CC), 0.25; RHO (AA), 0.000025; 
rs2855557 (AA), 0.178084; rs2625961 (GG), 0.207025. 
 
Mutations in the rhodopsin gene have previously been shown to result in RP. However, 
most of the RHO mutations have been found in families with adRP 
(http://www.hgmd.cf.ac.uk/ac/index.php) whereas only two mutations have been shown to 
cause RP with an autosomal recessive mode of inheritance [14, 15]. 
In this study, we have identified the c.448G>A mutation in the RHO gene in two 
different consanguineous arRP families from Pakistan and also determined the frequency 
of pathogenic allele in the normal population. While determining the population frequency 
we found the c.448G>A mutation in heterozygous state in 1 out of 100 control samples, 
but we did not find it in any of the other 28 families from our RP panel that were screened 
for the c.448G>A mutation. Further investigations of the family of the heterozygous 
individual from the control samples resulted in the identification of an additional arRP 
family (RP53). DNA sequencing revealed the same causative mutation in one branch of the 
family. There seems to be genetic heterogeneity of the RP in this family, as individual III-
12 may either carry a second, yet unidentified, variant in the RHO intronic sequences or a 
mutation in a different gene. The statistical analysis for the association/ correlation showed 
that the mutant allele A is significantly associated (p<0.05) with the disease phenotype 
because the AA genotype is always observed in known affected individuals and is absent 
from the normal population (Table 3A, B, Figure 4). 
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This c.448G>A mutation has previously been reported to cause arRP in an Indian family 
from southern India [15], which is ethnically different and geographically isolated from the 
present families. We therefore compared, in the two Pakistani families and the Indian 
family, some of the SNP’s from the surrounding region of RHO to determine if they share 
a haplotype suggesting a founder mutation in these families. Indeed, our analysis revealed 
a shared haplotype in the patients of the three families suggesting a common ancestry. This 
is remarkable as the three families belong to diverse ethnic groups and have lived at their 
present location for several generations with no relative having moved to any other part of 
the subcontinent, at least for the last 10 generations, thus any commonality in ancestry 
must be more than a couple of hundred years old. 
Genetic screening of RP families is not only helpful in understanding the molecular 
mechanism of the disease; it is also important for genetic counseling. Traditional 
consanguineous marriages are major risk factors for autosomal recessive diseases, 
including retinopathies. Families have little knowledge of the inheritance of the diseases, 
and through such studies as the present one, many families could be counseled 
appropriately, as it was done for members of families RP21 and RP53. 
The rod visual pigment rhodopsin (Rho) consists of the apoprotein, opsin, and the 
covalently bound chromophore, 11-cis-retinal [21]. This protein is a heptahelical G-
protein-coupled receptor synthesized at high level in the rod inner segment and transported 
subsequently to rod outer segment [22]. The seven transmembrane segments (H1-H7) are 
sequentially linked by extracellular (E1-E3) and cytoplasmic (C1-C3) loops [23]. The first 
reported null mutation p.(Glu249Ter) associated with arRP was shown to abolish the 
function of the helices H6 and H7 which contains the retinal binding site. Remarkably, this 
mutation caused an abnormal ERG pattern even in heterozygotes [14]. 
Residue Glu150, which is embedded at the edge of the phospholipid bilayer, is located near 
the C-terminal region of the C2 loop which is important for proper folding of opsin and its 
binding to transducin, thus for the initiation of the phototransduction cascade [24]. 
However, Zhu et al. [25] have shown that the homozygous p.(Glu150Lys) change does not 
affect binding of opsin to transducin, but instead it affects the export of the protein opsin 
from the Golgi apparatus. This is due to improper glycosylation of the protein, which 
results in retention of the protein inside the Golgi leading to insufficient supply of opsin to 
the rod outer segments. The processing of Rho protein has been shown to be normal in the 
p.(Glu150Lys) heterozygotes [25]. In addition, the mutation changes a highly conserved 
nucleotide (phastCons: 1.00) and amino acid. The online pathogenicity prediction 
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programs PolyPhen and SIFT predict this change to be probably damaging (score: 0.998) 
and deleterious (score: 0.00), respectively, and thus the mutation is likely pathogenic [27, 
28].  
We conclude that linkage and mutation analysis of known retinal disease genes in 
Pakistani patients with RP have resulted in the identification of a RHO mutation in two out 
of 30 families which very likely have a common ancestor and are also distantly related 
with the Indian family previously found to harbor this mutation. We have also observed 
genetic heterogeneity in one of these two families. These findings have facilitated accurate 
genetic counseling of patients and unaffected family members. 
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ABSTRACT 
Purpose: To identify the genetic defects underlying retinitis pigmentosa (RP) in Pakistani 
families. 
Methods: Genome-wide high-density single nucleotide polymorphism (SNP) microarray 
analysis was performed using DNA of nine affected individuals from two large families 
with multiple consanguineous marriages. Data were analyzed to identify homozygous 
regions that are shared by affected sibs in each family. Sanger sequencing was performed 
for genes previously implicated in autosomal recessive RP and allied retinal dystrophies 
that resided in the identified homozygous regions. Probands from both families underwent 
fundus examination and electroretinogram measurements. 
Results: The tubby-like protein 1 gene (TULP1) was present in the largest homozygous 
region in both families. Sequence analysis identified a previously reported mutation 
(c.1138A>G; p.(Thr380Ala)) in one family and a novel pathogenic variant (c.1445G>A; 
p.(Arg482Gln)) in the other family. Both variants were found to be present in a 
homozygous state in all affected individuals, were heterozygously present in the unaffected 
parents, and heterozygously present or absent in normal individuals. Affected individuals 
of both families showed an early-onset form of RP. 
Conclusions: Homozygosity mapping, combined with candidate-gene analysis, 
successfully identified genetic defects in TULP1 in two large Pakistani families with early-
onset retinitis pigmentosa. 
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INTRODUCTION 
The major cause of inherited blindness in humans is retinitis pigmentosa (RP; OMIM 
268000). The clinical symptoms of RP are the loss of night vision in the early phase of 
disease, later followed by peripheral vision loss, tunnel vision, and sometimes complete 
blindness [1]. Progression of the disease is mainly caused by the gradual loss of rod 
photoreceptor cells, which are mostly responsible for vision under low light conditions, 
and the subsequent loss of cone photoreceptor cells, which are involved in color vision 
under bright light conditions. The clinical diagnosis is based on fundus examination and 
electrophysiological analysis of rod and cone photoreceptor-cell function by measuring the 
scotopic and photopic responses, respectively, using electroretinography (ERG). The 
disease’s characteristics are the presence of pigmentary deposits (bone spicules) in the 
peripheral fundus, diminished or no ERG responses from rod and cone photoreceptor cells, 
and attenuation of the retinal blood vessels [1]. The disease is highly genetically 
heterogeneous, since 55 different genes and three loci have been identified as being 
associated with non-syndromic RP (RetNet, Nov. 8, 2011). All Mendelian forms of 
inheritance have been observed for RP. Digenic forms and rare mitochondrial inheritance 
have also been reported [1-4]. 
Tubby-like protein 1 (TULP1; OMIM 602280) belongs to the tubby-like protein 
family. The TULP1 gene is located on the short arm of chromosome 6 [5]. TULP1 is 
expressed specifically in the retina [5,6], and the encoded protein is thought to be involved 
in protein trafficking, such as the transport of rhodopsin from the inner segment to the 
outer segment via the connecting cilium [7]. The aim of the current study was to identify 
the underlying genetic causes of autosomal recessive RP (arRP) in Pakistani families by 
using genome-wide homozygosity mapping and Sanger sequencing of known retinal 
disease genes in the homozygous regions. We identified disease-causing mutations in 
TULP1 in two large families. 
 
METHODS 
Ethics committee/institutional review board approval: Before initiating this study, 
approval for this work was granted by ethics committee/institutional review board of Shifa 
College of Medicine/Shifa International Hospital, Islamabad, Pakistan and signed informed 
consent was obtained from all participating individuals in both families.  
Ascertainment of families and clinical analysis: Two families from the Punjab province 
with individuals having night vision and daytime vision loss were included in the study. 
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Their pedigrees were drawn (Figure 1A,B) using Haplopainter [8], and venous blood 
samples were collected in acid citrate dextrose containing vacutainers (Becton Dickinson, 
Franklin Lakes, NJ). Fundus examinations were done, and ERG [9] measurements were 
made for probands in both families. 
Genotype analysis and homozygosity mapping: DNA was extracted by using a standard 
phenol chloroform extraction protocol [10] and stored at 4 °C. HumanOmniExpress (>700 
K) single nucleotide polymorphism (SNP) microarrays from Illumina Inc. (San Diego, CA) 
were employed to search for homozygous regions in six affected individuals (Figure 1A) in 
family A and three affected individuals (Figure 1B) in family B. Genotype data were 
analyzed with Homozygosity Mapper [11], an online tool for homozygosity mapping using 
SNP genotyping data. Haplotype comparisons were also done for affected and normal 
individuals to identify the homozygous regions that were identical in all the affected 
individuals in each family. 
Sequence analysis and mutation detection: Prior to Sanger sequencing, the 15 protein-
coding exons of TULP1 and their flanking intronic sequences were amplified by PCR 
using standard conditions and reagents. PCR primers were designed with the online 
primer-designing tool Primer3 [12] (available on request). Amplified PCR products were 
electrophoresed in 2% agarose gels containing ethidium bromide, and DNA bands were 
visualized on an ultraviolet transilluminator. PCR products were purified on PCR clean-up 
purification plates (NucleoFastTM PCR, Cat. No. 743100.10; MACHEREY-NAGEL, 
Düren, Germany), according to the manufacturer’s protocol. Purified PCR products were 
subsequently used for Sanger sequencing in an automated DNA sequencer (Big Dye 
Terminator, version 3, on a 3730 DNA analyzer; Applied Biosystems, Foster City, CA). 
Sequencing results were analyzed by using Vector NTI AdvanceTM 2011 software from 
Life Technologies/Invitrogen (Bleiswijk, Netherlands), by assembling the sequenced 
contigs and then visualizing the aligned sequences of the exons. 
Pathogenicity assessment of identified variants: Identified missense variants were 
assessed for possible causality by using sorting intolerant from tolerant (SIFT) analysis and 
polymorphism phenotyping (Polyphen).  
Restriction fragment length polymorphism analysis: Restriction fragment length 
polymorphism analysis was performed to detect the presence or absence, of the identified 
mutations, in 100 ethnically matched control individuals. For the mutation identified in 
family A, restriction enzyme HpyCH4III was used, whereas in family B, restriction 
enzyme MspI was used. In both families, restriction enzyme recognition sites were 
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abolished in the mutant sequences. Purified PCR products were used for restriction enzyme 
digestion, according to the manufacturer’s protocol (New England BioLabs, Ipswich, MA). 
Evolutionary conservation of amino acids: To check the evolutionary conservation of the 
mutated amino acids, the TULP1 orthologous protein sequences of the following species 
were aligned with the Vector NTI Advance® 2011 software: humans (H. sapiens, 
ENSP00000229771); chimpanzees (P. troglodytes, ENSPTRP00000007764); mice (M. 
musculus, ENSMUSP00000049070); dogs (C. familiaris, ENSCAFP00000001922); 
chickens (G. gallus, ENSGALP00000009613); frogs (X. tropicalis, 
ENSXETP00000000899); tetraodons (T. nigroviridis, ENSTNIP00000004001); fruitflies 
(D. melanogaster, FBpp0088961); honeybees (A. mellifera, GB19892-PA); roundworms 
(C. elegans, F10B5.4), blood flukes (S. mansoni, Smp_058730__mRNA); and Arabidopsis 
(A. thaliana, AT1G76900.1). 
Three-dimensional structure prediction: Project HOPE [13] was used to predict the 
possible structural changes in the mutant TULP1 proteins identified in our study using a 
normal human TULP1 structure (PDB-file 3C5N). 
 
RESULTS 
In both families (Figure 1), the average age of disease onset was in the first decade of life. 
Ophthalmic examination of affected individuals from both families revealed the presence 
of attenuated retinal vessels and the optic disc to have a waxy, pale appearance (Figure 2). 
A yellow perifoveal annular ring, a characteristic feature of individuals carrying TULP1 
mutations, was also clearly visible in family A (Figure 2A,B). In family B, the perifoveal 
ring was in the process of development (Figure 2C,D). Upon ERG, scotopic and photopic 
electrophysiological responses of rod and cone photoreceptors, respectively, were 
diminished in affected members of both families (Table 1). Neither nystagmus nor eye 
poking were present in either family. 
Genome-wide SNP microarray data of six affected individuals of family A were 
analysed with the help of Homozygosity Mapper, which revealed a single homozygous 
region (Figure 3A) of 3.9 Mb (from 32.9 Mb to 36.8 Mb; hg19) on chromosome 6, flanked 
by SNPs rs3132131 and rs236411. This homozygous region harbored TULP1, a gene 
known to be mutated in patients with Leber congenital amaurosis (LCA) and arRP. The 
sequence analysis identified a previously reported mutation, c.1138A>G; p.(Thr380Ala) 
[14, 15] in this family (Figure 1C). 
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Figure 1. Pedigrees and TULP1 genotyping results for families A and B. A: This is the 
pedigree of family A in which the presence of the c.1138A>G variant (M) was found in a 
homozygous state in all affected individuals. As expected for causal autosomal recessive 
variants, unaffected parents are heterozygous, and normal individuals carry one or no 
mutant allele. B: This is the pedigree of family B in which the presence of the c.1445G>A 
variant (M) was shown in a homozygous state in the 6 affected individuals, and 
heterozygously in an unaffected sibling, parents and grandparents of affected persons. C: 
This is the sequence electropherogram showing the nucleotide change from adenine to 
guanine in the proband of family A (upper panel), and sequence electropherogram of a 
control individual showing the wild-type adenine (lower panel). D: This is the sequence 
electropherogram of the proband carrying the mutant adenine in family B (upper panel); 
and the sequence electropherogram of a control individual with the normal guanine (lower 
panel). Probands are indicated with arrows; asterisks indicate the individuals that were 
tested using HumanOmniExpress (>700 K) SNP microarrays. M/M, homozygous 
c.1138A>G (in family A) or homozygous c.1445G>A (in family B); +/M, heterozygous 
mutations present; +/+, two wild-type alleles present. 
Chapter  2B 
 
58 
 
 
Figure 2. Fundus photographs of affected individuals from both families and of a normal 
individual. A, B: Right and left fundus, respectively, of the proband of family A (see 
arrow, Figure 1A), representative of the fundus appearance of all affected members of this 
family. Arrows indicate yellow perifoveal annular rings. C, D: Right and left fundus, 
respectively, of the proband of family B (see arrow, Figure 1B). Arrowheads point to the 
developing perifoveal annular rings. E, F: Right and left fundus, respectively, of a normal 
individual. 
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Table 1. Comparison of ERG responses of affected individuals of families A and B with a control individual. 
Measured parameters using monopolar electrodes Adaptation 
Flash strength 
(cds/m2) 
Proband 
Family A 
Proband 
Family B 
Control 
Normal 
values 
Scotopic 25 dB b-wave amplitude (µV) Dark 0.01 13.30 21.80 244.40 >185 
Scotopic 0 dB b-wave amplitude (µV) Dark 3.0 22.70 22.20 650.00 >419 
Oscillatory potential amplitude (µV) Dark 3.0 56.40 47.90 187.70 >110 
Photopic 0 dB b-wave amplitude (µV) Light 3.0 12.00 15.70 86.90 >102 
Photopic 30 Hz flicker amplitude (µV) Light 3.0 6.10 1.46 65.60 >70 
Age of affected individuals from families A and B at the time of investigation was 20 years.
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Similarly, genome-wide SNP microarray data analysis of three affected individuals of 
family B, resulted in the identification of six homozygous regions. After haplotype 
comparison, two regions, a 4.8 Mb region on chromosome 6 (from 33.8 Mb to 38.6 Mb, 
flanked by SNPs rs9296102 and rs7761629) and a 1.4 Mb region on chromosome 7 (from 
132.4 Mb to 133.7 Mb, flanked by SNPs rs924368 and rs10249912), were found to be 
identical in all the affected individuals. TULP1 resides in the homozygous region on 
chromosome 6 (Figure 3B), and the sequence analysis revealed a novel mutation, 
c.1445G>A; p.(Arg482Gln); Figure 1C). The homozygous chromosomal region on 
chromosome 7 did not contain a gene previously implicated in an inherited retinal disease 
such as arRP or LCA. 
 
Figure 3. Homozygosity mapping results for families A and B. Homozygosity-mapper 
plots show the homozygous regions in the affected individuals in both families (red lines). 
Homozygous regions that show identical haplotypes for all affected individuals within a 
family are indicated by arrows. Panel A represents family A and panel B represents family 
B.  
 
In families A and B, the variants c.1138A>G and c.1445G>A, respectively, were found to 
be present in a homozygous state in all affected individual, were heterozygous present in 
the unaffected parents, and absent or heterozygous present in normal individuals (Figure 
1A,B). Both wild-type nucleotides were shown to be highly conserved, as evidenced by 
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their phylogenetic P-value [16] scores of 2.87 (c.1138A) and 6.10 (c.1445G) for family A 
and B, respectively. In addition, the encoded amino acids, p.(Thr380) and p.(Arg482), 
located in the C-terminal tubby domain, are highly conserved among different vertebrate 
and invertebrate species, while in a plant (Arabidopsis), isoleucine is present instead of 
threonine (Figure 4). These amino acids are completely conserved among the tubby, 
TULP1, TULP2, and TULP3 proteins [17]. SIFT predicts that both TULP1 variants are 
“not tolerated,” whereas Polyphen predicts that both are “probably damaging,” with 
prediction scores of 0.827 and 1.000 for p.(Thr380Ala) and p.(Arg482Gln), respectively. 
 
 
Figure 4. Conservation of mutated amino acids among different species. Amino acids 
identical to human tubby-like protein 1 (TULP1) amino acids are shaded in gray. The 
positions of the amino acids in the respective polypeptides are indicated. 
 
A three-dimensional-structure prediction analysis by project HOPE predicts that the 
p.(Thr380Ala) mutation, due to the smaller size of the alanine residue, causes an empty 
space in the protein and possible rearrangements of surrounding residues (Figure 5A,B). 
Any hydrogen bonds made by threonine will also be lost, because alanine is a hydrophobic 
residue. Very close to p.(Thr380) is a predicted inositol triphosphate binding site that 
might also be influenced by local conformational changes. The p.(Arg482Gln) variant 
changes a positively charged amino acid (arginine) to a neutral residue (glutamine), which 
results in the loss of interactions with negatively charged residues in its vicinity (Figure 
5C). In view of its location in the three-dimensional structure, these changes may result in 
a loss of external interactions. The p.(Thr380Ala) and p.(Arg482Gln) variants were not 
detected in 100 healthy ethnically matched control individuals. 
      p.(Thr380Ala)            p.(Arg482Gln) 
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Figure 5. Three-dimensional domain architecture of the tubby domain of TULP1 wild type 
and mutant proteins. A: Preferred predicted secondary structure of normal tubby-like 
protein 1 (TULP1) with Thr380 and Arg482 indicated in green. In yellow, the inositol 
triphosphate molecules that are predicted to bind the tubby domain of TULP1. B: Predicted 
structure of part of the p.(Thr380Ala) mutant protein in affected individuals of family A. 
The smaller size of the alanine residue may lead to rearrangements of surrounding residues 
and thereby affect putative inositol triphosphate binding. C: Part of the predicted structure 
of the p.(Arg482Gln) mutant protein found in affected individuals of family B. The 
p.(Arg482Gln) variant changes a positively charged amino acid (arginine) to a neutral 
residue (glutamine), which leads to loss of interactions with two negatively charged 
residues in its vicinity. Wild-type interactions are indicated with yellow blocks. 
 
DISCUSSION 
In the current study, we report on two large families with several consanguineous 
marriages and multiple individuals with early-onset RP that were found to carry TULP1 
mutations. Family A had 27 affected individuals who resided in the northern part of the 
Punjab province. This family had a strong custom of marrying inside the family. TULP1 
mutations were previously reported to cause LCA, a congenital form of severe vision 
impairment or blindness and early-onset RP [14, 15, 18-31]. There is clinical and genetic 
overlap between (early-onset) arRP and LCA [32, 33], and often it is very difficult to 
differentiate between these two conditions. Mutations in Crumbs homolog 1 (CRB1), 
Lecithin retinol acyltransferase (LRAT), Mer tyrosine kinase protooncogene (MERTK), 
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Retinal pigment epithelium-specific protein, 65-KD (RPE65), Spermatogenesis associated 
protein 7 (SPATA7), and TULP1 have been identified in individuals with LCA and arRP 
[18-21, 34-47]. If a severe form of rod–cone dystrophy is observed beyond early 
childhood, and when there are no features reminiscent of LCA, such as nystagmus, or eye 
poking, the phenotype is classified as early-onset RP. 
TULP family proteins (TUB, TULP1, TULP2, and TULP3) have crucial roles in 
embryonic development in vertebrates and take part in the proper functioning of the central 
nervous system [6, 48]. TULP1 is expressed specifically in the rod and cone photoreceptor 
cells [5, 6], and is involved in the transport of rhodopsin [7]. In Tulp1−/− mice, 
photoreceptor degeneration precedes synaptic malfunction, and thus TULP1 may have a 
function in photoreceptor synapse development [49]. A mutation of the same residue 
p.(Arg482Trp) was earlier found in combination with p.(Leu504fs*140) in five affected 
individuals with severe early-onset RP [50]. 
The structural analyses of the TULP1 C-terminal domains of the mutant proteins 
suggest that the missense mutations identified in our study might have resulted in the 
destabilization of the mutant proteins, or might have influenced the putative interactions of 
the tubby domain. Among different species of animals and plants, p.(Arg482) is located in 
the signature sequence (F-[KRHQ]-G-R-V-[ST]-x-A-S-V-K-N-F-Q) of the Tubby family 
of proteins, and this signature sequence contains 11 invariant amino acids that are highly 
conserved (Prosite) [5]. Replacement of the wild-type residue with the mutant glutamine 
might affect the signature sequence; this might ultimately prevent the mutant TULP1 
protein from functioning normally. 
In family A, the presence of a typical yellow-colored perifoveal annular ring was 
also indicative of TULP1 involvement [24]; whereas in family B, the ring formation was 
incomplete (Figure 2C,D). The bone spicules absent from both families might still develop 
later in life. The age of both individuals who were clinically evaluated was 20 years. 
The previously identified mutation p.(Thr380Ala) has only been reported in two unrelated 
Pakistani families [14, 15]. Our findings concerning this mutation in yet another Pakistani 
family suggested that c.1138A>G might be a Pakistani founder mutation, although no link 
was established between any of these families. One family belonged to a northern area of 
Pakistan [14] while the other belonged to the southern part of Punjab [15]. Our family 
belonged to the northern part of Punjab, which, however, does not exclude the possibility 
that this mutation represents a founder mutation in Pakistan. 
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Including our findings, 26 different TULP1 mutations have been identified in 33 families 
(Table 2). TULP1 mutations were found in 4.3% (10/231) of LCA families [14, 18, 24, 25, 
27, 29, 30] and 2.4% (23/948) of arRP families [15, 19-24, 26, 28, 30, 31, 50]. TULP1 
mutations causing arRP or LCA include two nonsense, two frame-shift, and seven splice-
site mutations; a six-base-pair duplication; and 14 missense mutations (Table 2). Splice-
site and protein-truncating mutations are distributed throughout the gene (Figure 6A), 
whereas the missense mutations are only present in the C-terminal tubby domain of 
TULP1 (Figure 6B). 
 
Figure 6. TULP1 gene, protein structure, and pathologic variants identified in patients with 
LCA and arRP. A: Gene organization and distribution of splice site variants (above the 
gene) and nonsense and frame-shift variants (below the gene). B: Protein domain structure 
of tubby-like protein 1 (TULP1) showing missense changes and a two-amino acid 
duplication in the tubby, C-terminal domain. The novel missense variant is indicated in 
bold. 
 
TULP1 mutations are a frequent cause of LCA and arRP, and therefore represent an 
attractive therapeutic target. Thus far, TULP1 mutations have been found in a total of 136 
individuals with LCA or arRP (Table 2). Through our studies, 33 additional patients with 
TULP1 mutations might benefit from genetic counseling and future gene-augmentation 
therapy. In conclusion, we were able to identify one novel (c.1445G>A; p.(Arg482Gln)) 
and one previously identified (c.1138A>G; p.(Thr380Ala)) disease-causing mutation in 
TULP1 in Pakistani families with early-onset RP. 
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Table 2. TULP1 mutations causing arRP or LCA. 
Exon/intron Mutations: Allele 1 Allele 2 Phenotype Number of families Number of cases Reference 
Intron 2, Exon 12 c.99+1G>A; p.(?) c.1204G>T; p.(Glu402*) LCA 1/179 1/179 [18] 
Intron 4, Exon 5, 10 c.350-2_350delAGA; p.(?) c.901delC; p.(Gln301Argfs*9) arRP 1/49 2/49 [22] ** 
Intron2, Exon 14 c.99+1G>A; p.(?) c.1376T>A; p.(Ile459Lys) arRP 1/536 1/536 [20] 
Intron 7 c.718+2T>C; p.(?) c.718+2T>C; p.(?) juvenile RP 2/86 286 [24] 
Exon 10 c.901C>T; p.(Gln301*) c.901C>T; p.(Gln301*) LCA 5/37 42/117 [29] 
Exons 10, 11 c.932G>A; p.(Arg311Gln) c.1025G>A; p.(Arg342Gln) arRP 1/2 2/4 [31] 
Intron 10 c.999+5G>C; p.(?) c.999+5G>C; p.(?) juvenile RP 1/86 1/86 [24] 
Exon 11 c.1102G>T; p.(Gly368Trp) c.1102G>T; p.(Gly368Trp) LCA 1/179 1/179 [18] 
Exon 12 c.1138A>G; p.(Thr380Ala) c.1138A>G; p.(Thr380Ala) LCA, early onset arRP 1/14, 1/5, 1/2 3/64, 4/23, 27/33 [14,15] and this study 
Exon 12 c.1145T>C; p.(Phe382Ser) c.1145T>C; p.(Phe382Ser) arRP 1/59 2/59 [23] 
Exon 12 c.1199G>A; p.(Arg400Gln) c.1199G>A; p.(Arg400Gln) arRP 1/34 2/34 [28] 
Exon 12 c.1198C>T; p.(Arg400Trp) c.1198C>T; p.(Arg400Trp) LCA 1/179 1/179 [18] 
Exons 13, 14 c.1259G>C; p.(Arg420Pro) c.1471T>C; p.(Phe491Leu) arRP 1/536 2/536 [20] 
Exon 14 c.1381C>G; p.(Leu461Val) c.1381C>G; p.(Leu461Val) juvenile RP 1/86 1/86 [24] 
Exon 14 c.1445G>A; p.(Arg482Gln) c.1445G>A; p.(Arg482Gln) early onset arRP 1/2 6/33 This study 
Exon 14 c.1466A>G; p.(Lys489Arg) c.1466A>G; p.(Lys489Arg) early onset arRP, arRP 4/5, 1/171 19/23, 1/171 [15,19]*** 
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Intron 14 c.1495+1G>A; p.(?) c.1495+1G>A; p.(?) arRP 2/2 33/33 [21] 
Intron 14 c.1495+2dupT; p.(?) c.1495+2dupT; p.(?) early onset arRP 1/1 3/3 [26] 
Intron 14 c.1496-6C>A; p.(?) c.1496-6C>A; p.(?) arRP 1/171 1/171 [19] 
Exons 14, 15 c.1444C>T; p.(Arp482Trp) 
c.1511_1521delTGCAGTTCGGC; 
p.(Leu504fs*140) 
early onset arRP 1/1 5/5 [50] 
Exon 15 
c.1582_1587dupTTCGCC; 
p.(Phe528_Ala529dup) 
c.1582_1587dupTTCGCC; 
p.(Phe528_Ala529dup) 
LCA 1/1 7/7 [25]**** 
**Variant labelled as c.937delC. ***Same change at protein level but labeled as c.1502G>A at the cDNA level. ****Change labelled as 
c.1593_1594TTCGCC (FA531-532dup). The variants identified in this study are marked  in bold. Patients with visual loss, nystagmus and 
night blindness after the age of six months but not later than six years are diagnosed as juvenile RP [24]. 
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Retinitis pigmentosa (RP) is a progressive retinal degeneration, which primarily affects rod 
photoreceptor cells. Typical RP features include nyctalopia, bone spicule pigmentation, 
attenuation of retinal arterioles, and reduced electroretinogram (ERG) [1]. Defects in 36 
genes are known for autosomal recessive RP (arRP) (http://www.sph.uth.tmc.edu/retnet), 
which explain the disease in about 50% of the patients [2].  
Homozygosity mapping has been very successful in identifying genetic defects in 
the Pakistani population as >80% of families show consanguinity. Homozygosity mapping 
was utilized to identify genetic defects in four consanguineous Pakistani families. Patients 
were informed about the aims and objectives of the project before obtaining consent. 
Affected persons from families RP03, RP48, and RP55 had typical features of classical RP 
(Table 1). In family RP27, early-onset RP was observed along with macular degeneration, 
which is indistinguishable from Leber congenital amaurosis, as reported previously in 
some cases (Table 1) [3]. 
Genomic DNA samples of selected persons were analyzed using whole genome 
single nucleotide polymorphism arrays (Figure 1A). Family RP27 was genotyped using the 
Illumina 6K array, while families RP03, RP48, and RP55 were analyzed on Human 
OmniExpress platforms. The genotype data were analyzed with Homozygosity Mapper 
[http://www.homozygositymapper.org], the output plots and details about the homozygous 
regions are presented in Figure 2 and Table 2 respectively. Sanger sequencing was used to 
identify causative variants and to screen the identified mutations in probands from 50 
unsolved Pakistani retinal dystrophy (RD) families to rule out founder effects. 
RP03: Of the eight homozygous regions shared by the affected persons, the second largest 
harbored a known arRP gene ABCA4 (MIM#601691). Sequence analysis revealed a 
homozygous nonsense mutation, c.6658C>T; p.(Gln2220*), segregating with the disease 
(Figure 1A). This null mutation was previously reported in a heterozygous state in a person 
with isolated cone-rod dystrophy (CRD) [4]. The genotypic results are in agreement with 
the genotype–phenotype model described for ABCA4 mutations, where two severe 
mutations, such as in RP03, can cause a severe phenotype like RP [4, 5].  
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Table 1. Clinical features of the probands with arRP or LCA 
Family 
Age at  
examination (yrs) 
Age of onset 
 (yrs) 
Fundus ERG 
VA  
(RE, LE) 
Diagnosis 
RP03 30 10-15 ARV, peripheral BSP,  
prominent macular degeneration 
Rod-cone pattern 6/60, 6/60 RP 
RP27 35 2-5 prominent macular degeneration, 
widespread BSP 
Extinguished LP Early onset RP/LCA 
RP48 33 10-20 ARV, peripheral BSP,  
macular degeneration 
Rod-cone pattern CF RP 
RP55 45 25-30 ARV, peripheral BSP,  
prominent macular degeneration 
Rod-cone pattern 6/60, 6/60 RP 
ARV, attenuated retinal vessels; BSP, bone spicule pigmentation; CF, counting finger; LE, Left eye; LP, light perception; RE, right eye; VA, visual acuity. 
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Table 2. Homozygous regions found in arRP/LCA families 
Family Chr. Flanking SNPs Region in Mbp (hg19) Size in Mb Ranking ArRP/LCA-associated genes 
RP03 
1 rs743117;rs716581 94.4-102.3 7.9 2 ABCA4 
2 rs20349;rs17722726 134.6-137.6 3.0 7 - 
4 rs730349;rs936232 21.2-25.8 4.6 5 - 
4 rs543337;rs1461605 82.7-92.0 9.3 1 - 
6 rs2894891;rs1475270 100.2-106.7 6.5 3 - 
7 rs4728251;rs1424376 131.8-137.7 5.9 4 - 
14 rs1007813;rs9324014 96.0-100.2 4.2 6 - 
14 rs17172;rs872945 101.4-103.5 2.1 8 - 
RP27 
6 rs875590;rs9364286 166.1-169.2 3.1 4 - 
8 rs753012;rs115429695 8.9-11.8 2.9 5 - 
17 rs7221818;rs1860300 5.8-11.1 5.3 1 AIPLI, GUCY2D 
17 rs2017167;rs34727469 32.5-36.8 4.3 3 - 
21 rs1892687;rs13625 36.3-40.6 4.3 2 - 
RP48 2 rs6734093;rs12693396 182.2-185.7 3.5 1 CERKL 
RP55 5 rs7711546;rs10515714 143.6-154.9 11.3 1 PDE6A 
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RP27: The largest homozygous region contained two known arLCA genes, i.e. AIPL1 
(MIM#604392) and GUCY2D (MIM#600179). Sequencing of all exons of GUCY2D 
revealed no variation. Sequencing of AIPL1 revealed a nonsense mutation, c.834G>A; 
p.(Trp278*), which is the most common AIPL1 mutation described worldwide, including 
Pakistan [3]. 
RP48: A single homozygous region on chromosome 2 was identified, that encompassed a 
known arRP gene CERKL (MIM#608381). Sequence analysis of CERKL revealed a 
nonsense mutation, c.847C>T; p.(Arg283*), which was first identified in two Spanish 
families and 7 other probands with arRP [6]. 
RP55: A single homozygous region on chromosome 5 was observed, which contained 
PDE6A (MIM#180071). Sequence analysis revealed a novel homozygous missense 
variant, c.1630C>T; p.(Arg544Trp), segregating with the disease (Figure 1A). Eighteen 
different mutations have been reported in PDE6A, the majority (56%; 10/18) are missense 
[7]. The variant was considered to be likely pathogenic as it was not detected in 80 
ethnically matched controls, and online prediction tools (PolyPhen2 and SIFT) predict it to 
be damaging. Homology based protein modeling analysis of mutant and wild type proteins 
indicate that the mutation likely disrupts the hydrogen and ionic interactions between the 
monomers and will destabilize the structure and affect the function of protein (Figure 1B).  
In conclusion, through homozygosity mapping and sequence analysis, we were able 
to identify the genetic defects in 55% Pakistani RD families. The identification of genetic 
defects will not only be helpful in genetic counseling but will also be beneficial in 
selecting patients that are eligible for gene therapy in near future. 
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Figure 1A. Pedigree structure of retinal dystrophy families and segregation analysis of 
pathological variants. M1 (ABCA4; c.6658C>T; p.(Gln2220*)), M2 (AIPL1; c.834G>A; 
p.(Trp278*)), M3 (CERKL; c.847C>T; p.(Arg283*)), M4 (PDE6A; c.1630C>T; 
p.(Arg544Trp)). Individuals genotyped using whole genome SNP arrays are marked with 
asterisks. Arrows point to the probands. Figure 1B. Three dimensional (3D) structure of 
heterotetrameric complex, cyclic guanosine monophosphate phosphodiesterase (cGMP-
PDE). I: Structure of PDE6A (gray) and PDE6B (tan) protein complex in the native 
conformation. Arg544 is colored green. II: Part of PDE complex showing the location of 
the mutant residue, on the surface, close to the monomer interaction site. II: Close-up of 
the mutation. Wild-type and mutant residues are shown and coloured green and red, 
respectively. Yellow dots indicate the hydrogen bond formed by the wild-type residue, 
which will be lost due to the mutation. 
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Figure 2. Output of Homozygosity Mapper for four arRP families. The numbers on the top indicate the chromosomes.Bars extending above 
0.8 represents putative homozygous regions in all affecetd individuals. 
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ABSTRACT 
Purpose: To describe two novel mutations in the Eyes shut homolog (EYS) gene in two 
families with autosomal recessive retinitis pigmentosa (arRP) from Pakistan and Indonesia. 
Methods: Genome-wide linkage and homozygosity mapping was performed using single 
nucleotide polymorphism (SNP) microarray analysis in affected members of the two arRP 
families. Sequence analysis was performed to identify genetic changes in protein coding 
exons of EYS. 
Results: In the Indonesian and Pakistani families, homozygous regions encompassing the 
EYS gene at 6q12 were identified, with maximum LOD scores of 1.8 and 3.6, respectively. 
Novel missense variants in the EYS gene p.(Asp2767Tyr) and p.(Asp3028Tyr) were found 
in the Pakistani and Indonesian families, respectively, that co-segregate with the disease 
phenotype. Interestingly, the missense variants are located at the same homologous 
position within the 4th and 5th laminin A G-like domains of EYS. 
Conclusions: To date, mostly protein truncating mutations have been described in EYS, 
while only very few patients have been described with pathogenic compound heterozygous 
missense mutations. The mutations p.(Asp2767Tyr) and p.(Asp3028Tyr) described in this 
study affect highly conserved residues at homologous positions in laminin A G-like 
domains and support the notion that missense mutations in EYS can cause arRP. 
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INTRODUCTION 
The term retinitis pigmentosa (RP) describes a clinically diverse and genetically 
heterogeneous group of progressive hereditary degenerative disorders with a worldwide 
prevalence of approximately 1 in 4000 individuals [1-3]. RP is characterized by nyctalopia, 
progressive mid-peripheral visual field loss, and at later stages involvement of the macula 
and complete loss of visual acuity [4]. The clinical diagnosis of RP relies upon the bilateral 
presence of intraretinal pigment deposits, commonly known as bone spicules, attenuation 
of retinal vessels, atrophy of the peripheral retinal pigmented epithelium and waxy pallor 
of the optic disc [4].  
RP is familial in about 60% of the cases, and can present all documented forms of 
inheritance [3]. To date, 45 causative genes and 9 loci have been identified 
(http://www.sph.uth.tmc.edu/retnet/). Twenty-seven genes have been identified for the 
autosomal recessive form of RP (arRP) which together are believed to account for ~50% of 
all the cases [5]. Most of these genes account for 1-2% of arRP cases, while ABCA4, EYS 
and USH2A seem to be more frequently mutated in arRP patients [2,6-8]. 
EYS [OMIM 612424], a gene that is expressed specifically in the retina, has been 
implicated in the pathology of arRP two years ago [7,8]. Recent reports suggest a global 
involvement of EYS, with a high prevalence of protein-truncating mutations in this gene [9-
12]. In the present study, we report two families from Pakistan and Indonesia that harbor 
homozygous missense mutations in EYS. 
 
METHODS 
Patients and clinical evaluation: The present study comprises two consanguineous 
families with arRP. Family RP50 (Figure 1A) was collected from the Punjab region of 
Pakistan, while family W09-0046 (Figure 1B) was from the Java island of Indonesia. This 
study was approved by the institutional review boards of the respective institutions and 
was conducted in accordance with the Declaration of Helsinki. 
The initial diagnostic criterion used for the recruitment of patients was the presence 
of night blindness. One affected proband and one normal individual from each family were 
selected for detailed clinical examination including fundoscopy and electroretinography 
(ERG). ERG recordings were performed in accordance with the guidelines provided by the 
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International Society for Clinical Electrophysiology of Vision (ISCEV) using a monopolar 
contact lens electrode (LKC Inc., Gaithersburg, MD) [13]. 
Genetic studies: DNA was extracted from peripheral blood using a standard protocol [14]. 
Genomic DNA of four affected individuals from family RP50 (Figure 1A) and two 
affected individuals from family W09-0046 (Figure 1B) were analyzed using Illumina 6K 
single nucleotide polymorphism (SNP) arrays that contain 6,090 SNP markers (Illumina., 
Inc., San Diego, CA, USA). To identify regions that might harbor the genetic defects in the 
two families, linkage analysis was performed using the Gene Hunter program (version 
2.1r5) in the easyLinkage plus software package (version 5.08) [15]. 
One affected individual from each family was selected for mutation analysis. All 44 
exons and the flanking intronic sequences of EYS were amplified using the polymerase 
chain reaction (PCR) utilizing the primers described previously [7]. The amplicons were 
subsequently analyzed by sequencing using dye termination chemistry (BigDye 
Terminator, version 1.1 on a 3730 DNA analyzer; Applied Biosystems Inc, Foster City, 
CA, USA). Segregation analysis was performed for the variants identified by sequence 
analysis. Restriction fragment length polymorphism (RFLP) analysis and amplification 
refractory mutation detection system (ARMS)-PCR were performed in controls and 
additional arRP patients to analyze the presence of sequence variants identified in this 
study. For the mutation detected in family RP50, a 510 bp product containing exon 44 was 
amplified for restriction digestion using primers ex44F: 5’-CAC AAT TGT GCT CAA 
GAT CTG-3’ and ex44R: 5’-TAC ATT TGA GCC ACC TTT TGC-3’. Restriction 
digestion with HphI yields two fragments of 130 and 380 bp for the wild type allele, while 
the mutant allele remains undigested. For the mutation in family W09-0046, an ARMS-
PCR was performed to screen 90 ethnically matched controls using the wild-type specific 
primer 5’-GGATGGGAATAGCTCAAAATGAAGAAAACG-3’ or the mutant allele 
specific 5’-GGATGGGAATAGCTCAAAATGAAGAAAACT-3’ primer, together with 
the common reverse primer 5-’GTTTAGAGCCACAAAGTTTTTATGTGGATC-3’. 
Various web-based bioinformatic tools were used to assess the pathogenic potential 
of the missense variants identified in this study, including project Hope 
(http://www.cmbi.ru.nl/hope/), Polymorphism Phenotyping (PolyPhen, 
http://genetics.bwh.harvard.edu/pph/index.html) and Sorting Intolerant From Tolerant 
(SIFT, http://sift.jcvi.org). To assess the evolutionary conservation, amino acid sequences 
of orthologous EYS proteins (XP_001918194, XP_001505792.1, XP_426198.2, 
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NP_001027571.2) and of the homologous human protein Laminin alpha 1 (LAMA1, 
XP_944360) were obtained from NCBI protein database 
http://www.ncbi.nlm.nih.gov/protein and were aligned with the protein sequence of human 
EYS using Vector NTI software (version 11).  
 
RESULTS 
Family RP50 (Figure 1A) consists of five generations with 7 affected individuals, one of 
which has deceased. All patients presented with night blindness that started early in the 
second decade of life. Fundus examinations revealed bone spicules at the retinal periphery, 
and attenuation of retinal vasculature (Figure 2A,B). The scotopic ERG, which represents 
the rod response, is more diminished compared to the photopic ERG, indicating a typical 
rod-cone dystrophy (Table 1). The low visual acuity (VA) in these patients is suggestive of 
macular involvement. The macular degeneration is vigorously progressive as indicated by 
significant loss of VA in less than two years (Table 2). 
 
Figure 1. Pedigree structure and segregation analysis of mutations in families. (A) Family 
RP50; M represents c.8299G>T. (B) Family W09-0046; M represents c.9082G>T. 
Genotypes are indicated below the genetic symbols. Asterisks indicate the individuals that 
were analyzed on SNP arrays. 
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Figure 2. Fundus photographs of arRP patients. Fundus photographs of the right eyes from 
affected individuals IV:4 (A)  and IV:6 (B) of family RP50. Age at the time of 
investigation of individuals IV:4 and IV:6  were 40 and 38 respectively. Bone spicule 
pigmentation at the retinal periphery, attenuation of retinal vasculature, and macular 
degeneration are evident in both cases.  
 
Table 1. ERG response comparison between affected and normal individual of family RP50 
 Adaptation 
Flash  
strength 
IV:6 IV:8 
Normal  
values* 
Scotopic 25 dB b-wave amplitude (µV) Dark 0.01 (cds/m2) 12.6 175.5 >141 
Scotopic 0 dB b-wave amplitude (µV) Dark 3.0 (cds/m2) 38.6 469.4 >387 
Oscillatory potential amplitude (µV) Dark 3.0 (cds/m2) 133.1 284.9 >75 
Photopic 0 dB b-wave amplitude (µV) Light 3.0 (cds/m2) 32.4 156.7 >82 
Photopic 30 Hz flicker amplitude (µV) Light 3.0 (cds/m2) 28.5 92.1 >56 
*Normal values at 30-40 years of age. Age at the time of investigation of individual IV:6 
(affected) and IV:8 (normal) were 38 and 32, respectively. 
 
Family W09-0046 (Figure 1B) consists of four generations with two affected and two 
healthy individuals that were available for genotyping. Onset of the night blindness was at 
adolescence, whereas fundus examination revealed bone spicules and arterial attenuation 
(no fundus picture available). All patients had a very low visual acuity.  
Genome-wide linkage analysis in four affected individuals (III:7, IV:6, V:1, V:2) 
from family RP50 revealed only one region with a significant LOD score of 3.6. The 
region spans 25.2 Mb between rs283545 and rs2998367, and encompasses the EYS gene 
(Table 3). A similar analysis in two affected individuals (IV:3, IV:4) from family W09-
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0046 revealed three regions with a maximum LOD-score of 1.8 (Table 3). The largest of 
these homozygous regions (69.5 Mb; flanked by rs2763122 and rs1486039) also 
encompasses the EYS gene. 
Table 2. Clinical characteristics of families RP50 and W09-0046 
 
Visual Acuity (unaided) 
At current age At the time of diagnosis 
Family Patient Age Gender Age of Onset RE (OD) LE (OS) RE (OD) LE (OS) 
RP50 
IV:4 42 Female 12-15 20/630 20/630 20/400 20/400 
IV:6 40 Male 12-15 20/125 20/400 20/125 20/125 
W09-0046 
IV:3 48 Male 16-18 ND ND 20/400 20/400 
IV:4 42 Male 16-18 ND ND 20/400 20/400 
Results at current age is indicated in the table while the age at the time of diagnosis for 
individuals IV:4 and IV:6 from RP50 were 40 and 38 years and for IV:3 and IV:4 from 
family W09-0046, were 46 and 40, respectively. ND = not determined, RE= right eye, LE= 
left eye.  
 
Table 3. Linkage analysis of families RP50 and W09-0046 
Family Chr. LOD Flanking SNPs hg18 position (Mb) 
RP50 6 3.6 rs283545; rs508367 51,07-76,27 
 10 3.1 rs2394829; rs703990 73,01-80,60 
W09-0046 5 1.8 rs444984; rs1030154 154,43 – 164,98 
 6 1.8 rs2763122; rs1486039 7,42- 76,96 
 16 1.8 rs741175; rs2925508 11,07-18,77 
 
Sequence analysis of all 44 exons and flanking intronic regions of EYS revealed novel 
homozygous missense mutations, c.8299G>T; p.(Asp2767Tyr), and c.9082G>T; 
p.(Asp3028Tyr), in the probands of families RP50 and W09-0046, respectively (Figure 3). 
Sequence analysis in all relatives available for genotyping indicated that the two missense 
mutations segregate with the disease in the respective families (Figure 1). Missense 
mutation p.(Asp2767Tyr) was not found in a panel of 81 Pakistani probands affected with 
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RP. Likewise, this variant was not found in 90 ethnically matched control individuals from 
Pakistan. ARMS analysis for the missense mutation p.(Asp3028Tyr) in 90 controls from 
the Indonesian population also yielded no carrier of the mutation. 
 
Figure 3. EYS mutation analysis. Sequence chromatograms of EYS mutations in normal 
(A, C) and affected (B, D) individuals of families RP50 and W09-0046 respectively. The 
encoded amino acids are indicated above the respective codons. The substituted 
nucleotides are indicated by arrows. 
 
In-silico analysis:  
Intriguingly, at the protein level, the aspartic acid (D) residues at positions 2767 and 3028 
that are mutated in the Pakistani and Indonesian family, are located at homologous 
positions in the 4th and 5th laminin A G-like domain of EYS (Figure 4A). Both missense 
changes result in the substitution of a tyrosine residue (Y) for an aspartic acid (D). The 
wild type aspartic acid, being negatively charged and hydrophilic, might be involved in the 
ionic interactions at the surface, whereas the tyrosine it is substituted for is an uncharged 
and less hydrophilic residue. As such, the missense changes might abolish ionic 
interactions or alter protein conformation. In an alignment of laminin A G-like domains of 
5 EYS orthologous proteins, the aspartic acid residues D2767 and D3028 in the 4th and 5th 
laminin A G-like (Figure 4B) domains of human EYS are conserved in 17 of 19 
homologous sequences. In addition, in most of the laminin G domains from the human 
laminin alpha 1 (LAMA1) protein an aspartic acid residue is present at the same position 
within these domains (Figure 4B). These data suggest that the presence of an aspartic acid 
residue at that position in the laminin A G-like domains is very important for the proper 
functioning of these domains. 
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Figure 4. Domain architecture and amino acid sequence comparison of EYS orthologues. 
(A) Domain architecture of human EYS, indicating the position of mutations in the 
functional domains. c.8299G>T; p.(Asp2767Tyr) lies in 4th while c.9082G>T; 
p.(Asp3028Tyr) lies in the 5th laminin A G-like domain. (B) Sequence comparison of 
laminin A G-like domains of EYS and its orthologues and human laminin alpha 1 
(LAMA1). The arrow indicates the position of the mutated aspartic acid residue in the 
alignment. 
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DISCUSSION  
In the present study we describe two homozygous missense mutations in the EYS gene 
which has recently been identified as the mutated gene at the RP25 locus at 6p12.1-q15 
[7,8]. The RP25 locus was designated to be a major locus for arRP as ~20% of the Spanish 
arRP families and many other families were linked to this locus [16]. Numerous EYS 
mutations have recently been identified in ~5-10% of arRP patients from different ethnic 
backgrounds [7,8,10-12]. 
EYS spans 2 Mb of genomic DNA and to date is the largest gene identified to be 
specifically expressed in the retina. Immunolocalization studies in the adult pig retina 
revealed that EYS is present only in the outer photoreceptor cell layer where it is confined 
to the rod outer segments along with rhodopsin [8]. The function of EYS in the human 
retina is not yet established but its ortholog in Drosophila, known as eyes shut or 
spacemaker, is involved in luminal space formation, that optically isolates neighboring 
rhabdomers from photoreceptor cells in the compound eye and thus enable each 
photoreceptor to act as an independent optical unit [7,8,17]. In Drosophila, the absence of 
EYS functionally results in “photoreceptor fusion”, a structure that resembles the 
“primitive” ommatidium in most insects like ants and bees [17,18]. To form the open 
rhabdomer configuration, EYS needs to interact with Prom1, another protein implicated in 
arRP, and absence of any of these proteins results in a closed rhabdomer formation [18]. In 
a Prom1-/- mouse model, the absence of Prom1 leads to progressive degeneration of cone 
and rod photoreceptors due to impaired morphogenesis of the photoreceptor disks. It is 
therefore thought that human EYS is also involved in correct morphogenesis of 
photoreceptors [18-20]. 
EYS consists of 21 epidermal growth factor (EGF) like domains at the amino 
terminus, followed by five carboxy terminal laminin A G-like domains with alternating 
EGF like domains [7,8]. The conserved domain database reveals that in EYS orthologues, 
the laminin A G-like domain architecture is well conserved, although the different 
orthologous EYS proteins have variable numbers of these domains. Given the similarities 
in sequence and domain architecture of EYS compared to laminin proteins, we speculate 
that in vivo EYS might attain a structure similar to the laminin G (LG) domain complex. 
Laminin-1, one of the two basic components of basement membranes, forms a cruciform 
structure, with three laminin chains α, β, and γ, arranged in heterotrimeric geometry. The 
α-chain of laminin-1 forms an extended structure and, like EYS, carries five globular 
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domains at its C-terminus, termed LG domains. These LG domains form a sandwich 
structure where LG1-LG3 attain a clover leaf arrangement, which is connected through a 
small linker to the C-terminal LG domain pair formed by the LG4 and LG5, with LG4 
being positioned at the distal end [21,22]. This LG domain complex in laminin forms the 
receptor binding site, where LG1-LG3 binds integrin while the LG4-LG5 pair binds the 
transmembrane glycoprotein dystroglycan (DG). Considering this, and the in-silico 
prediction of the mutations we identified in the 4th and 5th LG domains of EYS, our data 
suggest that these mutations might impair the interaction of EYS with putative cellular 
partners. 
The novel missense mutations identified here are conspicuously located at the same 
homologous position in laminin A G-like domains of EYS, while most of the previously 
identified pathogenic mutations are protein truncating [7,8,11]. Recently, compound 
heterozygous missense mutations p.(Cys2139Tyr) and p.(Gly2186Glu) have been 
described in a Chinese family, while another missense variant p.(Arg589Gly) was found in 
conjunction with a protein truncating mutation p.(Tyr2555*) in a sporadic RP patient [10]. 
The variant p.(Cys2139Tyr) resides in the 21st EGF like domain of the EYS, while 
p.(Gly2186Glu) is located in the 2nd laminin A G-like domain. The alignment of the 
laminin A G-like domains indicates that p.(Gly2186) is not fully conserved in all the other 
laminin domains, neither of EYS nor of laminin alpha (data not shown). Audo et al. 
described novel EYS variants in 29 families, but only in one family, compound 
heterozygous missense mutations p.(Ile1232Phe) and p.(Leu1869Met) were identified on 
two different alleles [12]. Both mutations are not located in any of the functional domains 
of EYS. Several other missense variants were found heterozygously and not conclusively 
considered pathogenic or were not shown to segregate via different alleles [12]. The 
p.(Asp2767Tyr) and p.(Asp3028Tyr) mutations in our study are the first homozygous 
missense variants that independently show pathogenic potential. Based on the maximal 
LOD-score of 1.8, however we cannot be completely certain that the EYS variant 
c.9082G>T; p.(Asp3028Tyr) in family W09-0046 is causative. 
Taken together, our data not only reveal the importance of the laminin A G-like 
domains in the functioning of the EYS protein, but also the critical role of the mutated 
residue aspartic acid for laminin A G-like domains.  In addition, the identification of novel 
EYS mutations in the Pakistani and Indonesian population further supports a global 
involvement of EYS mutations as a cause of arRP. 
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ABSTRACT 
Purpose: To identify the underlying genetic defect in a consanguineous Pakistani family 
with autosomal recessive RP (arRP).  
Methods:  
Ophthalmologic analysis was performed in selected persons, including visual acuity 
assessment, fundoscopy and electroretinography. Genome-wide homozygosity mapping 
was performed for two affected and three unaffected individuals using single nucleotide 
polymorphism arrays. After exclusion of retinal candidate genes residing in homozygous 
regions, the proband was analyzed using exome sequencing. Pathogenicity of the candidate 
disease-causing variants in the homozygous regions was assessed by in-silico analysis.  
Results: Ophthalmologic examination revealed typical features of RP. A homozygous 
missense variant (c.3269G>A; p.(Arg1090Gln)) was identified in SNRNP200, which has 
previously only been associated with autosomal dominant RP (adRP). Segregation analysis 
indicated that the variant segregates with the disease in the family in an autosomal 
recessive manner.  
Conclusions: The SNRNP200 variant p.(Arg1090Gln) affects the same amino acid residue 
as a known adRP-associated mutation, p.(Arg1090Leu), which has been shown to impair 
splicing by disrupting the unwinding of the tri-snRNP complex. In-silico analysis also 
supported the causality of the p.(Arg1090Gln) mutation. Since this mutation appears only 
to be causative when present in a homozygous state, we hypothesize that p.(Arg1090Gln) 
is a hypomorphic mutation, which would be the first autosomal recessive RD-associated 
defect in the splicing machinery. 
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INTRODUCTION 
Splicing is mediated by a spliceosome complex composed of specialized RNAs and 
associated proteins (U1, U2, U4, U5 and U6) called small nuclear ribonucleoproteins 
(snRNPs) [1]. Mutations in the constituents of the splicing machinery or other associated 
components would be expected to affect the expression of a large number of genes. 
Strikingly, in the majority of cases such mutations cause tissue-specific pathogenesis [2]. 
Similarly, mutations in the core spliceosome components are thought to be lethal, but 
mutations in genes encoding components of pre-mRNA splicing factors (PRPF3, PRPF6, 
PRPF8, PRPF31, RP9 and SNRNP200) solely cause non-syndromic autosomal dominant 
(ad) retinitis pigmentosa (RP) [2, 3]. RP is a progressive inherited retinal disease that 
initially involves rod photoreceptor cell degeneration and is clinically characterized by 
nyctalopia in early stages, bone spicule pigmentation in the periphery, reduced 
electroretinogram (ERG) response and tunnel vision or complete blindness in later stages. 
All pre-mRNA splicing factors implicated in RP are components of a spliceosome subunit 
called the U4/U5/U6 tri-snRNP complex, which forms the catalytic core for intron excision 
[2]. The retinal phenotype has been modeled by gene knock-down in zebrafish, in which a 
genome-wide transcriptome analysis revealed that the most severely affected transcripts 
correspond to genes expressed in the retina [4]. Studies in genetically modified mice 
suggest that the RPE might be the primary cell type affected by defective spliceosome 
components, and the aberrantly spliced gene products are toxic, thus leading to retinal 
degeneration [5]. These splice factor genes SNRNP200 codes for hBRR2, which is part of 
the U5 snRNP, which together with U4 and U6 aligns the RNA for intron excision [1, 3]. 
Therefore, a mutation that affects this complex formation may result in intron retention of 
the mRNA. As intron retention frequently introduces nonsense codons, such mRNAs may 
be subjected to nonsense-mediated degradation, and hence the protein product will be 
absent.  
In this study, we identified a hypomorphic SNRNP200 mutation that affects the 
same amino acid residue previously mutated in persons with adRP, and segregates with 
autosomal recessive RP in a Pakistani family. 
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METHODS 
Patients and clinical evaluation: The present study was approved by the institutional 
review board of the Shifa College of Medicine, Islamabad, Pakistan. Informed consent was 
obtained from the participants before blood was obtained by venipuncture. DNA was 
extracted by a standard phenol-chloroform method [6]. Ophthalmologic examination was 
performed for multiple individuals and included visual acuity assessment and fundoscopy. 
Electroretinography (ERG) was performed according to the standard protocol described by 
the International Society for Clinical Electrophysiology of Vision (ISCEV) [7].  
Genotype analysis and homozygosity mapping: Genomic DNA of two affected (IV:7 and 
V:4) and two normal individuals (IV:6 and V:2) were analyzed using Illumina 6K single 
nucleotide polymorphism (SNP) arrays (Figure 1). To determine the homozygous genomic 
segments that are shared between affected individuals, the online tool Homozygosity 
Mapper was used to analyze the SNP array data [8]. Genes that are known to be associated 
with non-syndromic autosomal recessive retinal dystrophies and present in homozygous 
regions, were analyzed by Sanger sequencing.  
Exome sequencing: For one affected individual (IV:7), all the exons in the genome were 
analyzed by next generation sequencing (exome NGS) methodology to find the causative 
variant. Enrichment was done with the Agilent’s SureSelectXT Human All Exon v.2 kit 
(50MB), that captures exonic sequences of about 21,000 genes (Agilent Technologies, Inc. 
Santa Clara, CA). Sequencing was performed on a 5500xl Genetic Analyzer platform (Life 
Technologies, Bleiswijk, Netherlands). Sequence reads were aligned to the human genome 
(hg19) using Lifescope v2.1 (Life Technologies, Bleiswijk, Netherlands), followed by 
variant calling on the aligned sequence by implying DiBayes algorithm and SOLiD Small 
Indel Tool. Exonic variants in the largest homozygous regions were prioritized based on 
nucleotide (PhyloP) and protein conservation (multiple sequence alignment) [9]. An 
independent genome-wide variant filtration step was also performed to rule out the 
involvement of other putatively pathogenic variants outside of the homozygous regions. In 
addition, various online tools were utilized to assess the pathogenicity of potentially 
pathogenic missense variants, which include sorting intolerant from tolerant (SIFT) 
analysis and polymorphism phenotyping v2 (Polyphen-2), and have your protein explained 
(HOPE) [10-12]. 
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RESULTS 
Ophthalmologic examination of the affected proband revealed typical features of retinitis 
pigmentosa (Figure 1 and Table 1), such as attenuated retinal vessels, waxy pallor of the 
optic disks, and peripheral bone spicule pigmentation [13]. ERG patterns were also 
suggestive of rod-cone disease (data not shown), as the scotopic ERG responses, which 
represent the activity of rod photoreceptors, were more severely affected than cone 
photoreceptor derived photopic responses [7]. 
 
 
Figure 1. Pedigree of arRP family, mutation segregation, and fundoscopic analysis. (A) 
Pedigree structure and segregation of mutation (c.3269G>A; p.(Arg1090Gln)) in 
autosomal recessive retinitis pigmentosa family RP29. The arrow denotes the proband; 
asterisks indicates individuals genotyped with single nucleotide polymorphism (SNP) 
microarrays. (B) Fundus photographs of the proband (V:4) and a normal (V:2) sib of 
family RP29. Examination of the fundi revealed bone spicule pigmentation at the periphery 
(arrows), attenuated retinal vessels (arrowheads), and macular degeneration (open arrow) 
in the affected individual V:4. 
 
Homozygosity mapping analysis revealed 18 homozygous regions larger than 2 Mb that 
were shared by the affected individuals and not present in the unaffected relatives (Table 
2). The largest of these regions on chromosome 2 contained the CNGA3 gene, previously 
implicated in achromatopsia, a congenital cone disorder (CD) characterized by 
photophobia, reduced visual acuity, nystagmus and inability to discriminate between colors 
[14-16]. Sequence analysis of CNGA3 did not yield any potentially pathological change in 
the coding sequence [15, 16]. 
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Table 1. Clinical features of the affected and normal individuals of family RP29 
Individual 
Age at examination 
(years) 
Age of onset 
(years) 
Fundus ERG 
VA 
both eyes 
Diagnosis 
IV:2 43 NA 
Normal retinal vessels 
and macula 
ND Normal Normal 
IV:7 27 10-15 
Attenuated retinal vessels,  
peripheral bone spicule pigmentation, 
macular degeneration 
ND CF RP 
V:2 18 NA 
Normal retinal vessels, 
and  macula 
Normal Normal Normal 
V:4 15 10-20 
Attenuated retinal vessels,  
peripheral bone spicule pigmentation 
Rod-cone pattern 6/60 RP 
CF, counting fingers; ERG, electroretinography; NA, not applicable; ND, not determined; RP, retinitis pigmentosa; VA, visual acuity. 
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The second (14.3 Mb) and third (12.9 Mb) largest regions, both on chromosome 10, 
contained the arRP-associated gene RGR and the arCD-associated gene PDE6C, 
respectively. Sequence analysis of RGR and PDE6C did not reveal any causative variant in 
the coding regions. Other genes associated with either syndromic or non-syndromic 
inherited RD, present in the homozygous regions, included DFNB31 (12 exons), KLHL7 
(11 exons), PAX2 (11 exons), RBP4 (5 exons), SNRNP200 (45 exons), and USH1C (21 
exons).  
Exome NGS of one affected individual yielded a total of 43,732 variants, 5,143 of 
which were not present in SNP databases. There were 840 non-synonymous exonic 
variants, of which 12 were present in one of the homozygous regions. Only 6 of the 12 
variants had a PhyloP score >2.0, and three of these variants were predicted to interrupt a 
protein domain. One of the homozygous missense variants (c.3269G>A; p.(Arg1090Gln)) 
affects a protein domain in the adRP-associated gene SNRNP200. This gene resides within 
the largest (14.6 Mb) homozygous region identified in family RP29. 
Filtering independent of homozygous regions yielded 733 homozygous variants 
that were not present in dbSNP, of which 105 were non-synonymous. Only 42 variants had 
a PhyloP >2, and 23 of these were found in less than 0.5% of our in house exome variant 
database (1,154 exomes). The variant in SNRNP200, c.3269G>A; p.(Arg1090Gln), ranked 
third among these variants when sorted by PhyloP scores. The first and second ranked 
variants were in genes ATP6V0A2 (MIM: 611716) and GBF1 (MIM: 603698) respectively, 
but they were outside of any functional domain. In addition, PolyPhen-2 and SIFT predict 
the SNRNP200 variant to be damaging (score 1) and deleterious, respectively. 
Sequence analysis of the variant in the family revealed that it segregates with the RP 
phenotype in an autosomal recessive manner (Figure 1). The variant is not present in the 
exome variant server (URL: http://evs.gs.washington.edu/EVS/ accessed 12 December 
2012), which contains exome data of 6,500 individuals. In addition, the variant is absent 
from 1000 genomes, our in-house exome variant database (containing exome data of 1,154 
individuals), and 180 population-matched control individuals. The variant also was not 
present in probands of 50 other unsolved retinal dystrophy families from Pakistan. 
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Table 2. Homozygous regions >2 Mb, obtained for family RP29 
Chr. Flanking SNPs 
Chromosomal position 
(hg19, Mb) 
Size of homozygous 
regions (Mb) 
Ranking of 
Homozygous region 
Genes associated with 
non-syndromic arRD 
2 rs1015117;rs1567804 86,7-101,3 14,6 1 CNGA3 (arACHM) 
10 rs2227551;rs2039305 75,6-89,9 14,3 2 RGR (arRP) 
10 rs7094359;rs6580 92,3-105,2 12,9 3 PDE6C (arCD/ACHM) 
20 rs6049970;rs764597 24,8-33,2 8,4 4 NA 
7 rs2906667;rs1568658 21,8-29,1 7,3 5 NA 
10 rs907;rs16927648 64,9-72,2 7,3 6 NA 
9 rs1407392;rs1060545 112,4-117,8 5,4 7 NA 
12 rs9300302;rs4883148 3,9-8,6 4,7 8 NA 
11 rs10832503;rs961746 15,7-20,2 4,5 9 NA 
15 rs1122702;rs288394 93,8-98,1 4,3 10 NA 
13 rs1334857;rs9582993 84,5-88,8 4,3 11 NA 
13 rs7981931;rs1556800 96,9-100,8 3,9 12 NA 
2 rs925229;rs3792253 24,2-28,0 3,8 13 NA 
1 rs488595;rs485874 15,7-19,1 3,4 14 NA 
5 rs728693;rs9216 156,8-159,8 3,0 15 NA 
20 rs761461;rs1007272 18,3-20,9 2,6 16 NA 
18 rs715351;rs923641 61,2-63,9 2,7 17 NA 
7 rs1860482;rs963314 145,4-147,8 2,4 18 NA 
ACHM, achromatopsia; ar, autosomal recessive; CD, cone dystrophy; NA, not applicable; RD, retinal dystrophy; RP, retinitis pigmentosa.  
Genes in bold were analyzed by Sanger sequencing. 
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DISCUSSION 
In a three-generation pedigree with arRP, homozygosity mapping and exome sequencing 
revealed a homozygous missense variant (c.3269G>A; p.(Arg1090Gln)) in SNRNP200. 
This gene encodes Brr2, a homolog of yeast Brr2p, that is part of the spliceosome complex 
[1].  The variant segregates with the phenotype in the pedigree (composed of two affected 
and 9 unaffected family members) and was not present in population-matched controls 
(n=180), 6,500 Caucasian individuals, 1000 genomes and in 1,154 predominantly Dutch 
exomes.  
Intriguingly, this variant overlaps with a known adRP-associated mutation 
(c.3269G>T; p.(Arg1090Leu)), that was identified in a Chinese family with 12 affected 
individuals [17]. In vitro functional assays performed in yeast using a Brr2p construct 
containing the equivalent of the human p.(Arg1090Leu) mutation revealed splicing 
impairment, supporting the causality of that mutation [3].  
The crystal structure of human Brr2 (hBrr2) indicates that Arg1090 is located in the 
ratchet helix of the helical bundle domain (HB), which forms a unidirectional tunnel for 
RNA molecules thereby promoting directional and processive unwinding of RNA. In this 
structure, the Arg1090 residue seems to be in direct contact with the RNA molecule, and 
mutation of this residue may disrupt the duplex unwinding activity of hBrr2 [1, 3, 18]. The 
p.(Arg1090Leu) variant identified in the adRP family changes a polar and basic amino acid 
arginine to a nonpolar and hydrophobic leucine residue (Grantham distance 102), while in 
the arRP family it changes to an uncharged yet polar glutamine residue (Grantham distance 
43). We therefore hypothesize that the arRP variant represents a hypomorphic mutation, 
which is only pathogenic when present in homozygous state (Figure 2). Considering that 
an overlapping mutation causes adRP, p.(Arg1090Gln) likely impairs the unwinding of tri-
snRNP complex to a lesser degree than the adRP variant. 
This is the first report that links a defect in the splicing machinery with autosomal 
recessive retinal degeneration. Previously, for all the splicing factors the pathological 
mechanism for adRP was described to be defective triple-snRNP assembly or U4/U6 
unwinding, that in principle reduces splicing efficiency [4]. Similarly for SNRNP200 
associated adRP, the molecular basis for disease is considered to be insufficient activation 
of hBrr2 helicase activity, that impairs Brr2 dependent U4/U6 duplex unwinding [1, 3]. 
Thus it appears that reduced activity of hBrr2 underlies RP [4, 19, 20]. So far, only 
heterozygous missense mutations have been identified in SNRNP200 (Figure 3). The same 
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is true for the other adRP-associated genes RP9, PRPF3 and PRPF6. For PRPF8, the 
majority (i.e. 12 of 19) of the mutations are heterozygous missense changes while the 
remaining are frameshift mutations, which are conspicuously clustered in the last exon (i.e. 
exon 43) [3, 17, 21-29]. Based on this position, nonsense-mediated decay (NMD) of 
PRPF8 mRNA is not expected to occur [29, 30]. We hypothesize that all mutations 
reported in these five genes are hypomorphic variants resulting in relatively mild 
deficiencies of the respective splice factors [3, 17, 21, 22, 31]. In contrast to the other 
components of the U4/U5/U6 tri-snRNP complex, the mutation spectrum of PRPF31 
encompasses deletions (i.e. 26 of 52 mutations), some of which span the entire gene, splice 
variants, missense and nonsense variants [31-36]. Despite diverse mutational spectrum 
studies in zebrafish and mouse models support a haploinsufficiency disease model for 
PRPF31 [4, 5, 32].   
 
Figure 2. Proposed disease model associated with mutations in SNRNP200. Variants M1 
(found heterozygously in persons with adRP) and M2 (found in a homozygous state in 
persons with arRP) reduce the cellular protein activity to the same level. Residual activity 
of the splicing machinery above a certain threshold likely is essential in view of the 
ubiquitous and crucial function of the splicing machinery. 
 
 
Figure 3. Schematic structure of hBrr2 and location of the RP associated mutations. 
Different domains in hBrr2 are indicated along with mutations associated with adRP. The 
mutation identified in the arRP family is indicated in bold. Interestingly, all the mutations 
identified so far in hBrr2 are located in the N-terminal cassette. H1, helicase domain 1; H2, 
helicase domain 2; helix bundle, HB; helix–loop–helix, HLH; Ig-like, IG; winged helix, 
WH (adapted from Santos KF et al. 2012 and Hahn D et al 2010) [1, 18]. 
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We hypothesize that the adRP-associated SNRNP200 variant (M1 in Figure 2), leads to a 
major reduction of activity (~60%), of this protein, which is sufficient to cause disease 
when present in a heterozygous state. The arRP-associated variant (M2), however, is 
thought to reduce the protein activity to a lesser extent (e.g. ~30% in our model), and hence 
is only pathogenic when present in a homozygous state. In our model the residual activity 
of SNRNP200 at the cellular level would be ~60% in both inheritance models. Complete 
loss-of-function alleles are not observed in RP patients and hence expected to be lethal. 
This hypothesis is supported by mice studies in which targeted disruption of Snrnp200 by a 
transgene (LV2229) in both alleles results in embryonic lethality [37]. In addition, in D. 
melanogaster, disruption of both copies of the SNRNP200 orthologue l(3)72Ab (lethal (3) 
72Ab) is lethal at the embryonic stage [38]. U4/U6 unwinding assays for our mutation are 
warranted to test this hypothesis. 
In conclusion, we have identified a SNRNP200 missense variant, p.(Arg1090Gln), 
that is associated with arRP and predicted to have a mild but significant effect on the 
activity of the protein. 
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ABSTRACT  
Purpose: To identify the genetic defect underlying autosomal recessive retinitis 
pigmentosa (arRP) in patients from two consanguineous Pakistani families.   
Methods: Patients of two consanguineous families were genotyped with SNP microarrays 
for genome-wide linkage analysis. The search for potential candidate genes within the 8 
Mb overlapping homozygous region in these families revealed the presence of CLRN1, a 
gene previously known to cause Usher syndrome type III (USH3), which was analysed by 
direct sequence analysis. The clinical diagnosis was based upon the presence of night 
blindness, fundoscopic findings, electroretinography (ERG) results. Additionally pure tone 
audiometry was performed to rule out Usher syndrome.  
Result: Sequencing of CLRN1 revealed novel missense mutations p.(Pro31Leu) and 
p.(Leu154Trp) segregating in two families. Analysis of fundus photographs indicated 
attenuation of the retinal vessels, and bone spicule pigmentation in the periphery of the 
retina. ERG responses are indicative of a rod-cone pattern of the disease. Audiometric 
assessment revealed no hearing impairment and thereby excludes Usher syndrome. 
Subcellular localization studies demonstrated the retention of the mutant proteins in the 
endoplasmic reticulum, whereas the wild type protein was mainly present at the cell 
membrane.  
Conclusions: The RP-associated mutations p.(Pro31Leu) and p.(Leu154Trp) may 
represent hypomorphic mutations, because the substituted amino acids located in the 
transmembrane domains remain polar, whereas more severe changes have been detected in 
patients with USH3. These data indicate that mutations in CLRN1 are associated not only 
with USH3, but also with non-syndromic arRP.  
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INTRODUCTION 
Retinitis pigmentosa (RP, MIM#268000) consists of a group of photoreceptor degenerative 
disorders, initially characterized by impairment of night vision and mid-peripheral visual 
field loss. A hallmark feature of RP is the formation of pigmentary deposits in the retina, 
commonly known as bone spicules, along with mild to severe loss of rod function gauged 
by electroretinography (ERG) [1-3]. 
Clinically and genetically, RP is a very heterogeneous disease. Several syndromic 
forms of RP exist where individuals suffer from other disease such as deafness in Usher 
syndrome, and obesity and renal abnormalities in Bardet-Biedl syndrome. Genetically, RP 
exhibits multiple modes of inheritance, and to date 48 genes and 8 loci have been 
described. Autosomal recessive RP (arRP) accounts for approximately 20% to 30% of the 
cases; approximately 40-55% are isolated cases, which for the majority likely also 
represent autosomal recessive cases. The percentage of autosomal recessive cases has been 
found to be as high as 97% in the Pakistani population (M.I.K., M.A., A.H., S.T.A.S., 
R.W.J.C., A.I.d.H, R.Q., F.P.M.C., M.A., et al., unpublished data). Twenty-six genes have 
been identified for arRP which explain the etiology of 50-60% of all recessive cases [3]. 
These genes encode proteins which exert diverse functions in the retina including 
phototransduction, vitamin A metabolism and ciliary transport [3]. Mutations in the 
USH2A gene have been reported to cause both Usher syndrome type II (USH2), and non-
syndromic arRP [4-7]. 
In the current study we describe 2 Pakistani families with arRP caused by 2 
different missense mutations in the CLRN1 gene. Mutations in this gene have previously 
only been associated with Usher syndrome type III (USH3), which is characterized by 
progressive postlingual hearing loss, in addition to RP of variable onset and severity [8, 9]. 
Patients with USH3 may also have normal or mildly reduced vestibular responses [9]. This 
study demonstrates that mutations in the CLRN1 gene can also cause non-syndromic RP 
without hearing loss. Functional analysis of the missense mutations in transfected cultured 
cells indicates that the mutant proteins are not targeted to the plasma membrane, and 
support pathogenicity of both variants.  
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METHODS 
Subjects: Two families, RP06 and RP18 (Figures 1 A, B), consisting of 5 and 6 affected 
individuals, respectively, were recruited from central Punjab, Pakistan. The affected 
individuals of these families were characterized to suffer from RP based upon loss of night 
vision and progressive visual field loss. Blood samples were collected from all available 
affected and normal individuals after obtaining an informed consent in accordance to the 
declaration of Helsinki. This study was approved by the Shifa College of Medicine/Shifa 
International Hospital Ethics Committee and Institutional Review Board. 
Linkage analysis: DNA was isolated using a standard organic extraction method [10]. 
DNA samples of all 5 affected individuals (IV:4, IV:5, IV:6, V:1 and V:2) of family RP06 
were analyzed with 6K Illumina  arrays (Illumina, Inc, San diago, CA) containing 6,090 
single-nucleotide polymorphism (SNP) markers. DNA samples of 5 affected individuals 
(III:1, III:3, III:6, IV:2 and IV:4 ) of family RP18 were analyzed for 11,555 single-
nucleotide polymorphism using the Affymetrix 10K array (Affymetrix, Santa Clara, CA). 
Multipoint linkage analysis was performed with the Gene Hunter program (version 2.1r5) 
in the easyLinkage Plus software package (version 5.08) using the Asian single-nucleotide 
polymorphism allele frequencies [11].  
Mutation analysis: Potential candidate genes in the identified linkage intervals were 
sequenced to identify the causative variants, using dye termination chemistry (BigDye 
Terminator, version 1.1 on a 3730 DNA analyzer; Applied Biosystems Inc, Foster City, 
CA). Segregation analysis was performed by sequence analysis, while additional RP cases 
and ethnically matched control individuals were screened with an amplification refractory 
mutation system-polymerase chain reaction (ARMS-PCR) [12]. 
Clinical Evaluation: Clinical investigations included pure tone audiometry, fundoscopy, 
and ERG in accordance to the guidelines of the International Society for Clinical 
Electrophysiology of Vision (ISCEV) [13] using a monopolar contact lens electrode (LKC 
Inc., Gaithersburg, MD). 
Bioinformatic evaluation of the mutations: To assess the conservation of the mutated 
amino acids of the clarin-1 protein at the substitution positions, the amino acid sequences 
of various orthologues were obtained from the NCBI protein database and aligned with the 
human sequence (NP_777367.1) using Align software in Vector NTI program, version 11 
(Invitrogen, Carlsbad, CA). Web-based servers including PolyPhen (available at 
http://genetics.bwh.harvard.edu/pph) and SIFT (available at http://sift.jcvi.org) were used 
to assess the pathogenic potential of the mutations. The SMART database (available at 
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http://smart.embl-heidelberg.de) was used to identify the positions of the functional 
domains of the clarin-1 protein.  
Functional analysis of the mutations: To determine the subcellular localization of 
wildtype clarin-1, and the two mutant proteins, full-length cDNA constructs were 
generated using commercially available Gateway cloning technology (Invitrogen, 
Carlsbad, CA), according to the manufacturer’s instructions. Human testis cDNA 
(Marathon; Clontech Laboratories, Inc., Palo Alto, CA) was used as a template to amplify 
the full-length clarin-1 cDNA (CLRN1; NM_174878; available at  
http://www.ncbi.nlm.nih.gov/Genbank; NCBI, Bethesda, MD) using the forward primer 
5’- atg cca agc caa cag aag aaa atc -3’ and the reverse primer 5’- tca gta cat tag atc tgc agc 
-3’. Mutant constructs carrying the missense mutations p.(Pro31Leu) and p.(Leu154Trp) 
were generated using site-directed mutagenesis of the wildtype clarin-1 plasmid with 
phusion DNA polymerase (Finnzymes, Espoo, Finland). The expression vector pDEST733 
was used, which generates a fusion protein with monomeric red fluorescent protein 
(mRFP) at the N-terminus (Invitrogen, Carlsbad, CA). 
The subcellular localizations of the wildtype and mutant clarin-1 proteins in 
hTERT-RPE1 cells (Clontech Laboratories, Inc., Palo Alto, CA) were determined by 
transfecting these cells with pDEST733-clarin-1 wildtype, p.(Pro31Leu), and 
p.(Leu154Trp) constructs using the Effectene transfection reagent (Qiagen, Hilden, 
Germany) according to the manufacturers’ instructions, resulting in clarin-1 proteins fused 
to mRFP at the N-terminus.  
A construct encoding a palmitoylation-myristoylation-cyan fluorescent protein 
(CFP) fused with the intracellular domain (icd) of USH2A was cotransfected with the 
pDEST733-clarin-1 constructs, resulting in plasma membrane-anchored-USH2A_icd, 
which was used as a marker for the plasma membrane [14]. Twenty-four hours after 
transfection, the cells were washed with PBS and fixed with methanol. A mouse 
monoclonal antibody to protein disulphide isomerase (PDI) was used as an endoplasmic 
reticulum marker (Abcam, Cambridge, UK). A goat-anti-mouse secondary antibody (Alexa 
Fluor 488, Molecular Probes-Invitrogen Carlsbad, USA) was used for visualization and the 
cells were embedded with Vectashield containing DAPI (Vector Laboratories, 
Peterborough, UK). Photographic images of the cells were obtained with an Axio 
imagerZ1 fluorescence microscope (Zeiss, Switzerland) equipped with an AxioCam MRm 
camera (Zeiss). Images were processed using Axiovision Rel.4.6 and Adobe Photoshop 
(Adobe Systems, San Jose, CA). 
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RESULTS 
Linkage and mutation analyses 
Linkage analysis in the consanguineous Pakistani family RP06 revealed 5 regions with a 
LOD score of >3.0, on chromosomes 1, 3, 5 and 11 (Table 1). The region on chromosome 
3 with a LOD score of 3.32 between rs1009621 and rs1563436 was the only interval that 
was homozygous in all affected individuals, and encompassed the CLRN1 gene. Mutations 
in this gene have previously been associated with USH3, which is characterized by 
progressive post-lingual hearing loss, RP, and normal or mildly reduced vestibular 
responses. Sequence analysis of all coding and non-coding exons of CLRN1 revealed a 
novel missense mutation (c.461T>G; p.(Leu154Trp)) in exon 3 (Figure 1C). Sequence 
analysis in all available family members revealed that the mutation segregates with the 
disease in family RP06 (Figure 1A). Amplification refractory mutation system-polymerase 
chain reaction analysis of a panel of 81 Pakistani RP patients and 90 ethnically matched 
controls yielded no carriers of this mutation. 
 
Table 1. Linkage analysis of the families RP06 and RP18 
Hz , homozygous; ‡ LOD, Logarithm of odds; †SNP, single nucleotide polymorphism.  
*Total SNPs in regions with indicated LOD score. 
 
Linkage analysis in the other consanguineous Pakistani family, RP18, yielded 2 regions 
with a maximum LOD score of 2.40 (Table 1). The largest homozygous region spans about 
15 Mb on chromosome 3 between rs724016 and rs718142. Sequence analysis of the 
CLRN1 gene which resides in the interval also revealed a missense mutation (c.92C>T; 
Family Chr. LOD‡ Flanking SNPs† 
hg18 position 
(Mb) 
Total 
 SNPs* 
Stretch of 
Hz SNPs 
RP06 1 3.20 rs1526480;rs10785852 90,98-104,41 22 4 
 3 3.32 rs1009621; rs1563436 149,67-173,26 40 30 
 3 3.30 rs7628308;rs1515504 179,31-191,13 30 4 
 5 3.18 rs1989154; rs906678 147,83-150,76 6 1 
 11 3.30 rs892336; rs961746 5,56- 20,18 22 3 
RP18 3 2.40 rs724016; rs718142 142,59-158,95 57 51 
 8 2.40 rs1816371; rs1356763 98,35-129,87 124 38 
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p.(Pro31Leu)) in exon 1 of CLRN1 (Figure 1D). The mutation also segregated with the 
disease (Figure 1B) and was found neither in 81 unrelated Pakistani RP patients, nor in 90 
ethnically matched controls from the Pakistani population. 
 
 
 
 
Figure 1.  Identification of CLRN1 mutations in two consanguineous Pakistani families. 
(A, B) Pedigrees and segregation analysis of CLRN1 mutations in families RP06 and 
RP18. M1 represents c.461T>G; p.(Leu154Trp) and M2 represents c.92C>T; 
(p.Pro31Leu). (C, D) Sequence chromatograms of CLRN1 mutations in affected 
individuals of families RP06 and RP18; the substituted nucleotides are underlined. (E, F) 
Sequence alignments of CLRN1 orthologues. The arrows indicate the mutated amino 
acids, which are completely conserved throughout vertebrate evolution p.(Leu154) or 
completely conserved in mammals p.(Pro31). 
 
  
C              D 
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Clinical evaluations 
Both families were recruited because the affected individuals suffered from RP. The 
identified mutations in CLRN1, a gene known to be involved in Usher syndrome, 
warranted further clinical assessment to rule out hearing impairment. Therefore, detailed 
clinical analyses were performed during a follow-up visit, which included fundoscopy, 
ERG and audiometry. Analysis of the fundus of the affected individuals of both families 
indicated attenuation of the retinal vessels, waxy appearance of the optic disc and bone 
spicule pigmentation in the periphery of the retina (Figures 2A-C). ERG analyses revealed 
that the scotopic responses, which are indicative of the activity of the rod photoreceptors, 
were more severely diminished than the photopic responses (Table 2). 
 
Table 2. ERG response of affected individuals from families RP06 and RP18 
 
RP06_IV:6 
(Age: 39 years) 
RP18_III:1 
(Age: 37 years) 
Normal Values  
(Age: 40 years) 
Scotopic 25 dB b-wave  
amplitude (µV)  
23.4 31.1 >141 
Scotopic 0 dB b-wave 
 amplitude (µV)  
70.9 68.7 >387 
Photopic 0 dB b-wave  
amplitude (µV)  
60.9 59.7 >82 
Photopic 0 dB 30Hz Flicker 
Amplitude (µV)  
4.3 3.8 >56 
 
No hearing problems were reported by the patients. To completely rule out any hearing 
impairment, selected patients of both families underwent audiometric assessment. Two out 
of 5 affected individuals (IV:4 and IV:6) and 1 unaffected individual (III:1) of family RP06 
and 1 affected individual (III:1) of family RP18 underwent pure tone audiometry. The 
audiograms of all examined individuals were found to be within the normal range (Figure 
2D) and no hearing impairment was observed. In contrast, USH3 patients generally suffer 
from severe hearing loss at this age [9]. 
 
In-silico analysis of mutations 
Alignment of the clarin-1 protein sequences of various orthologues shows that the 2 
substituted amino acids in both families were highly conserved in other species (Figures 
1E,F). The pathological potential of both substitutions evaluated with PolyPhen predicted 
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that both substitutions are probably damaging, and SIFT analysis revealed that both are not 
tolerated. Both mutations affect residues that are located in transmembrane domains of 
clarin-1, which is a member of the tetraspanin family (Figure 3). The p.(Pro31Leu) 
mutation identified in family RP18 is located at the extracellular end of the first 
transmembrane domain, while the p.(Leu154Trp) mutation identified in family RP06 is 
located at the end of the third transmembrane domain.  
 
 
Figure 2. Clinical features of families RP06 and RP18. (A-C) Fundus photographs of two 
affected individuals (A: RP06 (IV:6), B: RP18 (III:1)) and one unaffected individual (C: 
RP18 (IV:1)). (D) Audiograms of three affected individuals and one unaffected individual 
of families RP06 and RP18. Mean hearing threshold was calculated of 27 Usher syndrome 
type III (USH3) patients with 5 different CLRN1 mutations [9], demonstrating severe 
hearing loss in USH3 patients whereas hearing in affected individuals of families RP06 
and RP18 is normal. 
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Subcellular localization of wildtype and mutant clarin-1 proteins 
To determine the subcellular localization of wildtype clarin-1 and the 2 mutant proteins, 
full-length wildtype and mutant CLRN1 constructs were transfected in hTERT_RPE cells. 
Since clarin-1 is normally expressed at the plasma membrane [15, 16], a construct 
encoding a palmitoylation-myristoylation-cyan fluorescent protein fused to the intracellular 
domain of USH2A (palmyr-USH2A) was used as a marker of the plasma membrane [14]. 
Wildtype clarin-1 was found to be present throughout the cell and at the plasma membrane 
as demonstrated by colocalization of the protein with palmyr-USH2A (Figure 4A). The 
mutant clarin-1 proteins carrying the missense mutations p.(Pro31Leu) and p.(Leu154Trp) 
were detected throughout the cell, but not at the membrane (Figures 4B,C). The mutant 
clarin-1 proteins were almost exclusively observed within the endoplasmic reticulum (ER), 
as shown by colocalization with an ER marker (protein disulfide isomerase), whereas only 
a partial colocalization was observed with the wildtype clarin-1 protein (data not shown). 
Together, these data indicate that the 2 mutant clarin-1 proteins are not properly targeted to 
the plasma membrane but retain at the ER. 
 
 
Figure 3. The clarin-1 protein and position of mutations identified in Usher syndrome type 
III (USH3) and autosomal recessive RP (arRP) patients. Nonsense and frameshift 
mutations identified in USH3 patients are indicated in white, missense mutations identified 
in USH3 patients are indicated in yellow, and an in-frame insertion-deletion mutation 
identified in USH3 is marked in blue. Missense mutations identified in arRP families in 
this study are filled red.  
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Figure 4. Subcellular localization of wildtype and mutant clarin-1 proteins in hTERT-
RPE1 cells. hTERT-RPE1 cells were cotransfected with constructs encoding mRFP-clarin-
1 fusion proteins (red in A, B and C) and a marker for the plasma membrane 
(palmitoylated-myristoylated-CFP fused to the intracellular domain of Usher syndrome 
type II A (USH2A); green in A’, B’ and C’). Subcellular localization studies were 
performed for (A) wildtype mRFP-clarin-1, (B) mutant mRFP-clarin-1 carrying the 
missense mutation p.(Pro31Leu), and (C) mutant mRFP-clarin-1 carrying the missense 
mutation p.(Leu154Trp). Overlay demonstrates colocalization of wildtype mRFP-clarin-1 
with the plasma membrane (yellow in A’’), while the mutant mRFP-clarin-1 proteins were 
detected throughout the cell, but not at the plasma membrane (B’’ and C’’). 
 
DISCUSSION 
For the present study, we describe 2 Pakistani arRP families with novel missense mutations 
in the CLRN1 gene that segregate with the disease. The p.(Pro31Leu) mutation identified 
in family RP18 is located at the extracellular end of the first transmembrane domain, 
whereas the p.(Leu154Trp) mutation identified in family RP06 is located at the end of the 
third transmembrane domain. The patients from both families suffered from progressive 
night blindness accompanied by loss of peripheral visual field. Clinically, the patients of 
both families presented typical features of RP including arterial attenuation, bone spicule 
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deposition and a waxy appearance of the optic disc. None of the affected members of either 
family had any apparent auditory abnormality, which was confirmed by audiometry. 
Mutations in the CLRN1 gene have previously been associated with USH3, which accounts 
for a small proportion of all Usher syndrome cases [17, 18]. Interestingly, mutations in 
CLRN1 have only been reported in patients of European ancestry, mostly Finnish and 
Ashkenazi Jewish [16, 18, 19]. Five of the 12 CLRN1 mutations detected in USH3 patients 
create premature stop codons and hence may lead to translational termination and/or 
nonsense-mediated decay of the mRNA. Six of the mutations identified in USH3 patients 
are amino acid substitutions p.(Cys40Gly), p.(Asn48Lys), p.(Ser105Pro), p.(Met120Lys), 
p.(Ala123Asp) and p.(Leu150Pro) and 1 mutation leads to an in-frame insertion-deletion 
p.(Ile153_Leu154delinsMet). Recently, it was shown that mutant clarin-1 proteins carrying 
one of the missense mutations identified in USH3 patients p.(Asn48Lys), p.(Met120Lys), 
p.(Ala123Asp) and p.(Leu150Pro) or the p.(Ile153_Leu154delinsMet) mutation, are 
retained in the ER and are not inserted into the plasma membrane [17]. Our results, and 
those of others, demonstrate that wildtype clarin-1 protein is localized at the plasma 
membrane and also found in the ER, indicating that clarin-1 is processed through the ER to 
the plasma membrane [15-20]. We demonstrate in our current study that the clarin-1 
mutant proteins carrying the RP-associated mutations p.(Pro31Leu) and p.(Leu154Trp) are 
only detected in the ER, suggesting that these proteins are also retained in the ER and are 
not properly transported to the plasma membrane.  
The residues affected by the mutations identified in this study in families with 
autosomal recessive RP p.(Pro31Leu) and p.(Leu154Trp) are located in the transmembrane 
domains (Figure 4). Three of the missense mutations identified in USH3 patients affect 
residues in the extracellular and intracellular loops, which could have a more damaging 
effect compared to mutations in the transmembrane domains. The p.(Asn48Lys) mutation 
in the extracellular loop affects a glycosylation site, and lack of glycosylation has been 
shown to lead to misfolding, mislocalization and degradation of the protein [15]. The 
p.(Cys40Gly) mutation affects a cysteine residue in the first extracellular loop, which 
might be involved in the formation of disulfide bonds and/or protein interactions. Three 
other missense mutations p.(Ser105Pro), p.(Met120Lys) and p.(Leu150Pro) and the in-
frame insertion-deletion mutation p.(Ile153_Leu154delinsMet) found in USH3 patients 
affect residues which are located in the transmembrane domains. Two p.(Met120Lys) and 
p.(Leu150Pro) were found in compound heterozygous state with a nonsense mutation 
p.(Tyr176*) and a missense mutation p.(Asn48Lys) in the extracellular loop which affects 
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glycosylation, respectively, and therefore probably cause a more severe phenotype [19, 
21]. The p.(Ile153_Leu154delinsMet) mutation found in USH3 patients inserts a 
methionine residue and removes 2 amino acids, including the Leu154 residue which was 
found to be mutated in family RP06 in this study [22]. Because this mutation leads to an 
in-frame amino acid deletion in the transmembrane domain, it could potentially have a 
more severe effect than a missense mutation. The (p.Ser105Pro) missense mutation found 
in USH3 is located in the middle of the second transmembrane domain and changes a polar 
to a non-polar residue [9], whereas the missense mutations p.(Pro31Leu) and 
p.(Leu154Trp), described in autosomal recessive RP in this study, are located at the 
boundaries of the first and third transmembrane domain, respectively, and in both cases the 
substituted amino acid remains non-polar. Perhaps the position of the substituted amino 
acids in the transmembrane domains, and the side chain polarity of the substituted amino 
acids may explain the differences in phenotypes. The RP-associated mutations 
p.(Pro31Leu) and p.(Leu154Trp) may represent hypomorphic mutations, which would 
suggest that the retina may be more vulnerable to impaired clarin-1 function than the inner 
ear.   
The findings presented here show that mutations in the CLRN1 gene, besides 
USH3, can also cause non-syndromic arRP. Similar findings have been reported for 
mutations in the USH2A gene, which can cause Usher syndrome type II and non-
syndromic arRP [4-7]. Functional analysis of the missense mutations in transfected 
cultured cells indicates that the mutant proteins are not targeted to the plasma membrane, 
and support pathogenicity of both variants. This study adds CLRN1 to the growing list of 
genes which can cause syndromic and non-syndromic forms of retinal degeneration [4-7, 
23-26].  
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ABSTRACT 
Purpose: To identify the underlying genetic causes of fundus albipunctatus (FA) in 
Pakistan, a rare form of congenital stationary night blindness that is characterized by the 
presence of white dots in the mid-periphery of the retina and delayed dark adaptation. 
Methods: Two families with FA were identified by fundus examination and genome-wide 
single nucleotide polymorphism genotyping was performed for two individuals from 
family A and six individuals from family B. Genotyping data were subsequently used to 
identify the identical homozygous regions present in the affected individuals of both 
families using the online homozygosity mapping tool Homozygosity Mapper. Candidate 
genes selected from the homozygous regions were sequenced. 
Results: Three identical homozygous regions were identified in affected persons of family 
A (on chromosomes 8, 10 and 12), whereas a single shared homozygous region on 
chromosome 12 was found in family B. In both families, the homozygous region on 
chromosome 12 harboured retinol dehydrogenase 5 gene (RDH5), in which mutations are 
known to be causative for FA. RDH5 sequence analysis revealed a novel five base pair 
deletion, c.913_917delGTGCT; p.(Val305Hisfs*29), in family A, and a novel missense 
mutation, c.758T>G; p.(Met253Arg), in family B. 
Conclusions: We identified two novel disease causing RDH5 mutations in Pakistani 
families with FA, which will improve the diagnosis and genetic counseling, and may even 
lead to treatment of this disease in these families. 
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INTRODUCTION 
Fundus albipunctatus (FA) (MIM:136880) or flecked retina disease was described for the 
first time by Lauber [1]. FA is a rare form of congenital stationary night blindness (CSNB) 
and is characterized by the presence of typical white dots on the whole fundus or 
concentrated in the mid-peripheral region of the retina, with or without macular 
involvement and a delay in dark adaptation. The inheritance pattern of the FA is autosomal 
recessive (ar) [2-5]. In one family a male and his two daughters showed FA, which could 
be due to autosomal dominant or pseudo-dominant (i.e., autosomal recessive) inheritance 
[6]. Mutations in three genes, retinol dehydrogenase 5 (RDH5), retinaldehyde binding 
protein 1 (RLBP1) and retinal pigment epithelium-specific protein (RPE65) are known be 
associated with FA [7-10]. Retinitis punctata albescens has similar phenotypic 
characteristics but is progressive in nature and is mostly caused by mutations in RLBP1 
[8]. 
FA-causing mutations were first identified in RDH5, which is expressed 
predominantly in the retinal pigment epithelium (RPE) [7]. RDH5 encodes an enzyme that 
is part of the visual cycle, which involves a series of specialized enzymes and retinoid 
binding proteins, which are essential for the regeneration of the chromophore 11-cis-retinal 
[11-14]. RDH5 consists of 318 amino acids and is highly conserved among different 
species [15]. Within the RPE cells RDH5 resides in the smooth endoplasmic reticulum 
(SER) [16] where it is principally involved in the chromophore regeneration by catalyzing 
the final step in the biosynthesis of 11-cis-retinal [7, 17-20]. The current study explores the 
molecular mechanisms behind FA in Pakistani families, using high density single 
nucleotide polymorphism (SNP) microarrays and sequence analysis of known FA genes 
located in the identified homozygous regions. Using this approach we identified two novel 
mutations in RDH5 in two families with FA. 
 
METHODS 
Approval of the Study: Approval for this study was granted by the Ethics 
Committee/Institutional Review Board (EC/IRB) of Shifa College of Medicine/Shifa 
International Hospital, Islamabad. Signed informed consent was obtained from members of 
both families participating in the current study. 
Family collection and clinical evaluation: Families A and B (Figure 1) reside in remote 
areas of Pakistan and were part of a cohort of 83 families with retinitis pigmentosa (RP) 
and allied retinal diseases. Blood samples were collected from affected and normal 
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individuals of both families and DNA was extracted by a standard protocol [21]. Pedigrees 
were drawn using HaploPainter [22]. Both families were clinically evaluated by fundus 
examination and in addition electroretinography (ERG) measurements were recorded for 
family A. 
Homozygosity mapping analysis: All affected individuals from both families and one 
healthy person from family B were subjected to high density HumanOmniExpress SNP 
bead chip array-analysis. Genotyping data were analyzed with the online tool 
Homozygosity Mapper [23]. Haplotypes of affected and normal individuals were 
compared in each family to identify the identical homozygous regions shared by all 
affected individuals. 
Primer design and RDH5 sequence analysis: The online tool Primer3 [24] was used to 
design PCR primers (available on request). The five exons of RDH5 including their 
flanking exon-intron boundaries were amplified by polymerase chain reaction (PCR) using 
standard conditions and reagents. PCR amplified exonic fragments were 
electrophoretically separated on 2% agarose gels containing ethidium bromide and DNA 
bands were visualized under ultraviolet transillumination. PCR clean-up purification plates 
(NucleoFast® 96 PCR; Cat. No. 743100.10, Macherey-Nagel Germany), were used to 
purify the amplified fragments according to the manufacturer’s protocol. Sanger 
sequencing was then performed with Big Dye Terminator, version 3 and analyzed on a 
3730 DNA analyzer (Applied Biosystems, Inc., Foster City, CA). 
Vector NTI Advance (TM) 2011 software from Invitrogen Corporation (Carlsbad, CA), 
was used to analyze sequencing results of RDH5 exons. 
In-silico analysis: Sorting intolerant from tolerant (SIFT) 
(http://sift.jcvi.org/www/SIFT_enst_submit.html), Polymorphism phenotyping (Polyphen) 
(http://genetics.bwh.harvard.edu/pph2/) and Mutation Taster [25] were used to assess the 
possible pathological nature of a missense variant identified in this study. Project HOPE 
(http://www.cmbi.ru.nl/hope) [26] was used to analyze and predict the structural variations 
in mutant RDH5. 
Amino acid conservation: RDH5 protein sequences from different species including 
human (H. sapiens, ENSP00000257895), macaque (M. mulatta, 
ENSMMUP00000017380), mouse (M. musculus, ENSMUSP00000026406), dog (C. 
familiaris, ENSCAFP00000000084), cow (B. taurus, ENSBTAP00000056512), cat (F. 
catus, ENSFCAP00000012945), tetraodon (T. nigroviridis, ENSTNIP00000022889) and 
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round worm (C. elegans, F35B12.2) were aligned using Vector NTI Advance (TM) 2011to 
check the evolutionary conservation of the substituted amino acid in RDH5. 
 
RESULTS 
Clinical Studies 
Initial symptoms of visual complaints in patients from both families (Figure 1) were 
observed from early childhood. Fundus examination of affected individuals revealed the 
presence of white dots typical of FA in the mid-periphery of the retina (Figure 2; Table 1). 
ERG responses of cone and rod photoreceptors were diminished in affected individual IV-
1 of family A (Table 2). This individual had day-time vision problems, which confirms that 
cone photoreceptors were also affected. Macular degeneration was also observed in 
individual IV-1 of family A and individual IV-7 of family B. ERG results were not 
available for family B. The visual acuity (VA) of affected individual IV-7 of family B was 
different from the VAs of other individuals (VI-2, VI-3) of this family and the density of 
white dots was also variable, which indicates intra-familial phenotypic variability. Affected 
individuals of family B had normal day-time vision. 
Genetic Studies 
In family A three homozygous regions were identified that were shared by the affected 
persons (Figure 3A). The largest homozygous region spanned 24.5 Mb (hg19: 3.3-27.8 
Mb; flanked by SNPs rs4881131 and rs10764698) on chromosome 10. The second and 
third homozygous regions were 10.5 Mb (hg19: 46.4-56.9 Mb; flanked by rs11183300 and 
rs7314300) and 8.1 Mb (hg19: 25.9-34.0 Mb; flanked by rs9521585 and rs9555687) in 
length, and were located on chromosomes 12 and 8, respectively. The second largest 
region (10.5 Mb) on chromosome 12 harbored the FA-associated gene RDH5. RDH5 
sequence analysis identified a novel homozygous 5-bp deletion (c.913_917delGTGCT; 
p.(Val305Hisfs*29)) in family A (Figure 1C). 
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Table 3.2 Clinical features of affected individuals in both families. 
Individual Age (years) VA (RE, LE) Fundus Phenotype RPE Degeneration Retinoscopy 
Family A (IV-1) 35 6/12, 6/12 White dots, macular degenerative changes Yes ND 
Family B (IV-7) 45 6/18, 6/12 White dots, macular degenerative changes Yes HM 
Family B (VI-2) 17 6/6, 6/6 White dots, macula healthy No LHM 
Family B (VI-3) 10 6/6, 6/6 White dots, macula healthy No LHM 
 
HM, hypermetropia; LE, left eye; LHM, low hypermetropia; RE, right eye; ND, not determined; RPE, retinal pigment epithelium; VA, visual acuity. 
 
 
Table 3.3 ERG responses of affected individual IV-1 of Family A in comparison with ERG responses of a control individual. 
Measured parameters using monopolar electrodes Adaptation Flash strength (cd.s/m2) Proband Family A Control 
Normal values 
 (Age=40 years) 
Scotopic 25 dB b-wave amplitude (µV) Dark 0.01 45.1 173.20 >141 
Scotopic 0 dB b-wave amplitude (µV) Dark 3.0 149.1 496.80 >387 
Oscillatory potential amplitude (µV) Dark 3.0 80.3 123.90 >75 
Photopic 0 dB b-wave amplitude (µV) Light 3.0 70.7 80.80 >82 
Photopic 30 Hz flicker amplitude (µV) Light 3.0 49.5 55.90 >56 
 
Age of affected individual at the time of investigation was 35 years 
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Figure 1. Pedigrees and sequencing results. (A). Segregation of the mutation in family A. 
(B). Segregation of the mutation in family B. (C. and D). Sequence electropherograms of 
affected individuals carrying homozygous variants (upper panels) and unaffected 
heterozygous carriers (middle panels) of families A (C.) and B (D.), along with the results 
of a control individual (wild-type [wt], lower panels). Arrows point to the probands; 
individuals tested with SNP microarrays are indicated with asterisks. 
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Figure 2. Fundus photographs of affected individuals from both families. (A, B). Right 
and left eye, respectively, of affected individual IV-1 of family A (see arrow, figure 1A). 
(C, D). Right and left eye, respectively, of affected individual IV-7 of family B (see arrow, 
figure 1B). (E, F). Right and left eye, respectively, of affected individual VI-2 of family B. 
(G, H). Right and left eye, respectively, of affected individual VI-3 of family B. 
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The mutation c.913_917delGTGCT; p.(Val305Hisfs*29) segregated in family A (Figure 
1A) consistent with an autosomal recessive inheritance pattern. Both affected individuals 
carried this mutation in a homozygous state, while both parents and an unaffected brother 
are heterozygous carriers. The mutation causes a frameshift in the open reading frame and 
results in the replacement of the last 14 amino acids of the RDH5 protein by 28 aberrant 
amino acids. This mutation is predicted to affect part of the transmembrane domain and 
elongates the cytosolic C-terminal tail. 
 
Figure 3. Homozygosity mapping results. (A). Plot of homozygous regions identified in 
affected individuals in family A using Homozygosity Mapper analysis. (B). Plot of 
homozygous regions identified in affected individuals in family B using Homozygosity 
Mapper analysis. Red lines indicated homozygous regions shared by affected individuals in 
each family. Arrows indicate the homozygous regions. 
 
In family B homozygosity mapping revealed a 8.9 Mb (hg19: 52.6-61.5 Mb) homozygous 
segment (Figure 3B) flanked by SNPs rs1894035 and rs1395538, encompassing the RDH5 
gene. RDH5 sequence analysis revealed a novel homozygous missense mutation 
(c.758T>G; p.(Met253Arg)) in this family. Segregation analysis confirmed that all affected 
individuals were homozygous for the mutation c.758T>G; p.(Met253Arg) (Figure 1B) 
suggesting that this variant may be disease-causing. The methionine at position 253 is a 
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highly conserved amino acid residue among different species (Figure 4) and c.758T is an 
evolutionarily highly conserved nucleotide with a PhyloP score of 4.40. SIFT predicted 
p.(Met253Arg) to be deleterious (score: 0.05) mutation, Polyphen classified this mutation 
as probably damaging (score: 0.992), and Mutation Taster predicted both mutations to be 
disease-causing.  
 
Figure 4. Amino acid conservation of amino acids 245-260 of RDH5 in different species. 
Grey shading indicates amino acids that are identical to human RDH5 amino acids. 
 
Structural analysis showed that there was a difference in charge and size of the wild-type 
Met253 and the mutant Arg253. The wild-type residue is uncharged whereas the mutant 
residue is positively charged. The wild-type residue is buried in the alpha helix and the 
mutant residue introduces a charge in this buried residue in the core of the protein or 
protein-complex, which can lead to misfolding of the protein. The mutant residue is bigger 
and probably will not fit in the core of the protein. The hydrophobicity of the wild-type and 
mutant residue also differs, and therefore, this mutation will cause the loss of hydrophobic 
interactions in the core of the protein. Ethnically matched control samples were not tested 
for these mutations, however, neither variant was found in dbSNP nor in 1000 genomes 
(http://www.1000genomes.org/). 
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DISCUSSION 
In this study, we have identified two novel disease-causing mutations in RDH5 in two 
unrelated consanguineous families with FA. Both families exhibited typical FA, as was 
evident from the presence of typical white dots in mid-peripheral regions of the retina. In 
both families the older patients, IV-1 in family A and IV-7 in family B, had macular 
degeneration which might suggest a progressive disease course in these families.  
Including our findings, 36 different mutations in RDH5 have been identified to 
date, which are associated with FA [7, 27-48]. FA patients carrying RDH5 mutations have 
a high phenotypic variability, ranging from non-progressive to progressive disease, a 
variable VA, variation in the density of white dots, and occasionally macular involvement. 
FA with or without cone-dystrophy has also been reported with varying degrees of severity 
[30, 37, 48]. A total of 85 FA patients of 68 different families carrying RDH5 mutations 
have been identified globally (Table 3A,B,C). These persons exhibited a high variability in 
phenotype but the presence of white dots was a common feature. In comparing the 
different phenotypes and genotypes associated with RDH5, it is difficult to establish a valid 
and clear-cut genotype-phenotype correlation. 
RDH5 is a transmembrane enzyme with a membrane embedded N-terminal 
domain, a catalytic ectodomain, a C-terminal transmembrane domain, and a cytosolic tail 
[16]. The topology of retinol dehydrogenases has been controversial as human retinal 
reductase 1 [49] and mouse retinol dehydrogenase 1 [50] have been reported to have a 
membrane-embedded N-terminal domain but no C-terminal transmembrane segment, 
which argues for a cytosolic ectodomain. RDH5 was suggested to have a cytosolic 
ectodomain without any C-terminal transmembrane domain [50].  
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Table 3. RDH5 mutations causing fundus albipunctatus 
Exon/intron Allele 1 Allele 2 Phenotype Families Cases Reference 
Exon 2 wt c.55A>G; p.(Arg19Gly) DWD 1 1 [48] 
Exon 2, 4 c.95delT; p.(Phe32Serfs*29) c.712G>T; p.(Gly238Trp) WD, MA 1 1 [47] 
Exon 2, 3 c.98T>A;  p.(Ile33Asn) c.469C>T; p.(Arg157Trp) WD 1 1 [39] 
Exon 2, 4 c.98T>C;  p.(Ile33Thr) c.712G>T; p.(Gly238Trp) DWD, RPED 1 1 [48] 
Exon 2 c.103G>A; p.(Gly35Ser) c.103G>A; p.(Gly35Ser) WD, CD, BE 1,1,1 2,1,1 [30,32,37,46] 
Exon 2, 5 c.103G>A;  p.(Gly35Ser) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1, 2 1, 2 [30,37,41] 
Exon 2, 5 c.124C>T;  p.(Arg42Cys) 
c.928delinsGAAG 
p.(Leu310delinsGluVal) 
WD 1 1 [41] 
Exon 2 c.129delT;  p.(Leu44Trpfs*17) 
c.129delT; 
p.(Leu44Trpfs*17) 
WD 1 1 [33] 
Exon 2, 5 
c.211_214dupGTGG; 
p.(Ala72Glyfs*15) 
c.801C>G; p.(Cys267Trp) WD 1 1 [33] 
Exon 2, 4 c.218C>T; p.(Ser73Phe) c.712G>T; p.(Gly238Trp) WD 1 1 [7] 
Intron 2, 4 c.310+1G>A;  p.(?) c.712G>T; p.(Gly238Trp) DWD 1 1 [48] 
Exon 3 c.319G>C; p.(Gly107Arg) c.319G>C; p.(Gly107Arg) WD, MD, SRP 1, 1 2, 1 [35,40] 
Exon 3, 5 c.319G>C; p.(Gly107Arg) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD, BE 1 1 [30] 
Exon 3 
c.346_347insGCA; 
p.(Gly116_Ile117insSer) 
c.346_347insGCA; 
p.(Gly116_Ile117insSer) 
DWD, RPED 1 1 [48] 
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Exon 3, 4 c.346G>C; p.(Gly116Arg) c.710A>C; p.(Tyr237Ser) NWD 1 1 [48] 
Exon 3 c.382G>A; p.(Asp128Asn) c.382G>A; p.(Asp128Asn) WD 1 1 [47] 
Exon 3, 4 c.382G>A; p.(Asp128Asn) c.712G>T; p.(Gly238Trp) WD 1 1 [43] 
Exon 3, 5 c.394G>A; p.(Val132Met) c.839G>A; p.(Arg280His) WD, CD, MD 1, 1, 3 1, 2, 3 [30,37,38,41] 
Exon 3, 5 c.416G>T; p.(Gly139Val) 
c.955T>C; 
p.(*319Argext*33) 
DWD, RPED 1 1 [48] 
Exon 3 c.470G>A; p.(Arg157Gln) c.470G>A; p.(Arg157Gln) DWD, RPED 1 1 [48] 
Exon 3, 4 c.470G>A; p.(Arg157Gln) c.712G>T; p.(Gly238Trp) WD 1 1 [45] 
Exon 3 c.490G>T; p.(Val164Phe) c.490G>T; p.(Val164Phe) WD, MA 1 1 [36] 
Exon 3, 5 c.530T>G; p.(Val177Gly) c.839G>A; p.(Arg280His) WD 1 1 [29] 
Exon 3, 5 c.530T>G; p.(Val177Gly) 
c.928_930delinsGAAGTT; 
p.(Leu310delinsEV) 
WF 1 1 [42] 
Exon 4 c.625C>T; p.(Arg209*) c.625C>T; p.(Arg209*) WD 1 1 [47] 
 
Exon 4, 5 
c.689_690delinsGG; 
 p.(Pro230Arg) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1 1 [44] 
Exon 4 c.712G>T; p.(Gly238Trp) c.712G>T; p.(Gly238Trp) WD, DWD, DWF 1, 1 2, 2, 1 [7,27,48] 
Exon 4, 5 c.718dupG; p.(Ala240Glyfs*19) c.841T>C; p.(Tyr281His) WD, BE, MD 1, 1 1, 1 [30,41] 
Exon 5 c.758T>G; p.(Met253Arg) c.758T>G; p.(Met253Arg) WD, MD 1 5 This study 
Exon 5 c.791T>G; p.(Val264Gly) c.791T>G; p.(Val264Gly) WD 1 3 [28] 
Exon 5 c.824_825del; p.(Arg275Profs*60) 
c.824_825del; 
p.(Arg275Profs*60) 
DWD, DWF, RPED 1 1 [48] 
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Exon 5 c.839G>A; p.(Arg280His) c.880G>C; p.(Ala294Pro) WD, MD 1 2 [27] 
Exon 5 c.839G>A; p.(Arg280His) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1, 1, 2 1, 1, 2 [30,37,40,41] 
Exon 5 c.841T>C; p.(Tyr281His) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD, MD 1, 1 1, 1 [34,41] 
Exon 5 c.880G>C; p.(Ala294Pro) c.880G>C; p.(Ala294Pro) WD 1 1 [47] 
Exon 5 
c.913_917delGTGCT; 
 p.(Val305Hisfs*29) 
c.913_917delGTGCT; 
p.(Val305Hisfs*29) 
WD, MD 1 2 This study 
Exon 5 
c.928delinsGAAG;  
p.(Leu310delinsGluVal) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD, BE, PP 1, 4, 1, 1, 4, 6 1, 4, 2, 1, 6, 6 [28,30,31,37,41] 
BE, bull’s eye; DWD, deep whitish dots; DWF, deep whitish flecks; MD, macular dystrophy; PP, photophobia; RPED, retinal pigment 
epithelium degeneration; WD, white dots. Mutations identified in this study are in bold. 
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However, another retinol dehydrogenase, cis-retinol/androgen dehydrogenase 1 (CRAD1), 
has been described in detail to have a RDH5-like structure with both a luminal ectodomain 
and cytosolic C-terminal domain, and a similar topology has been suggested for most of 
the retinol dehydrogenases [51]. The deletion/frameshift mutation p.(Val305Hisfs*29) 
identified in family A is located in the C-terminal transmembrane domain while the 
missense mutation p.(Met253Arg) is located in the catalytic ectodomain of RDH5 (Figure 
5). As the C-terminal transmembrane region is necessary to retain CRAD1 in the 
endoplasmic reticulum [51], the RDH5 mutation p.(Val305Hisfs*29) might affect the 
endoplasmatic reticulum localization of RDH5. Moreover, an elongated C-terminal 
cytosolic tail might also create problems in the proper functioning of RDH5 as the C-
terminus is thought to play a role in enzymatic activity and localization of CRAD1 and 
RDH5 [51]. 
Structural analysis of RDH5 performed with project HOPE suggests that the 
missense mutation p.(Met253Arg) may cause misfolding of the RDH5 protein because of 
the loss of hydrophobic interactions in the core of the mutant protein. Misfolding of the 
mutant protein may render it to degrade [52-54]. Absence of functional RDH5 enzyme 
leads to the accumulation of 11-cis-retinol [20] which in turn might result in 
malfunctioning of rod and cone photoreceptor cells. 
RDH5-associated disease can be prevented with proper genetic counseling of 
carriers of RDH5 mutations, and persons with this disease can be treated with 9-cis-β-
carotene supplementation. RDH5-/- mice were successfully treated with 9-cis retinal [55], 
and 9-cis-β-carotene was given to FA patients leading to major visual improvements [56]. 
9-cis-β-carotene is converted to 9-cis-retinal [57,58] which is more stable than 11-cis 
retinal [59]. The higher stability of opsin bound to 9-cis retinal slows down the visual 
cascade and thus minimizes the toxicity of accumulating by-products in the visual cycle 
[55,60,61]. After bleaching, in the rod-photoreceptors, 9-cis-retinal might be converted to 
all trans-retinol and subsequently, to 9-cis-retinol in the RPE. A stereospecific enzyme, 9-
cis-retinol dehydrogenase, is reported to be involved in the synthesis of 9-cis-retinoic acid 
by oxidizing 9-cis-retinol [62]. 9-cis-retinal treatment is suggested to induce the 
endogenous synthesis of 11-cis-retinal by its interaction with the retinoid X nuclear 
receptor [56,59,63].  
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Figure 5. Schematic representation of RDH5 and all the mutations thus far published. The 
membrane embedded N-terminus consists of 18 amino acids and the ectodomain, present 
in the lumen of the smooth endoplasmic reticulum (SER), spans amino acids 19 - 288. A 
C-terminal membrane spanning domain encompasses amino acids 289-310, and a small 
cytosolic tail of eight amino acids resides in the cytosol of RPE cells. Both missense and 
protein-truncating mutations are distributed across the entire protein. Mutations identified 
in this study are indicated in red. 
 
Based on our and other studies, we estimate that FA contributes to approximately 2% 
(4/208) of retinal dystrophy families in Pakistan and a total of 17 patients have been 
identified with FA [9]. Two FA families have been reported to carry RLBP1 mutations [9] 
while two other families with FA have RDH5 mutations (this study). In the current study 
we have identified seven additional FA patients who are candidates for the 9-cis-β-carotene 
therapy. 
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In conclusion, we have identified two novel disease causing mutations, 
c.913_917delGTGCT p.(Val305Hisfs*29) and c.758T>G; p.(Met253Arg), in two Pakistani 
families with FA. Our study expands the current mutation spectrum of RDH5 and 
contributes to the existing body of knowledge. In addition, this study will help clinicians in 
improving the diagnosis of FA by differentiating FA from retinitis punctata albescens, 
providing genetic counseling and prescribing the correct treatment to patients. 
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ABSTRACT 
Homozygosity mapping has been successful to map autosomal recessive inherited disease 
loci. The customary consanguineous nuptials in Pakistan underlies the frequent occurrence 
of autosomal recessive (ar) inherited disorders, including retinal diseases (RD). Pakistani 
families with arRD have been instrumental in finding ten RD-associated genes and have 
enabled the recognition of novel genotype-phenotype correlations for three genes. By 
employing homozygosity mapping, we report on the identification of the causal genetic 
defects in 8 families with arRD. In another 9 families, we excluded 8 genes previously 
implicated in ar retinitis pigmentosa and Leber congenital amaurosis, that were located in 
significant homozygous regions. For most families more than one homozygous region was 
identified with LOD scores varying between 1.8 and 4.0. Taking into consideration 
previous published studies, we could genetically solve 32 of 41 (78%) families, suggesting 
that the majority of genes underlying inherited non-syndromic RD have been identified. 
Ninety percent of mutations causing non-syndromic RD and all mutations causing 
syndromic forms in Pakistani families have not been reported in other human populations. 
Based on our inventory of all Pakistani RD-associated gene defects, we propose a cost-
efficient allele-specific analysis of 13 RD-associated variants that may capture up to 42% 
of the genetic causes. 
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INTRODUCTION 
Inherited retinal dystrophies (RD) are clinically and genetically heterogeneous disorders 
[1]. The clinical sub-classification of these diseases is based on the nature of the disease 
(stationary or progressive), the inheritance pattern, and the dysfunctional part of the retina 
[2]. The disease is either congenital, occurring early in life like Leber congenital amaurosis 
(LCA; MIM# 204000), or congenital stationary night blindness (CSNB; MIM# 310500), or 
might have a later onset such as in retinitis pigmentosa (RP; MIM# 268000), cone-rod 
dystrophy (CRD; MIM# 604116), and cone dystrophy (CD; MIM# 602093 )[3]. In 
addition to disorders that are confined to the eye, there are syndromic forms of the disease 
in which blindness due to retinal cell degeneration is either among the primary clinical 
symptoms or might be manifested at an advanced stage. The most common syndromic 
form of RD is Usher syndrome (USH; MIM# 276900), in which RP is coupled with 
variable degrees of hearing loss and vestibular dysfunction [4]. Other types of syndromic 
RD include Bardet-Biedl syndrome (BBS; MIM# 209900), Senior-Loken syndrome 
(SLSN; MIM# 266900), Joubert syndrome (JBTS; MIM# 213300), and Meckel syndrome 
(MKS; MIM# 249000), that exhibit severe overlapping clinical features in addition to 
retinal degeneration [5, 6]. 
The estimated worldwide prevalence of RD is 1 in 3,000 individuals [7]. RP is the 
most frequent among these diseases, affecting 1 in 4,000 individuals [8, 9]. In Pakistan the 
frequency of RD is not well defined but a hospital-based study estimated it to be 1 in 800 
patients, with autosomal recessive RP being the most prevalent [10]. In Pakistan more than 
60% of marriages are consanguineous and among them about 80% are between first 
cousins [11]. In several developing countries, as opposed to the Western countries, 
consanguinity has always been a major contributing factor in the high prevalence of 
autosomal recessive disorders [12]. Such consanguineous families are ideal for 
homozygosity based genetic mapping studies aimed at the identification of the underlying 
genetic defect [13, 14].  
Facilitated by several technological advances, 185 genes implicated in different 
inherited RD have been identified to date (http://www.sph.uth.tmc.edu/retnet/sum-
dis.htm). Among these genes, 119 are linked to non-syndromic forms of the disease with 
genetic overlap between different classes [1, 3, 15]. In the developed countries genetic 
testing using medium-to-high throughput genotyping methods is now being used for proper 
disease diagnosis [16]. This has resulted in the establishment of many genotype-phenotype 
correlations [16-18]. In the last two decades, several studies have described the genetic 
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causes of different retinal dystrophies in consanguineous Pakistani families. To date there 
is no comprehensive overview of all forms of RD that have been studied in Pakistan. In 
this study we describe homozygosity mapping and sequence analysis results for 17 
Pakistani RD families, which are part of a cohort of 41 randomly collected Pakistani RD 
families. In addition, we provide an overview of all published genetic data of syndromic 
and non-syndromic retinal dystrophies that have been described for Pakistani families. 
 
METHODS 
Genetic analyses of 41 RD families  
This study was dually approved by the institutional ethics committee and was conducted in 
accordance to Helsinki declaration. A panel of 41 retinal dystrophy families, including 38 
non-syndromic and 3 syndromic families (i.e., two BBS and one SNLS), were selected for 
single nucleotide polymorphism (SNP) microarray based genotyping. The non-syndromic 
cohort consisted of families with autosomal recessively inherited RP (n=31), CSNB (n=4), 
CD (n=2), and a family with X-linked RP. Details of the respective families are presented 
in Table 1. Preliminary analysis that included patient recruitment, sample collection and 
DNA isolation have been described previously [19, 20]. Novel genetic data of 17 families 
are presented here. Twenty-two families from this cohort were published elsewhere [19-
28]. The results of two families are also included [Ajmal et al., personal communication]. 
Genetic mapping of the panel of 41 families was carried out using single nucleotide 
polymorphism (SNP) microarrays from Illumina (10K), Affymetrix (6K), or 
HumanOmniExpress (700 K).  
As most of the families were consanguineous and pedigree analysis suggested an 
autosomal recessive mode of disease inheritance, the homozygosity mapping approach was 
utilized to find the causal gene. The genotype data were analyzed using an online 
Homozygosity Mapper tool [29]. Subsequently, using Gene Hunter in the easyLinkage 
program, parametric linkage analysis was performed to calculate the LOD scores for the 
homozygous regions[30]. 
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Table 1. Overview of retinal disease phenotypes and affected families. 
Phenotypes Clinical characteristics 
Families 
analyzed 
Affected 
individuals 
Solved 
families 
Solved 
patients 
RP early/late onset Peripheral vision loss, night blindness, 
bone spicule pigmentary deposits,  
reduced rod response 
32 187 23‡ 144 
CSNB (Oguchi, FA) Congenital stationary night blindness,  
whitish dots in fundus (FA),  
Mizuo phenomenon (Oguchi) 
4 19 4 19 
CD and ACHM Reduced central vision,  
poor color vision, photophobia,  
nystagmus, bull's eye macula 
2 8 2 8 
BBS Retinal dystrophy, polydactyly, obesity, 
intellectual disability 
2 4 2 4 
SLSN Early onset RP, end stage renal failure in first 
decade of life 
1 3 1† 3 
Total   41 221 32 178 
ACHM, achromatopsia; BBS, Bardet-Biedl syndrome; CD, cone dystrophy; CSNB, congenital stationary night blindness; FA, fundus 
albipunctatus;  RP, retinitis pigmentosa; SLSN, Senior-Loken syndrome. ‡7 of these families are part of this study, †part of this study. 
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Haplotypes were compared and only the regions that were identical in all the affected 
individuals of each family were considered further. Whenever available, genotype data 
from healthy individuals were used to exclude the regions that were found to be 
homozygous in both healthy and affected individuals. In case no unambiguous 
homozygous region was identified in families with multiple sibships, homozygosity 
mapping was performed for separate branches of the family. After haplotype analysis, 
regions were prioritized based upon size and/or the presence of genes known to be 
implicated in inherited RDs. Sequencing primers were designed from the UCSC genome 
browser (http://genome.ucsc.edu), using ExonPrimer. Sanger sequencing was carried out to 
screen exons and flanking intronic sequences of all RD genes residing in the homozygous 
regions in one proband from each family. Segregation analysis of identified mutations was 
also done using Sanger sequencing.  
Sequence variants were characterized based upon nucleotide conservation (PhyloP 
score), a bio-informatic prediction of the biological consequences of amino acid 
substitutions using PolyPhen (http://genetics.bwh.harvard.edu/pph/), and SIFT 
(http://sift.jcvi.org/), and whether the change affects an amino acid in a functional domain 
of the corresponding protein. Novel  variants were also checked in population-matched 
healthy controls by restriction fragment length polymorphism (RFLP) analysis and/or 
Sanger sequencing. The exome variant server (EVS; a database containing variants 
retrieved from the National heart, lung and blood institute exome sequencing projects), and 
an in-house exome database were also checked for the presence of putative pathogenic 
variants. 
 
Literature review 
A comprehensive literature review was performed for mutations and loci which have been 
described previously for Pakistani individuals with syndromic and non-syndromic retinal 
diseases. The Retinal Network (RetNet; https://sph.uth.tmc.edu/retnet/disease.htm), 
National Centre for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/), 
Online Mendelian Inheritance in Man  (OMIM; http://www.ncbi.nlm.nih.gov/pubmed/), 
and The Human Gene Mutation Database (HGMD; http://www.biobase-international.com-
/product/hgmd) were used to search for information and published literature. 
 
  
Chapter  7 
 
164 
 
RESULTS 
Homozygosity mapping and implication of previously identified causative genes in 8 
retinal disease families 
In 7 families with non-syndromic arRD (F01-F07), and one family (F08), with SLSN (Fig. 
1), homozygosity mapping not only revealed outstanding homozygous regions 
encompassing genes previously implicated in the respective phenotypes, but also enabled 
us to identify the causative mutations (Table 2). In two families novel mutations were 
identified in CNGA1 (MIM# 123825: c.1298G>A; p.(Gly433Asp) in F01), and CNGB1 
(MIM# 600724: c.2493-2A>G; p.(?) in F04). In five other unrelated non-syndromic 
Pakistani RP families, previously reported mutations were identified (Tables 3 and 4). 
These include two mutations in RPE65 (MIM# 180069: c.131G>A; p.(Arg44Gln) in F05 
and c.361del; p.(Ser121Leufs*6) in F02), one mutation in CRB1 (MIM# 604210: 
c.2234C>T; p.(Thr745Met) in F06), and one variant in TULP1 (MIM# 602280: 
c.1466A>G; p.(Lys489Arg) in F07) (Fig. 1, Table 3). In a family with nine affected 
individuals in four generations (F03; Fig. 1), X-linked inheritance was plausible. Sequence 
analysis of RPGR (MIM# 312610), revealed a previously identified mutation 
(c.2426_2427del; p.(Glu809Glyfs*25); Table 3). 
Finally, in family F08, with SLSN, a mutation affecting one of the canonical 
nucleotides of a splice acceptor site (c.488-1G>A; p.(?) was identified in IQCB1 (MIM# 
609237), (Table 4). Mutations in IQCB1 are the most frequent cause of SLSN, and the 
mutation we identified in family F08 has been reported in another Pakistani SLSN family 
[31].  
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Figure 1. Pedigrees of families with inherited retinal diseases and segregation analysis of 
mutations. In Family 03 an X-linked mutation segregates; in the other families the 
inherited pattern is autosomal recessive. Blacks symbols represent affected individuals; 
open symbols non-affected persons. M stands for mutation identified, + is wild-type allele, 
M/M indicates affected genotypes, +/M indicates carriers of the mutant allele, and +/+ 
indicates genotypes of normal individuals. 
 
Chapter  7 
 
166 
 
 
 
Table 2. Pedigree and genotyping information of the genetically solved families described in this study 
# 
Family 
#  
Affected 
Homozygous 
regions (n) 
>2 Mb 
Size of 
homozygous 
region (Mb) 
Individual 
ranking  
of region 
arRP/LCA 
gene in 
region 
Mutation 
identified 
Mutation 
F01 3 4 18.8 1 CNGA1 Yes c.1298G>A; p.(Gly433Asp) 
F02 4 2 5.2 1 RPE65 Yes c.361del; p.(Ser121Leufs*6) 
F03 9 NA NA NA RPGR Yes c.2426_2427del; p.(Glu809Glyfs*25) 
F04 9 1 6.5 1 CNGB1 Yes  c.2493-2A>G; p.(?) 
F05 3 2 1.6 2 RPE65 Yes c.131G>A; p.(Arg44Gln) 
F06 2 5 
13.4 2 CRB1 Yes c.2234C>T; p.(Thr745Met) 
4.5 3 LRAT No NA 
3.3 4 GUCY2D No NA 
F07 4 4 9.2 1 TULP1 Yes c.1466A>G; p.(Lys489Arg) 
F08 3 15 
30.3 1 IQCB1 Yes c.239G>A; p.(Arg80His) 
30.3 1 RHO No NA 
    LCA, Leber congenital amaurosis; Mb, mega bases; NA, not applicable; RP, retinitis pigmentosa. 
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Table 3. Mutations identified in Pakistani patients with non-syndromic retinal dystrophies 
Gene RefSeq Id Nucleotide variant Protein variant Phenotype # families # patients References 
ABCA4 NM_000350.2 c.6658C>T p.(Gln2220*) arRP 1 5 [23, 65] 
AIPL1‡ NM_014336.3 c.834G>A p.(Trp278*) EORP 11 25 [23, 36, 66, 67] 
BEST1‡ NM_001139443.1 c.418C>G p.(Leu140Val) adRP 1 4 [33] 
CERKL NM_001030311.2 c.316C>A p.(Arg106Ser) arRP 1 3 [68] 
CERKL NM_001030311.2 c.847C>T p.(Arg283*) arRP 1 6 [23, 69, 70] 
CLRN1† NM_001195794.1 c.92C>T p.(Pro31Leu) arRP 1 6 [22] 
CLRN1† NM_001195794.1 c.461T>G p.(Leu154Trp) arRP 1 6 [22] 
CNGA1 NM_00142564.1 c.626_627del p.(Ile209Serfs*26) arRP 1 7 [71] 
CNGA1 NM_00142564.1 c.1298G>A p.(Gly433Asp) arRP 1 3 This study 
CNGA3 NM_001298.2 c.822G>T p.(Arg274Ser) arCRD (ACHM) 1 4 [25] 
CNGA3 NM_001298.2 c.827A>G p.(Asn276Ser) arCRD (ACHM) 1 6 [72] 
CNGB1 NM_001297.4 c.412-1G>A p.(?) arRP 1 10 [24] 
CNGB1 NM_001297.4 c.2284C>T p.(Arg762Cys) arRP 1 5 [24] 
CNGB1 NM_001297.4 c.2493-2A>G p.(?) arRP 1 10 This study 
CNGB3 NM_019098.4 c.1825del p.(Val609Trpfs*9) arCRD (ACHM) 1 2 [25] 
CRB1 NM_201253.2 c.107C>G p.(Ser36*) arLCA 1 10 [67] 
CRB1 NM_201253.2 c.116C>A p.(Thr39Asp) arLCA 1 6 [73] 
CRB1 NM_201253.2 c.2234C>T p.(Thr745Met) arRP 1 2 [74]; this study 
CRB1 NM_201253.2 c.2536G>A p.(Gly846Arg) arRP 1 6 [73] 
CRB1 NM_201253.2 c.3101T>C p.(Leu989Thr) arLCA 1 8 [73] 
CRB1 NM_201253.2 c.3296C>A p.(Thr1099Lys) arRP 1 9 [24] 
CRB1 NM_201253.2 c.3343_3352del p.(Gly1115Ilefs*23) arRP 1 9 [75] 
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CRB1 NM_201253.2 c.3347T>C p.(Leu1071Pro) arRP 1 7 [73] 
CRB1 NM_201253.2 c.3962G>C p.(Cys1321Ser) arRP 1 5 [76] 
EYS NM_001142800.1 c.8299G>T p.(Asp2767Tyr) arRP 1 7 [20] 
GNAT1 NM_144499.2 c.386A>G p.(Asp129Gly) arCSNB 1 1 [77] 
GRK1 NM_ 002929 c.614C>A p.(Ser205*) arCSNB (Oguchi) 1 9 [19] 
GRK1 NM_ 002929 c.827+623_883del p.(?) arCSNB (Oguchi) 1 3 [78] 
IMPG2‡ NM_016247.3 c.1680T>A p.(Tyr560*) arRP 1 2 [28] 
LCA5‡ NM_181714.3 c.643del p.(Leu215Tyrfs*11) arLCA 1 4 [79] 
LCA5‡ NM_181714.3 c.1151del p.(Pro384Glnfs*17) arLCA 3 13 [39, 67] 
MERTK NM_00634.2 c.718G>T p.(Glu240*) arRP 1 4 [80] 
NMNAT1‡ NM_022787.3 c. 25G>A p.(Val9Met) arLCA 1 5 [40] 
NMNAT1‡ NM_022787.3 c.838T>C p.*280Glnext*16 arLCA 1 8 [41] 
PDE6A NM_000440.2 c.889C>T p.Gly297Ser arRP 1 4 [81] 
PDE6A NM_000440.2 c.1264-2A>G p.(?) arRP 1 5 [81] 
PDE6A NM_000440.2 c.1630C>T p.(Arg544Trp) arRP 1 3 [23] 
PDE6A NM_000440.2 c.2218-2219insT p.(Ala740Valfs*2) arRP 1 3 [81] 
PDE6B NM_000283.3 c.1160C>T p.(Pro387Leu) arRP 1 6 [82] 
PDE6B NM_000283.3 c.1655G>A p.(Arg552Gln) arRP 1 9 [82] 
PDE6B NM_000283.3 c.1722+1G>A p.(?) arRP 1 4 [24] 
PROM1 NM_006017.2 c.1726C>T p.(Gln576*) arRP 1 6 [83] 
RDH12 NM_152443.2 c.506G>A p.(Arg169Gln) arLCA/EORD 2 2 [84] 
RDH12 NM_152443.2 c.619A>G p.(Asn207Asp) arLCA/EORD 1 1 [84] 
RDH5 NM_001199771.1 c.758T>G p.(Met253Arg) arCSNB (FA) 1 6 [27] 
RDH5 NM_001199771.1 c.913_917del p.(Val305Hisfs*29) arCSNB (FA) 1 2 [27] 
Chapter  7 
 
169 
 
RHO NM_000539.3 c.448G>A p.(Glu150Lys) arRP 2 6 [21] 
RHO NM_000539.3 c.1045T>G p.(*349Gluext*52) adRP 1 8 [32] 
RLBP1 NM_000326.4 c.346G>C p.(Gly116Arg) arCSNB (FA) 1 4 [85] 
RLBP1 NM_000326.4 c.466C>T p.(Arg156*) arCSNB (FA) 1 6 [85] 
RP1† NM_006269.1 c.1118C>T p.(Thr373Ile) arRP 2 11 [46] 
RP1 NM_006269.1 c.1458_1461dup p.(Glu488*) arRP 2 9 [46, 86] 
RP1 NM_006269.1 c.4555del p.(Arg1519Glufs*2) arRP 1 5 [86] 
RP1 NM_006269.1 c.5252del p.(Asn1751Ilefs*4) arRP 1 4 [86] 
RPE65 NM_000329.2 c.131G>A p.(Arg44Gln) EORP 1 3 [87, 88]; this study 
RPE65 NM_000329.2 c.361del p.(Ser121Leufs*6) EORP 1 4 [87]; this study 
RPE65 NM_000329.2 c.751G>T p.(Val251Phe) arLCA 1 6 [67] 
RPGR NM_001034853.1 c.2426_2427del p.(Glu809Glyfs*25) xlRP 1 8 [89](het); this study
RPGRIP1 NM_020366.3 c.587+1G>C p.(?) arLCA 1 1 [67] 
RPGRIP1 NM_020366.3 c.1180C>T p.(Gln394*) arLCA 1 1 [67] 
RPGRIP1 NM_020366.3 c.1639G>T p.(Ala547Ser) arCRD 3 12 [90] 
RPGRIP1 NM_020366.3 c.2480G>T p.(Arg827Leu) arCRD, arLCA 2 8 [67, 90] 
RPGRIP1 NM_020366.3 c.3620T>G p.(Leu1207*) arLCA 1 1 [67] 
SAG NM_000541.4 c.916G>T p.(Glu306*) arCSNB (Oguchi) 1 1 [91] 
SEMA4A NM_022367.3 c.1033G>C p.(Asp345His) arRP/arCRD 4 4 [92] 
SEMA4A NM_022367.3 c.1049T>G p.(Phe350Cys) arRP/arCRD 4 4 [92] 
SEMA4A NM_022367.3 c.2138G>A p.(Arg713Gln) (het) arRP/arCRD 1 4 [92] 
SLC24A1‡ NM_004727.2 c.1613_1614del p.(Phe538Cysfs*23) arCSNB 1 5 [44] 
SPATA7 NM_018418.4 c.253C>T p.(Arg85*) arLCA/arRD 2 3 [93] 
SPATA7 NM_018418.4 c.960dup p.(Pro321Thrfs*6) arLCA/arRD 1 6 [93, 94] 
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TTC8† NM_144596.2 c.115-2A>G p.(?) arRP 1 4 [45] 
TULP1 NM_003322.3 c.1138A>G p.(Thr380Ala) EORP 3 30 [26, 67, 95] 
TULP1 NM_003322.3 c.1445G>A p.(Arg482Gln) arRP 1 8 [26] 
TULP1 NM_003322.3 c.1466A>G p.(Lys489Arg) arRP 4 19 [95, 96]; this study 
ZNF513 NM_144631.5 c.1015T>C p.(Cys339Arg) arRP 1 4 [42, 97] 
 
ACHM, achromatopsia; ad, autosomal dominant; ar, autosomal recessive; CSNB, congenital stationary night blindness; CRD, cone rod 
dystrophy; EORD, early onset retinal dystrophy; EORP, early onset RP; FA, fundus albipunctatus; het, heterozygous; LCA, Leber congenital 
amaurosis; RD, retinal dystrophy; RefSeq Id, reference sequence identifier; RP, retinitis pigmentosa; xlRP, X-linked RP; in bold lettering 
mutations identified in this study; ‡novel gene identification; †novel phenotype association.  
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Table 4. Mutations identified in Pakistani patients with syndromic retinal dystrophies 
Gene RefSeq Id Nucleotide variant Protein variant Phenotype # families # patients References 
AHI1 NM_017651.4 c.2370dup p.(Lys791*) arJBTS 1 2 [98] 
ARL13B NM_182896.2 c.236G>A p.(Arg79Gln) arJBTS 1 3 [99] 
ARL6 NM_032146.3 c.123+1119del p.(?) arBBS 1 1 [100] 
BBS1 NM_02464.9.4 c.47+1G>T p.(?) arBBS 1 2 [Ajmal et al., personal communication] 
BBS1 NM_02464.9.4 c.442G>A p.(Asp148Asn) arBBS 1 2 [Ajmal et al., personal communication] 
BBS2 NM_031885.3 c.1237C>T p.(Arg413*) arBBS 1 1 [101] 
BBS5 NM_152384.2 c.2T>A p.(Met1Lys) arBBS 2 2 [101] 
BBS10 NM_024685.3 c.271dup p.(Cys91Leufs*5) arBBS 2 4 [102] 
BBS10 NM_024685.3 c.1091del p.(Asn364Thrfs*5) arBBS 1 1 [102] 
BBS10 NM_024685.3 c.1958_1967del p.(Ser653Ilefs*4) arBBS 1 2 [Agha et al., personal communication] 
BBS10 NM_024685.3 c.2121dup p.(Lys708*) arBBS 1 1 [102] 
BBS12 NM_152618.2 c.1589T>C p.(Leu530Pro) arBBS 2 2 [101] 
BBS12 NM_152618.2 c.2102C>A p.(Ser701*) arBBS 1 3 [103] 
TTC8 NM_144596.2 c.1049+2_1049+4del p.(?) arBBS 1 3 [104] 
CC2D2A‡ NM_001080522.2 c.2003+1G>C p.(?) arJBTS 1 5 [37] 
CDH23‡ NM_022124.5 c.1114C>T p.(Gln372*) arUSH1 1 3 [38] 
CDH23 NM_022124.5 c.2587+1G>A p.(?) arUSH1 1 4 [105] 
CDH23 NI NI p.(Arg1305*) arUSH1 1 4 [105] 
CDH23‡ NM_022124.5 c.3106_3106+11delinsTGGT p.(Gly1036delinsTrpCys) arUSH1 1 5 [38] 
CDH23‡ NM_022124.5 c.6050-9G>A p.(?) arUSH1 4 13 [38] 
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CDH23‡ NM_022124.5 c.6050-1G>C p.(?) arUSH1 1 6 [38] 
CDH23‡ NM_022124.5 c.6054_6074del p.(Val2019_Val2025del) arUSH1 1 3 [38] 
CDH23‡ NM_022124.5 c.6845del p.(Asn2282Thrfs*91) arUSH1 1 3 [38] 
CDH23‡ NM_022124.5 c.7198C>T p.(Pro2400Ser) arUSH1 1 4 [38] 
CDH23‡ NM_022124.5 c.8150A>G p.(Asp2717Gly) arUSH1 1 3 [38] 
CDH23‡ NM_022124.5 c.8208_8209del p.(Val2737Alafs*2) arUSH1 2 11 [38] 
CEP290 NM_025114.3 c.5668G>T p.(Gly1890*) arJBTS 1 1 [106, 107] 
IQCB1 NM_001023570.2 c.488-1G>A p.(?) arSLSN [31]; this study 
IQCB1 NM_001023570.2 c.1465C>T p.(Arg489*) arSLSN 1 1 [31] 
IQCB1 NM_001023570.2 c.1796T>G p.(*599Serext*2) arSLSN 1 1 [106] 
NPHP4 NM_015102.3 c.3272dup p.(Ser1092Valfs*11) arSLSN 1 1 [31] 
PCDH15‡ NM_001142763.1 c.7C>T p.(Arg3*) arUSH1 1 5 [43] 
PCDH15‡ NM_001142763.1 c.1927C>T p.(Arg643*) arUSH1 1 3 [108] 
PCDH15‡ NM_001142763.1 c.3389-2A>G p.(?) arUSH1 1 3 [43] 
TCTN2 NM_024809.3 c.1873C>T p.(Gln625*) arJBTS 1 4 [109] 
TMEM67 NM_153704.5 c.647del p.(Val217Leufs*5) arMKS 1 2 [110] 
TMEM67 NM_153704.5 c.715-2A>G p.(?) arMKS 1 1 [110] 
TMEM67 NM_153704.5 c.1127A>C p.(Gln376Pro) arMKS 2 2 [110] 
TMEM67 NM_153704.5 c.1575+1G>A p.(?) arMKS 3 5 [110] 
USH1G NM_173477.2 c.163_164+13del p.(Gly56*) arUSH1 1 4 [111] 
Ar, autosomal recessive; BBS, Bardet-Biedl syndrome; JBTS, Joubert syndrome; MKS, Meckel syndrome; NI, not indicated; RefSeq Id, 
reference sequence identifier; SLSN, Senior-Loken syndrome; USH1, Usher syndrome type 1; in bold, mutations identified in this study; 
‡novel gene identification; †novel phenotype association.  
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Homozygosity mapping and exclusion of previously identified causative genes in 9 
retinal disease families 
Homozygosity mapping in three families (F09, F11, and F16), did not yield homozygous 
regions >2 Mb encompassing genes previously implicated in arRP or arLCA (Fig. 2; Table 
5). In the remaining 6 families, we excluded 8 arLCA or arRP genes located in 
homozygous regions (Fig. 2; Table 5).  
 
Figure 2. Pedigrees of the unsolved arRP families. Black symbols represent affected 
individuals; open symbols non-affected persons. 
 
Among these 9 families homozygous regions in two families reached significant LOD 
scores (>3.3) on chromosome 5 (F12), and chromosomes 11 and 10 (F09), respectively, 
while in two families (F10 and F16), LOD scores of 2.7 and 3.0 were observed, which is 
highly suggestive of linkage at chromosomes 1 (F10), and chromosomes 4 and 17 (F16).
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Table 5. Homozygosity mapping data of families without mutations in genes associated with arRP and LCA 
# 
Family
# Affected 
persons 
Chr. Flanking SNPs 
Chromosomal positions
(in hg19) 
Size of  
Hz 
regions (Mb)
Ranking 
Hz regions
LOD
score
Excluded 
arRP/LCA-associated 
genes 
F09 7 11 rs1825015;rs1944086 36,960,292-63,036,867 26.1 1 4.02 - 
  10 rs1986519;rs2181019  101,757,025-108,311,696 17.2 2 3.9 - 
  6 rs2050137;rs1416207  139,491,756-143,889,275 4.6 3 2.81 - 
  6 rs1367669;rs717796  123,647,417-127,789,979 4.1 4 1.65 - 
  12 rs951062;rs3847896  19,988,377-23,159,966  4.1 5 2.04 - 
F10 3 1 rs559809;rs6537756 67,035,336-113,099,290 46.1 1 2.7 ABCA4, RPE65 
F11 2 2 rs1356056;rs744397 170,232,853-178,859,118 8.6 1 1.18 - 
  15 rs782944;rs403844 61,338,477-67,296,638 5.9 2 1.90 - 
  5 rs923898;rs4702266 2,903,307-5,397,628 2.5 5 1.85 - 
F12 5 4 rs894486;rs717614 4,308,513-10,104,788 9.7 1 3.07 PDE6B 
  16 rs957078; rs163235 14,019,704-20,651,378 6.6 2 1.68 - 
  10 rs3852447;rs951308  71,737,065-76,617,479 4.9 3 2.24 - 
  12 rs1525895;rs2320519  33,966,496-38,259,123 4.3 4 2.54 - 
  6 rs1367669;rs717796  123,647,417-127,789,979 4.1 5 2.31 - 
  16 rs724466;rs2188353  22,797,852-26,444,828 3.6 6 1.20 - 
  12 rs934159;rs1042503  100,296,887-103,246,700 2.9 8 2.84 - 
  14 rs721379;rs1861891  75,902,562-78,509,980 2.6 9 1.30 - 
  4 rs1108429;rs1377290  87,165,644-89,719,368 2.5 10 2.30 - 
  5 rs723698;rs368337 146,756,993-148,815,759 2.1 11 3.34 - 
F13 5 9 rs2254168;rs1045287  113,189,213-130,774,369 17.6 1 2.54 - 
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  1 rs1768673;rs2136875 220,205,020-226,606,536 6.40 2 2.20 - 
  11 rs2156449;rs2001625 126,533,749-130,598,213 4.1 3 2.51 - 
  17 rs1062935;rs599314 78,939,857-80,728,072 1.8 4 1.63 PDE6G 
F14 2 2 rs1015117;rs1567804 86,740,863-101,343,638 14.6 1 1.8 - 
  10 rs2227551;rs2039305 75,669,190-89,987,183 14.3 2 1.5 RGR 
  10 rs7094359;rs6580 92,304,910-105,206,874 12.9 3 1.5 - 
  12 rs9300302;rs4883148 3,867,471-8,614,238 4.7 4 1.4 - 
F15 5 17 rs1848550;rs1984661 6,745,641-12,650,777 5.9 1 1.8 AIPL1, GUCY2D 
  21 rs1014803;rs2836301 37,094,040-39,677,589 2.6 3 1.8 - 
F16 4 17 rs7946;rs1394385   17,409,560-31,689,618 14.3 1 3.0 - 
  4 rs719786;rs1396539  109,396,732-121,108,516 11.7 2 3.0 - 
  4 rs1118570;rs963065  96,602,391-102,065,631 5.5 3 3.0 - 
F17 3 17 rs11079195;rs8079450 53,904,453-70,355,300 16.4 1 2.4 - 
  15 rs11853534;rs2238292 37,033,338-50,551,632 13.5 2 2.4 - 
  1 rs4255388;rs10920369 188,770,589-202,203,337 13.4 3 2.4 CRB1 
  11 rs11222749;rs2212450 99,968,814-112,826,867 12.8 4 2.4 - 
  16 rs11646672;rs4783573 66,487,206-68,840,588 2.3 5 2.4 - 
Homozygous regions with LOD scores >1.0 are indicated. ar, autosomal recessive; LCA, Leber congenital amaurosis; Mb, mega bases; 
RP, retinitis pigmentosa; Hz, homozygous. Note: Regions with low LOD scores carry haplotypes that are relatively frequent in the 
Pakistani population (data not shown). 
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In the remaining five families (Fig. 2), the limited number of affected individuals that were 
tested restrict the maximally achievable LOD score. Details about the homozygous regions 
of the respective families are presented in Table 5.  
 
Overview of molecular genetic studies in non-syndromic RD in Pakistan 
Forty-four studies thus far reported the genetic causes of non-syndromic RD including 
arCRD, arCSNB, arLCA, and arRP in Pakistani persons, most of which belong to 
consanguineous families. Together with the results presented here, genetic data of a total of 
460 Pakistani RD patients from 106 families (Table 3), have been described. Among these 
retinal phenotypes, arRP was found to be the most frequently occurring RD (64%), 
followed by arLCA (18%), arCSNB (8%), and arCRD (7%; Table 3; Fig. 3). 
Autosomal recessive inheritance predominates in the RD families (97%) and only two 
studies have described mutations in RHO (MIM# 180380), and BEST1 (MIM# 607854), 
causative of autosomal dominant RP [32, 33]. The compiled data showed that out of 119 
genes known to be involved in non-syndromic RD, 35 different genes have been reported 
to be mutated in families of Pakistani origin (Table 3; Fig. 4), reflecting the genetic 
heterogeneity of the disease in this population. The most frequently mutated genes were 
AIPL1 (MIM# 604392), CRB1, SEMA4A (MIM# 607292), TULP1, RPGRIP1 (MIM# 
605446), and RP1 (MIM# 180100: Fig. 4). Most of the reported mutations and those we 
identified in our cohort (Tables 2, 3 and 4), were novel to this population except for 
mutations in ABCA4 (MIM# 601691), CRB1, CERKL (MIM# 608381), RPE65, RPGR 
(MIM# 312610), and SPATA7 (MIM# 609868), which were initially identified in persons 
of different ethnicity (Table 3). 
 
Overview of molecular genetic studies in syndromic RDs in Pakistan 
Data of 50 syndromic RD families with a total of 127 affected individuals were collected 
from 20 studies. Usher syndrome represented about 38% (19/50), of the families in this 
group, whereas BBS (30%), and MKS (14%), JBTS (10%), and SLSN (8%), accounted for 
the other families (Table 4; Fig. 5). The most commonly mutated gene associated with 
syndromic RD in the Pakistani population is cadherin 23 (CDH23: MIM# 605516), 
mutated in persons with Usher type 1, followed by TMEM67 (MIM# 609884), the gene 
mutated in persons with autosomal recessive MKS (Table 4; Fig. 6). 
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Figure 3. Distribution of non-syndromic Pakistani RD families according to their 
phenotypes. Ad, autosomal dominant; ar, autosomal recessive; CRD, cone-rod dystrophy; 
CSNB, congenital stationary night blindness; LCA, Leber congenital amaurosis; RP, 
retinitis pigmentosa; xl, X-linked. 
 
Figure 4. Occurrence of gene defects in non-syndromic RD families in Pakistan. Numbers 
of families with mutations in respective genes are indicated between parentheses. 
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Figure 5. Prevalence of syndromic RD phenotypes. BBS, Bardet-Biedl syndrome; JBTS, 
Joubert syndrome; MKS, Meckel syndrome; SLS, Senior-Loken syndrome; USH, Usher 
syndrome. 
 
 
Figure 6. Occurrence of gene defects in syndromic RD families in Pakistan. Numbers of 
families with mutations in respective genes are indicated between parentheses. 
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DISCUSSION 
The Pakistani population is known for its high rate of consanguinity (>60%), but it still is 
remarkable that 97% of randomly sampled families with inherited RDs show an autosomal 
recessive inheritance model. It therefore is not surprising that Pakistani families have been 
instrumental to pinpoint the underlying gene defects through homozygosity mapping [34, 
35]. Genetic studies of Pakistani families with RD have previously resulted or aided the 
identification of ten novel RD genes, i.e. AIPL1 [36], BEST1 [33], CC2D2A (MIM# 
612013), [37], CDH23 (MIM# 605516), [38], IMPG2 (MIM# 607056), [28], LCA5 (MIM# 
611408), [39], NMNAT1 (MIM# 608700), [40, 41], ZNF513 (MIM# 613598), [42], 
PCDH15 (MIM# 605514), [43], and SLC24A1 (MIM# 603617), [44]. In CLRN1 (MIM# 
606397), and TTC8 (MIM# 608132), genes previously implicated in the syndromic retinal 
phenotypes USH3 (MIM# 276902), and BBS (MIM# 209900), causal mutations were 
identified in persons with non-syndromic arRP [22, 45]. In addition, RP1, already known 
to be mutated in adRP, harbored recessive mutations in 3 Pakistani families [46]. Five RD 
loci including three non-syndromic, i.e. CORD8 (MIM# 605549), [47], RP29 (MIM# 
612165), [48], and RP32 [49], and two syndromic, i.e. USH1H (MIM# 612632), [50], and 
USH1K [51], have also been identified in Pakistani families.  
In the 106 families with non-syndromic RDs that have been reported so far from 
Pakistan, mutations were most frequently found in AIPL1 (10%), CRB1 (8%), SEMA4A 
(8%), TULP1 (8%), RPGRIP1 (8%), and RP1 (6%; Table 3; Fig. 4). A direct comparison 
with other RD populations is difficult as comprehensive studies of this kind are rare. A 
recent study on the screening of Saudi Arabian RD families showed similar results as RP1 
(15%), TULP1 (12%), RPGRIP1 (12%), and CRB1 (9%), were found to be frequently 
mutated [52]. This should not come as a surprise as these populations share a similar 
genetic background [53]. 
A general literature study revealed arRP-associated mutations in USH2A (12%; 
MIM# 276901), ABCA4 (8%), PDE6B (7%; MIM# 180072), CNGB1 (6%), and PDE6A 
(5%; MIM# 180071), [54]. In a more recent study of 230 Dutch persons with isolated or 
arRP [55], the most frequently mutated genes were EYS (11%; MIM# 602772), and CRB1 
(11%), followed by USH2A (10%), ABCA4 (9%), and PDE6B (7%). The absence of 
USH2A variants in Pakistani patients is probably due to the fact that the most frequent 
arRP-associated variant, c.2299delG; p.(Glu767Serfs*21), almost invariably is found in 
compound heterozygous states with the second mutation that is considered to be mild [56], 
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precluding its detection in a homozygosity mapping approach. Other differences can only 
be attributed to divergent genetic backgrounds of these populations [57, 58]. 
The four most frequent variants, p.(Trp278*) in AIPL1, p.(Lys489Arg) in TULP1, 
p.(Asp345His), and p.(Phe350Cys) in SEMA4A (Table 3), explain about 22% of the non-
syndromic RD families. The p.(Trp278*) variant has been identified as the most frequent 
AIPL1 variant in many LCA studies [59, 60], suggesting that this variant is relatively old. 
Although 108/115 variants listed in Tables 3 and 4 have only been identified in Pakistani 
patients, 8 variants (LCA5, p.(Pro384Glnfs*17); RPGRIP1, p.(Ala547Ser) and 
p.(Arg827Leu); SEMA4A, p.(Asp345His) and p.(Phe350Cys); TULP1, p.(Thr380Ala); 
TMEM67, c.1575+1G>A and p.(Gln37Pro)), are more frequent than others and have not 
been identified in other studies. We therefore consider them to be population-specific. 
Likewise, variants such as p.(Met390Arg) in BBS1 (MIM# 209901), and p.(Cys91Leufs*5) 
in BBS10 (MIM# 610148), that account for most of the BBS cases in the French population 
[61] were not found in Pakistani BBS cases. The 8 frequent variants mentioned above, 
together with 5 other variants RDH12 (MIM# 608830), p.(Arg169Gln); RHO, 
p.(Glu150Lys); RP1, p.(Thr373Ile), p.(Glu488*), SPATA7, p.(Arg85*), account for 
approximately 42% of all non-syndromic RD families in Pakistan. A cost-effective initial 
genetic screening for Pakistani persons with RD therefore could be to analyze these 
variants or a larger subset of variants such as listed in Tables 3 and 4, using arrayed primer 
extension (APEX) analysis or other allele-specific genotyping methods [62-64], that could 
be specifically designed for the Pakistani population. 
By employing the approach of homozygosity-mapping and subsequent sequence 
analysis of known RD-associated genes residing in homozygous regions, 32 out of 41 
(78%), families have been solved (Fig. 7). These include 17 families (8 solved, 9 
unsolved), which are described in here and 24 families solved previously [19-28].   
In a total of 26 out of 32 families we performed homozygosity mapping and 
subsequent sequence analysis of candidate genes previously implicated in inherited retinal 
diseases. In most of these families 96% (i.e. 25/26), the linked region contained the known 
retinal disease gene that harbored the pathogenic mutations (Tables 2 and 3). The causative 
mutation in 22 of 26 families (85%) was found in the largest homozygous region, which is 
not unexpected as the largest regions generally contains the largest number of genes. 
Sequence analysis of previously identified RD-associated genes that are located in 
homozygous regions was successful in 31 of 40 (78%), families with presumed autosomal 
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recessive inheritance. In a comparable study of multiplex families 36/63 (57%), were 
solved using the similar approach [52].  
 
 
Figure 7. Genes mutated in current cohort of 41 families. Numbers of families with 
mutations in respective genes are indicated between parentheses. *Novel autosomal 
recessive RP genes identified in this cohort. 
 
Employing homozygosity mapping and candidate gene analysis, the genetic cause could 
not be determined in 9 families with arRP (Fig. 2, Table 5). For these families LOD scores 
of homozygous regions varied from 1.8 to 4.0. Highly suggestive linkage (LOD >2.7), was 
found for two families (F10 and F16), and significant LOD scores (>3.3), were found for 
F09 and F12. However, only in family F10 a single homozygous region of 46.1 Mb was 
found on chromosome 1 (LOD score 2.7), which was overlapping with the RP32 locus 
(MIM# 609913), [49]. The remaining five families showed multiple homozygous regions 
due to a smaller number of affected individuals. In each of these families, the homozygous 
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regions can harbor the causative mutation, but we cannot exclude other possibilities. First, 
we cannot rule out deep-intronic causal variants in the ‘excluded’ RD-associated genes. 
Second, we assume that affected individuals from these consanguineous families carry 
homozygous mutations but, considering that there is consanguinity in ~60% of Pakistani 
families [11], compound heterozygous mutations may also be present in consanguineous 
families. Similarly, X-linked inheritance also can be suspected in families with a 
preponderance of affected males and no male-to-male transmission of gene defects. 
Indeed, among 6 tested families (F03, F06, F08, F11, F12 and F17), with these 
characteristics, we identified a causal RPGR mutation in one family (F03; Fig. 1). 
Our systematic approach yielded causal mutations in 78% (32/41), of families with 
inherited syndromic and non-syndromic RDs, suggesting for the first time that the majority 
of causal genes for inherited RDs have been identified. The next steps in our analyses will 
be the exclusion of mutations in genes previously implicated in allied syndromic and non-
syndromic retinal diseases, and if not successful, next generation sequencing of the 
respective exomes. 
In conclusion, we have provided a comprehensive overview of genetic causes of 
non-syndromic and syndromic retinal diseases in Pakistan, the results of which can be used 
to design a cost-effective screening platform for future genetic testing in Pakistan. In 
consanguineous families homozygosity directed sequence analysis facilitates mutation 
identification. In addition, under the assumption that homozygous mutations underlie the 
retinal phenotypes, we have identified novel candidate arRP loci in 9 families, which will 
facilitate the identification of novel causal genes. 
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This aim of this thesis was to identify the genetic defects in Pakistani patients with retinal 
dystrophies (RD), with a special focus on retinitis pigmentosa (RP). Knowing the genetic 
cause of such diseases may be beneficial for a number of reasons: first, it will enable us to 
better understand the pathological pathways/mechanisms that lead to retinal diseases. 
Second, establishing the genetic diagnosis aids a more accurate disease prognosis and 
planning for clinical follow-up. Third, it allows genetic counseling to be offered to patients 
and their relatives, to minimize the probability of disease transmission to the next 
generation. Finally, knowledge about the underlying genetic defect is also important for 
developing therapeutic interventions, a field that is still in its infancy but which poses a 
promising future. 
From a panel of 38 non-syndromic families, the causative genetic variant was identified in 
29 (76%) families. In one family with three affected siblings, a homozygous null mutation 
aided the identification of a novel arRP gene, IMPG2. In two families, we established a 
novel association of CLRN1 mutations with non-syndromic RP, previously, mutations in 
this gene were only known to cause Usher syndrome type III. This thesis also describes a 
link between splicing dysfunction and autosomal recessive RP (arRP), as a homozygous 
missense mutation in SNRNP200 co-segregates with arRP phenotype in one of the 
families.  
 
Clinical heterogeneity, diagnostic criteria and differential diagnosis 
Retinal dystrophies (RD) are clinically heterogeneous, hence it is important to distinguish 
the clinical subtype of an affected individual, i.e. to ascertain the correct differential 
diagnosis, which is crucial for disease prognosis and planning of clinical follow-up. It is 
also very helpful in providing the patient with the genetic diagnosis, as despite the genetic 
heterogeneity, many retinal dystrophy genes are associated with a particular clinical 
subtype of RD. 
Differential diagnosis of RD is one of the major challenges associated with ophthalmic 
practice, due to the fact that the clinical symptoms frequently overlap. For example, 
persons with RP and cone-rod dystrophy (CRD) at the end-stage of the disease lose their 
central as well as peripheral vision. This makes these dystrophic subtypes clinically 
indistinguishable from each other at this stage, and the diagnosis is usually based on the 
past history provided by the patient. To circumvent this problem, the need for an early 
diagnosis should be emphasized, as at advanced stages of the disease it is very difficult to 
differentiate between overlapping phenotypes. For this, the population needs to be 
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educated, that when they first experience any visual symptoms, no matter how subtle, they 
should visit an ophthalmologist immediately. In addition, proper clinical facilities need to 
be developed where a differential diagnosis can be established, which also requires proper 
education of the ophthalmologists. Considerable attention should be given to obtain the 
correct clinical history of the disease, not only from the patient but also from the parents 
and other relatives, as it can determine the course of the disease in the absence of 
ophthalmic examination records. 
 
Another diagnostic challenge is to distinguish between stationary and progressive forms of 
retinal dystrophy, as at initial stages they are clinically indistinguishable. In such cases the 
disease progression is measured over time and requires periodic visits to the 
ophthalmologist to determine the nature of the disease. In addition, sensitive and advanced 
ophthalmic techniques such as electroretinography (ERG) and spectral-domain optical 
coherence tomography (SD-OCT) are recommended, which are not part of routine 
investigations performed in most clinics, and may give insight into the nature of the 
disease [1]. The genetic prognosis is also helpful in making the distinction between 
different clinical subtypes. During the current study, on several occasions, the clinical 
diagnosis of the patients was reconsidered after identifying the genetic defect. For example 
in family RP19, which was initially diagnosed with arRP, linkage data were highly 
suggestive (LOD score 3.3) for the involvement of GRK1, a gene previously associated 
with a rare form of congenital stationary night blindness (CSNB) known as Oguchi disease 
[2]. This disease is generally characterized by nyctalopia and a metallic gray sheen of the 
fundus, which disappears after a prolonged period of dark adaptation. Sequence analysis of 
GRK1 identified a pathogenic variant, which segregates with the disease in the family. 
Based on the involvement of the gene in Oguchi disease, the clinical characterization of 
patients of family RP19 were re-examined to reconsider the diagnosis. It was observed that 
after a long period of dark adaptation, the metallic sheen of fundus disappeared in the 
proband, which thus confirmed the diagnosis of Oguchi disease. Similarly, two other 
families with fundus albipunctatus (FA) were initially misdiagnosed to have arRP. 
Homozygosity mapping aided the identification of probable pathogenic mutations in the 
RDH5 gene. The clinical diagnosis was re-evaluated and indeed the patients of both 
families were found to suffer from FA [3].  In families such as these and in other similar 
cases a  differential diagnosis can be established by a clinical geneticist with knowledge of 
ophthalmology or an ophthalmologist with experience in genetics of retinal diseases. 
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The need to recognize gene-specific phenotypes 
Sometimes, specific clinical features of retinal dystrophy may guide the identification of 
the underlying molecular genetic defect. For example, if there is a strong suspicion of FA, 
sequence analysis of RDH5 is the first logical step to take, as mutations in this gene are 
almost exclusively associated with FA [4, 5]. Similarly, although ABCA4 mutations cover 
a spectrum of retinal dystrophies, its genetic contribution towards Stargardt disease is more 
prominent than any other gene, as the majority of Stargardt patients (>90%) carry 
mutations in ABCA4 [6-8]. In addition there are some other less obvious genotype-
phenotype correlations, which may be indicative of the specific gene defect. For example, 
RP patients with preserved para-arteriolar RPE (PPRPE) and with extensive nummular 
pigmentation in the peripheral retina probably carry CRB1 gene defects [8, 9]. PPRPE is 
characterized by preservation of the retinal pigment epithelium (RPE) adjacent to and 
under the retinal arterioles, while there is a general loss of the RPE throughout the retina. 
The area of preserved retina varies, but this preservation is seen most consistently in the 
equator and peripheral regions of the eye [9, 10]. Similarly, patients with juvenile onset 
RP, who present with nyctalopia and a yellow perifoveal annular ring upon fundus 
examination, may carry mutations in TULP1 [11]. 
 
Establishing genotype-phenotype correlations 
Mutations in many different genes can cause the same retinal phenotype, but it is also 
known that mutations in a single gene can cause multiple related syndromic and non-
syndromic phenotypes. Previously, it had been shown that allelic variants in USH2A can 
cause either Usher syndrome type IIA (a combination of RP and hearing impairment) or 
non-syndromic RP. In two arRP families described in this thesis, genetic linkage suggested 
the involvement of CLRN1, a gene thus far only known to be associated with autosomal 
recessive Usher syndrome type IIIA (USH3A), which encompasses RP, sensorineural 
hearing loss, and variable vestibular dysfunction. Sequence analysis of CLRN1 identified 
two different homozygous missense mutations in these families. The mutations were 
located in the transmembrane domain of the protein and in-silico analysis predicted that 
both mutations could result in misfolding of clarin-1 proteins. An in vitro sub-cellular 
localization assay in hTERT-RPE1 cells indicated that the misfolded mutant protein was 
retained inside the endoplasmic reticulum and was not transported to the plasma 
membrane, where the wild type protein is located, indicating that both the amino acid 
alterations impair clarin-1 function. After identifying the genetic defect, the affected 
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individuals of both families were revisited to assess auditory and vestibular functions, and 
these were found to be within the normal limits in both families. Thus, the CLRN1 
missense mutations that segregated in these two unrelated families, were indeed found to 
cause non-syndromic RP. 
In contrast to CLRN1 and USH2A in which different mutations can cause either 
syndromic or non-syndromic RP, there are other genes that, depending on the type of 
mutation, are involved in either autosomal dominant (ad), or autosomal recessive (ar) RP, 
including BEST1, NR2E3, NRL, RHO, RPE65 and RP1. In this thesis, we report another 
example of such a gene, since we identified a mutation in SNRNP200, previously 
implicated in adRP, in a family with arRP. In a three generation pedigree, homozygosity 
mapping analysis indicated eighteen homozygous regions of >2 Mb, the largest of which 
resided on chromosome 2 and encompassed 15 Mb of genomic DNA. The involvement of 
three genes previously implicated in RD (i.e. CNGA3, RGR and PDE6C) and present in the 
homozygous regions, was excluded by sequencing. The largest homozygous region also 
contained SNRNP200, which initially was not analyzed by Sanger sequencing, as a 
recessive inheritance pattern was apparent for the family. However, upon exome 
sequencing and subsequent prioritization of the variants in the homozygous regions, a 
homozygous missense variant (i.e. c.3269G>A; p.(Arg1090Gln)) in SNRNP200 was 
identified that segregates with the disease in the family. The gene SNRNP200 encodes 
hBBR2, a homolog of yeast BRR2 that is a part of the spliceosome complex composed of 
specialized RNA and associated proteins (U1, U2, U4, U5 and U6) called small nuclear 
RNA proteins (snRNPs). hBRR2 is a part of the U5 snRNP that forms a spliceosome 
subunit (i.e. tri-snRNP complex) with U4 and U6, which aligns the RNA during splicing of 
the intron. Intriguingly, the variant identified in our arRP family overlaps with a known 
adRP mutation, c.3269G>T; p.(Arg1090Leu), which is known to impair splicing in vitro. 
We speculate that the p.(Arg1090Gln) variant identified in the arRP family also impairs the 
unwinding of tri-SNRNP complex similar to the adRP variant, although the effect is most 
likely hypomorphic. 
 
The power of homozygosity mapping  
Although a detailed phenotypic characterization of affected individuals is important to 
develop a differential diagnosis, considerable attention is also warranted to characterize the 
normal individuals in the pedigree, in order to facilitate the discovery of the genetic defect. 
From a genetic point of view, normal individuals in a pedigree can provide as much 
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information as affected individuals when using a homozygosity-mapping based approach. 
For example, common homozygous regions that are identical between affected and normal 
individuals are not plausible candidate regions to harbor the culprit mutations. In this way 
the number of candidate genes will be considerably reduced in the family under 
investigation. In addition, in routine ophthalmic genetic practice, segregation of a genetic 
variant within a family is considered a basic proof of pathogenicity. Hence, unaffected 
individuals need to be clinically characterized especially in families in which the disease 
manifests at later age. 
For the past two decades, homozygosity mapping has been the method of choice to 
identify the genetic defect in families with an autosomal recessive inheritance pattern of 
the disease. The technique has been shown to be effective and efficient in not only 
consanguineous but also in non-consanguineous families. As most of the families in our 
cohort are consanguineous, the homozygosity-based linkage approach was used as a 
starting method to locate the underlying genetic defects in these families.  
Of the 53 non-syndromic retinal dystrophic families that were genetically analyzed, 
we have been able to solve 30 (57%) of the families. In the majority of these cases, i.e. 
87% (26/30), mutations were identified in a gene previously associated with retinal 
disease. Of these 53 non-syndromic families, 43 (81%) were diagnosed with arRP. So far, 
we have been able to find the genetic defect in 23 (23/43) arRP families, and in a vast 
majority (19/23; 83%) of the families, the mutations were identified in genes previously 
implicated in arRP or LCA. The percentage of families with a mutation in a known gene is 
higher than the estimated numbers reported elsewhere, i.e. approximately 50-60% for arRP 
cases [12, 13]. This highlights the importance and success of homozygosity mapping in 
identifying the genetic defects, which in turn correlates with the high rate of consanguinity 
and the number of affected sibs in the pedigree. The remainder of the families, which have 
not yet been genetically resolved, are generally small, mainly with two or three affected 
individuals, which are often distributed among multiple branches of the family. As a result 
the linkage analysis results are inconclusive, or yield a large number of homozygous 
regions, which encompass many genes. Clearly, Sanger sequencing in the later case is 
laborious and cumbersome, hence these families are now being considered for next 
generation sequence analysis.  
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Targeted vs. exome NG sequencing 
Sanger sequencing technology is now being replaced by newer, more robust and high 
throughput technologies collectively known as “next generation sequencing” (NGS). In 
this technique either a set of candidate genes or genomic regions are enriched (targeted 
NGS), or all exons of the genome (exome NGS) or even the whole genome [14-16] are 
enriched and sequenced. 
Targeted re-sequencing of all identified retinal disease genes in one experiment is 
one potential application of this new sequencing technology [16-19]. The coding sequences 
of these candidate genes are selectively enriched/captured (e.g. with probes on an array) 
before subjecting them to amplification and subsequent sequencing. The advantage of this 
approach is that it is largely biased towards genes known to be associated with the disease 
of interest, which not only significantly reduces the number of variants one will find, but 
also minimizes the chances of coincidental findings. Similarly, this bias becomes a 
disadvantage when we consider the genetic heterogeneity of a disease like retinal 
dystrophy, where several genes still await discovery. In addition, such a platform needs to 
be updated on a regular basis, to add newly discovered disease genes. 
In families where linkage analysis has already been performed, the exonic 
sequences of all genes, or alternatively also intronic and promoter regions, within the 
linkage region can be selectively enriched and sequenced. This approach has been effective 
in the discovery of a number of genes causing different diseases including retinal 
dystrophies (e.g. C8orf37) [15]. However, this approach is mostly biased towards the 
identification of the genetic cause in large homozygous regions and it is obvious that with 
such an approach, one may miss a mutation in a very small homozygous region or patients 
carrying compound heterozygous mutations located outside the homozygous regions. 
Therefore, the preferred approach is generic exome sequencing, which produces a 
large number of variants and introduces the dilemma of coincidental findings, but offers 
the main advantage that it is an unbiased approach. One can adopt the strategy to first 
evaluate those variants that are present in genes known to be associated with a particular 
disease phenotype, or those residing inside a linkage region before assessing the plethora 
of variants spread all over the exome [20]. Unbiased exome sequencing is not only helpful 
in establishing the genetic diagnosis in a heterogeneous disease, but can also aid the 
identification of the genetic cause in small families or even in single patients when 
positional information is not available [21].   
 
Chapter  8 
 
204 
 
What’s next? 
The goal of the human genome project was to sequence the complete human genome and 
to understand the relationship between the genetic defects and disease etiology. The first 
genome sequence draft was published in 1998, and is being continuously improved and 
updated ever since. Despite the enormous progress that has been made, we have to strive 
further to achieve the next goal of the human genome project. The same is true for next-
generation sequencing, despite the fact that we are now able to sequence the exome and 
even the whole genome of an individual, quickly, more efficiently and cheaply [22]. The 
major hurdle that needs to be overcome is to distinguish the disease-causing variant(s) 
from the polymorphic benign variants, as on average 20,000 high-confidence variants are 
obtained in a single exome, corresponding to 1% of the genome. This number will increase 
exponentially when analyzing the entire genomes, thereby possibly reducing the clinical 
utility of whole-genome sequencing [21]. 
By now, many proof of principle studies have been conducted where next 
generation sequencing approaches have been successfully utilized to identify the genetic 
defects for different diseases [16-19]. In addition to variant interpretation problems, there 
are a number of other issues that need to be addressed before the method can be 
implemented in routine genetic diagnostics. Most importantly, GC-rich sequences are 
poorly enriched, resulting in a no or low sequence coverage of many exons mainly located 
at the 5' ends of genes. Also, the pyrosequencing method employed in ABI 454 
technologies is prone to miscalculate the number of nucleotides in a stretch of the same 
nucleotides (homo-polymers) and misinterprets such sequences as containing either an 
insertion or deletion leading to false positive results. The enrichment protocols largely rely 
on amplifying the coding segments of the largest of the isoform of a given gene, and thus 
may miss the coding sequences of other isoforms of the same gene with a restricted tissue 
distribution, and hence might be important from the disease perspective. Hopefully these 
problems will be solved with the advent of third generation sequencing technologies, for 
example the real time single molecule sequencing method (e.g. Pacific Biosciences, 
Helicos), which tends to eliminate the enrichment of the target prior to sequencing, thus 
avoiding the loss of DNA template during enrichment [23, 24]. In addition, new 
sequencing methodologies are also being developed that no longer rely on fluorescence 
signal detection. For instance the newly developed “Ion torrent” method relies on changes 
in pH to sense the release of a proton as a nucleotide is incorporated into the template [25]. 
This non-optical method is able to accurately resolve the number of nucleotides 
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incorporated in a homopolymer stretch and thus minimizes the number of false-positive 
and -negative variants [25]. 
 
Challenges faced by homozygosity mapping in the NGS era 
High-density SNP arrays, containing >500,000 SNPs spread over the human genome, have 
been frequently used during the past year, evidenced by many publications reporting the 
use of these arrays in identification of genetic causes of retinal dystrophies, and other 
diseases [26, 27]. But in 2011, when NGS technology became more widely available and 
was successfully implemented, the cost-effectiveness of SNP arrays was questioned. This 
is especially true for monogenic diseases like retinal dystrophies, where the contribution of 
genomic rearrangements (large genomic deletions and duplications) that can readily be 
identified using SNP arrays, are rare. Currently a single individual can be analyzed on a 
medially dense array (e.g. Illumina human OmniExpress that contains 700,000 markers) 
for about €400 (approximately USD500). For medium sized families with 3-4 affected and 
normal individuals, the total cost will be about €1,600, which corresponds to the amount of 
one exome sequencing experiment which currently costs about €1,500-2,000 (materials 
only). This price consideration indicates the potential of NGS to replace array-based 
linkage analysis. 
On the other hand, a single exome sequencing experiment on average yields about 
20,000 variants per sample. After discarding the variants that are frequently present in SNP 
and exome variant databases, and excluding non-coding and synonymous variants, there 
still remain >100 plausible candidate variants for each sample that need further evaluation. 
The additional information from linkage analysis can greatly reduce the number of 
potential disease-causing variants, usually by a factor ten. This method has already been 
proven to be effective in a large number of studies [15, 20, 28]. Yet another proof of this 
concept was demonstrated by our studies, as we were able to greatly reduce the number of 
variants per individual as by focusing mainly on regions of homozygosity (ROH) identified 
previously by linkage analysis. Pippucci et al. coined a new term i.e. EXome 
HOMozygosity (EX-HOM) for autozygome guided exome sequencing [20]. We believe 
that until we are able to understand the nature of all the synonymous and non-synonymous 
variants and develop bioinformatics protocols that will improve the differentiation between 
disease-causing and benign variants with high confidence, the EX-HOM approach or 
autozygome-guided exome sequencing seem to be the most effective method, i.e. to filter 
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the variants obtained after exome sequence analysis, and to cross compare that to the 
linkage data whenever available. 
 
Genetic diagnosis and gene therapy 
Establishing the genetic diagnosis of patients is also crucial for designing gene therapy, a 
therapeutic approach that holds a promising future [12, 29-31]. The proof of principle of 
gene therapy in inherited retinal diseases comes from the therapeutic intervention of 
LCA/early-onset RP due to RPE65 mutations, which has proven to be safe and moderately 
effective in clinical trials [12, 31, 32].  
For recessively inherited retinal diseases, the technique involves the surgical 
delivery of gene copies to the degenerating retina. The subsequent production of functional 
protein can circumvent the absence of that particular protein product due to a genetic 
defect in the native gene [33, 34]. The first studies performed in retinal degeneration (rd) 
mice showed that sub-retinal injection of a recombinant replication-defective adenovirus 
containing the murine cDNA for wild-type beta-subunit of the cGMP phosphodiesterase 
gene (PDE6B) successfully slows down the photoreceptor degeneration caused by a 
mutation in the murine orthologue of the gene [29, 34, 35].  
Later, in a naturally occurring RPE65-/- canine model of early onset blindness, 
intra-ocular delivery of recombinant adeno-associated virus (rAAV) carrying the wild-type 
RPE65 cDNA (rAAV-RPE65), was shown to improve retinal function and restore vision 
[36]. A follow-up study on the canine model treated with rAAV-RPE65 has shown that 
gene therapy stably rescued photoreceptor morphology and function over a period of eight 
years [37, 38]. This proof of principle experiment that rescued and restored vision in 23 of 
26 treated dogs, paved the way for human gene therapy for LCA due to mutations in 
RPE65. A slightly different rAAV serotype 2 (rAAV2) was chosen for the human trials as 
it preferentially targets the retinal pigmented epithelium (RPE) where endogenous RPE65 
is located. Eighteen subjects diagnosed with LCA/early-onset RP with mutations in RPE65 
were enrolled in the first trial, and received unilateral subretinal injections with rAAV2 
carrying the human RPE65 cDNA (rAAV2.hRPE65v2) [31, 39]. Follow-up studies have 
shown persistent improvement in retinal/visual function, which has been stable for 2-3 
years [31, 39, 40]. However, it was shown that the improvement in visual function is age-
dependent and younger patients appear to benefit more compared to older ones [31, 40]. 
This latter study describes the relationship between time of diagnosis and the treatment 
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window, which highlights the importance of early diagnosis of retinal diseases. In addition, 
it has been observed that patients who were diagnosed early in life and treated at an early 
stage of the disease, had better recovery of visual acuity compared to the individuals who 
were older and were treated at an advanced stage of the disease [31, 40]. Based on this 
observation it has been proposed that the efficacy of gene therapy correlates with the time 
period elapsed after the retinal degeneration has progressed [40]. 
Similarly, gene therapy for a photoreceptor-specific gene encoding aryl 
hydrocarbon receptor-interacting protein-like 1 (AIPL1) in which different mutations can 
cause arLCA, early onset RP (EORP) or adCRD, has also shown promising results in the 
respective mouse models [41]. Two murine models were used to demonstrate rescue i.e. 
Aipl1-/- mice which do not produce any AIPL1 protein at all, and have more severe retinal 
degeneration as compared to Aipl1h/h mice that show less severe retinal degeneration, 
because of the presence of reduced levels of AIPL1 production. Following sub-retinal gene 
delivery, long-term rescue of a photoreceptor-specific defect due to the depletion of AILP1 
was achieved [42, 43]. The promising results of these studies indicate that human clinical 
trials are feasible and most likely will be beneficial. 
Similarly, for 15 other genes associated with human RD, gene therapy has been 
successfully tested in small animal models. For five of these genes, gene therapy has 
entered phase 1 or 2 clinical trials (http://clinicaltrials.gov/ct2/home), i.e., ABCA4 
(STGD1, arCRD, arRP), CHM (choroideremia), RPE65 (LCA, arRP), MERTK (arRP) and 
MYO7A (Usher syndrome type 1B). These studies provide strong support in favor of gene 
replacement therapy for retinal degeneration in humans. In addition, none of these studies 
has thus far raised any major safety issues, which further strengthens the concept that in the 
near future the therapy will be feasible for broad clinical trials involving a large number of 
patients [31]. From our Pakistani patient cohort, two families diagnosed with EORP have 
pathologic mutations in the RPE65 gene, while in another family, a mutation has been 
identified in AIPL1. Individuals in all these three families are severely handicapped due to 
early and rapid loss of vision, thus potentially they can benefit from gene therapy.  
Although results obtained from the pre-clinical and clinical trials of gene 
augmentation therapy are promising, the intrinsic problem with these types of therapy is 
that they are gene-specific, thereby restricting the number of patients that may be eligible. 
In addition, on average it requires about 5 years to develop a gene-specific therapy before 
human trials can be conducted. This not only increases the costs exponentially, but it also 
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reduces the treatment window for the patient, which is even more important in rapidly 
progressing diseases such as retinal dystrophies.  
 
The genetic heterogeneity and rare genetic causes of disease 
The tremendous genetic heterogeneity of retinal dystrophies limits the applicability of gene 
therapy, considering that to date about 160 genes are known to cause a wide spectrum of 
retinal disease phenotypes. Yet these genes only explain the disease in about 60-70% of the 
subjects. Therefore, there is an emerging need to develop the genetic diagnosis for the 
remaining ~30-40% of the genetically uncharacterized subjects.  
Keeping in mind the great genetic heterogeneity of RD, one aspect to consider 
when designing gene therapy is the number of patients with a specific genetic defect, 
giving priority to the most frequently mutated genes [12]. As for the majority of genes, 
only 100-200 patients worldwide carry a mutation in that particular gene, pharmaceutical 
companies and grant foundations are not particularly interested to sponsor pre-clinical 
studies for such a small patient pool. Thus, it is not surprising that only a few gene-
augmentation trials are in progress for retinal disease genes and most of them are being 
done on a research basis, with limited budgets. In addition, the expertise is also limited, as 
the field for retinal gene therapy is still in its infancy. Considering all these points, the road 
to therapy for retinal diseases is challenging. To identify a significant number of patients 
with certain genetic defects, we need to collect a large number of families or probands with 
a specific phenotype and screen all these patients for mutations in known genes. This 
requires multi-center, cross-country and cross-continent collaborations between research 
groups. Indeed this is not an easy task, as the collaborations not only requires exchange of 
standardized patient data but also demand resources and capacity building, considering the 
fact that many of these patients live in underdeveloped countries. On the other hand, the 
scientific community need to design generalized therapy for the retinal diseases, which is 
ideally applicable in the vast majority of cases, irrespective of their underlying genetic 
defect. This is especially true for cases where a gene is only mutated in one or two families 
or a few simplex cases.  
Currently generalized therapeutic approaches are being tested in parallel, which aim 
to correct the pathophysiological pathways responsible for the disease or to modulate the 
secondary effects associated with the disease pathology [44, 45]. Historically, the most 
studied pharmacological interventions involve nutritional and drug supplements for 
example of “lutein” which is a naturally occurring carotene found in high quantity in green 
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leafy vegetables. A randomized trial involving 600 RP patients taking 15,000 IU/d of 
vitamin A, indicated that the supplementation is slightly beneficial as it slows down the 
retinal degeneration in treated patients [46]. Additional supplementation of 
docosahexaenoic acid, a long chain omega-3 fatty acid in these patients slowed the course 
of the disease even further [47]. Similarly, other nutritional supplementations have proven 
to be effective in modifying the course of different retinal disease, but they are not able to 
rescue the retinal integrity for a prolonged period of time and do not improve functional 
vision such as visual acuity and visual field [46-48]. 
In another approach, retinal precursor cells were transplanted in the degenerating 
retina, aiming to replace the damaged photoreceptors [49, 50]. In small rodent models, this 
approach has been able to restore the visual function. However these transplanted cells are 
not able to form synaptic connections with the host neurons, and they are subjected to 
immunological rejection or other inflammatory responses [34, 49, 50].  
The modulation of the secondary pathologic processes are also beneficial in some 
cases e.g. the modulation of photoreceptor apoptosis, which is a hallmark of many retinal 
degenerations. In this case it has been observed in a mouse model that caspase-3 activation 
correlates with photoreceptor degeneration [51, 52]. In a Drosophila model of retinal 
degeneration, eye-specific expression of anti-apoptotic proteins like p35 that target the 
caspase-3 mediated apoptotic pathway, successfully rescued the visual function indicating 
that this method could be beneficial in other organisms as well [53, 54].  
Similarly, the effect of neurotrophic factors like ciliary neurotrophic factor (CNTF), 
glial cell derived neurotrophic factor (GDNF) and vascular endothelial growth factor 165b 
(VEGF(165b)) on the survival of photoreceptors are being assessed [44, 49, 55]. Such 
factors may provide protection against photoreceptor loss; e.g. in a dog model of retinal 
degeneration (CNGB3 mutation), intra-vitreal injection of recombinant CNTF transiently 
restores cone function and thus vision [49, 56, 57]. The same photoreceptor protection was 
observed in 12 other models of photoreceptor degeneration after CNTF administration [58-
60]. The transient nature of the rescue and the inability of the neurotrophic factors to cross 
the blood-retinal barrier limits the applicability of these factors, although these problems 
can be circumvented with the advent of encapsulated cell technology (ECT) [56, 58, 59]. 
In this technique cells producing neurotrophic factors are enclosed within a polymer 
capsule and implanted into the eye, to produce neurotrophic factors locally for extended 
periods of time [58, 59]. In phase I safety trails involving 10 individuals with encapsulated 
CNTF, visual acuity improved and no adverse effects were recorded [61]. Recently a phase 
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II study has been launched (http://clinicaltrials.gov number NCT00447954), which 
involves 51 patients with age-related macular degeneration. The preliminary results 
indicate a dose-dependent increase in retinal thickness, which correlates with visual 
function stabilization and preservation of vision. The promising results from clinical trials 
advocate the applicability of this technique in a vast majority of patients, although the 
visual function restoration is less efficient as compared to the results obtained with gene 
therapy. In addition to the example described here, there are a number of other studies in 
progress that aim to restore or rescue vision in patients with retinal degeneration, which 
include for example the use of an electrical retinal prosthesis, and the use of splicing 
switching oligonucleotides to correct aberrant splicing [44, 62, 63].  
 
Genetic testing in Pakistan and other underdeveloped countries  
A large majority of patients with autosomal recessive retinal diseases lives in remote areas 
of densely populated third world countries like Afghanistan, Bangladesh, India and 
Pakistan [64-66]. This is largely due to consanguineous marriages, which are more 
common in these populations as people live in small communities and tribes [65]. 
Consanguinity is one of the major reasons for the high incidence of autosomal recessive 
disorders in these populations [65, 66]. In addition, inadequate resources and lack of 
healthcare facilities (both for diagnostic and clinical management purposes) further 
increase the incidence of diseases such as retinal disease, that although not treatable are 
still manageable in most cases. Another custom in such communities is marriages between 
two individuals with the same handicap (e.g. with visual impairment). In the case of 
recessive diseases, this may yield offspring that are all affected, increasing the disease 
burden when such a tradition is practiced. In addition, due to the disease burden most of 
these individuals are also less educated, which further exacerbates the economic condition 
of the family as a whole.  
The facts described above partly explain why there are so many patients in 
developing countries like Pakistan, the vast majority of which have not yet been 
genetically characterized. In Pakistan, all the efforts to genetically characterize patients 
have been due to research efforts of the various groups working in the area. If we are to 
eliminate the disease in the country we need to implement a national genetic testing policy, 
like in developed countries such as The Netherlands, France and Germany. In these 
countries the genetic diagnosis is routinely advised for patients with RD, and is covered by 
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the health insurance. The implementation of such a policy in Pakistan requires substantial 
financial resources. 
There are about ten research groups working on inherited retinal and other blinding 
disorders in Pakistan, and all of them are focusing on identifying the genetic defects. To 
the best of my knowledge none of the groups are involved in therapeutic trials that are in 
progress worldwide. In order to provide maximum benefit to patients, we believe that all 
groups working on RD need to pool their resources and join forces to provide genetic 
counseling and disease management options to the patients, along with the genetic 
diagnosis.  
Such disease management options open up avenues for RD patients to minimize 
complications associated with the disease. For example, the use of pink glasses are helpful 
in reducing photophobia in patients with achromatopsia, a congenital cone disorder. 
Similarly, provision of low vision aids, vocational guidance and mobility training are also 
helpful in improving the quality of life for visually impaired persons [44]. In addition, as 
the long-term goal of studies aimed at establishing the genetic diagnosis is to provide a 
therapeutic option to the patients, we also have to pool our resources to achieve that goal 
for Pakistani RD patients. As a first step towards the therapeutic goal, in this study we 
established a large data set of patients with specific genetic defects. We strongly believe 
that the scientific community and pharmaceutical companies aiming to provide therapy for 
retinal diseases can benefit from this work, as it will enable the recruitment of patients for 
gene-specific therapy or drug trials.  
 
Genetic counseling: what we can do right now 
As a part of global society, the scientific community is working hard to provide therapy to 
individuals who are on the verge of becoming, or are already, blind. The progress made 
thus far has raised hopes for patients to receive an effective therapy, although it is also 
evident that this will not be available soon for majority of patients. In the meantime we can 
provide genetic counseling to individuals of a family or clan in case the genetic cause of 
their disease has been identified. This will not only reduce the disease to be inherited 
(spread) to the future generations, but will also reduce the disease burden (number of 
handicaps) in the community. The work described in this thesis extends the list of the 
genetic variants reported in the Pakistani population, and will help to develop a cost-
effective mutation specific platform to identify the genetic defects in uncharacterized 
Pakistani RD patients, so that they can also benefit from counseling in the future. 
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Final remarks 
The results presented here have improved the genetic diagnoses of genetically 
uncharacterized individuals with retinal dystrophies. Results from this thesis highlight the 
importance of homozygosity mapping as a versatile tool to identify the genetic defect. On 
the other hand, together with next generation sequencing technology it can significantly 
reduce the number of candidate variants that need to be further evaluated. This thesis also 
highlights the need to continue research on genetically heterogeneous diseases like retinal 
dystrophy, until their pathologic mechanisms are completely understood. The results from 
this study will undoubtedly improve the understanding of the etiology of retinal diseases 
and will aid the development of new therapies for individuals with these diseases.  
 
  
Chapter  8 
 
213
 
REFERENCES 
1. Chen RW, Greenberg JP, Lazow MA, Ramachandran R, Lima LH, Hwang JC, 
Schubert C, Braunstein A, Allikmets R, Tsang SH. Autofluorescence imaging and 
spectral-domain optical coherence tomography in incomplete congenital stationary 
night blindness and comparison with retinitis pigmentosa. Am J Ophthalmol 2012; 
153:143-54 e2. 
2. Azam M, Collin RWJ, Khan MI, Shah STA, Qureshi N, Ajmal M, den Hollander AI, 
Qamar R, Cremers FPM. A novel mutation in GRK1 causes Oguchi disease in a 
consanguineous Pakistani family. Mol Vis 2009; 15:1788-93. 
3. Ajmal M, Khan MI, Neveling K, Khan YM, Ali SH, Ahmed W, Iqbal MS, Azam M, 
den Hollander AI, Collin RWJ, Qamar R, Cremers FPM. Novel mutations in RDH5 
cause fundus albipunctatus in two consanguineous Pakistani families. Mol Vis 2012; 
18:1558-71. 
4. Sergouniotis PI, Sohn EH, Li Z, McBain VA, Wright GA, Moore AT, Robson AG, 
Holder GE, Webster AR. Phenotypic variability in RDH5 retinopathy (Fundus 
Albipunctatus). Ophthalmology 2011; 118:1661-70. 
5. Schatz P, Preising M, Lorenz B, Sander B, Larsen M, Rosenberg T. Fundus 
albipunctatus associated with compound heterozygous mutations in RPE65. 
Ophthalmology 2011; 118:888-94. 
6. Burke TR, Tsang SH. Allelic and phenotypic heterogeneity in ABCA4 mutations. 
Ophthalmic Genet 2011; 32:165-74. 
7. Koenekoop RK. The gene for Stargardt disease, ABCA4, is a major retinal gene: a 
mini-review. Ophthalmic Genet 2003; 24:75-80. 
8. Koenekoop RK, Lopez I, den Hollander AI, Allikmets R, Cremers FPM. Genetic 
testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin 
Experiment Ophthalmol 2007; 35:473-85. 
9. den Hollander AI, ten Brink JB, de Kok YJM, van Soest S, van den Born LI, van Driel 
MA, van de Pol TJR, Payne AM, Bhattacharya SS, Kellner U, Hoyng CB, Westerveld 
A, Brunner HG, Bleeker-Wagemakers EM, Deutman AF, Heckenlively JR, Cremers 
FPM, Bergen AAB. Mutations in a human homologue of Drosophila crumbs cause 
retinitis pigmentosa (RP12). Nat Genet 1999; 23:217-21. 
10. Heckenlively JR. Preserved para-arteriole retinal pigment epithelium (PPRPE) in 
retinitis pigmentosa. Br J Ophthalmol 1982; 66:26-30. 
Chapter  8 
 
214 
 
11. den Hollander AI, Lopez I, Yzer S, Zonneveld MN, Janssen IM, Strom TM, Hehir-
Kwa JY, Veltman JA, Arends ML, Meitinger T, Musarella MA, van den Born LI, 
Fishman GA, Maumenee IH, Rohrschneider K, Cremers FPM, Koenekoop RK. 
Identification of novel mutations in patients with Leber congenital amaurosis and 
juvenile RP by genome-wide homozygosity mapping with SNP microarrays. Invest 
Ophthalmol Vis Sci 2007; 48:5690-8. 
12. den Hollander AI, Black A, Bennett J, Cremers FPM. Lighting a candle in the dark: 
advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 
2010; 120:3042-53. 
13. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006; 368:1795-809. 
14. Singleton AB. Exome sequencing: a transformative technology. Lancet Neurol 2011; 
10:942-6. 
15. Estrada-Cuzcano A, Neveling K, Kohl S, Banin E, Rotenstreich Y, Sharon D, Falik-
Zaccai TC, Hipp S, Roepman R, Wissinger B, Letteboer SJ, Mans DA, Blokland EA, 
Kwint MP, Gijsen SJ, van Huet RA, Collin RW, Scheffer H, Veltman JA, Zrenner E, 
den Hollander AI, Klevering BJ, Cremers FP. Mutations in C8orf37, encoding a ciliary 
protein, are associated with autosomal-recessive retinal dystrophies with early macular 
involvement. Am J Hum Genet 2012; 90:102-9. 
16. Neveling K, Collin RW, Gilissen C, van Huet RA, Visser L, Kwint MP, Gijsen SJ, 
Zonneveld MN, Wieskamp N, de Ligt J, Siemiatkowska AM, Hoefsloot LH, Buckley 
MF, Kellner U, Branham KE, den Hollander AI, Hoischen A, Hoyng C, Klevering BJ, 
van den Born LI, Veltman JA, Cremers FP, Scheffer H. Next-generation genetic testing 
for retinitis pigmentosa. Hum Mutat 2012; 33:963-72. 
17. Clark GR, Crowe P, Muszynska D, O'Prey D, O'Neill J, Alexander S, Willoughby CE, 
McKay GJ, Silvestri G, Simpson DA. Development of a diagnostic genetic test for 
simplex and autosomal recessive retinitis pigmentosa. Ophthalmology 2010; 117:2169-
77 e3. 
18. Audo I, Bujakowska KM, Leveillard T, Mohand-Said S, Lancelot ME, Germain A, 
Antonio A, Michiels C, Saraiva JP, Letexier M, Sahel JA, Bhattacharya SS, Zeitz C. 
Development and application of a next-generation-sequencing (NGS) approach to 
detect known and novel gene defects underlying retinal diseases. Orphanet J Rare Dis 
2012; 7:8. 
19. Gonzalez-del Pozo M, Borrego S, Barragan I, Pieras JI, Santoyo J, Matamala N, 
Naranjo B, Dopazo J, Antinolo G. Mutation screening of multiple genes in Spanish 
Chapter  8 
 
215
 
patients with autosomal recessive retinitis pigmentosa by targeted resequencing. PLoS 
One 2011; 6:e27894. 
20. Pippucci T, Benelli M, Magi A, Martelli PL, Magini P, Torricelli F, Casadio R, Seri M, 
Romeo G. EX-HOM (EXome HOMozygosity): a proof of principle. Hum Hered 2011; 
72:45-53. 
21. Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in 
genetic medicine. Am J Hum Genet 2009; 85:142-54. 
22. Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can exome 
sequencing do for you? J Med Genet 2011; 48:580-9. 
23. Ginolhac A, Vilstrup J, Stenderup J, Rasmussen M, Stiller M, Shapiro B, Zazula G, 
Froese D, Steinmann KE, Thompson JF, Al-Rasheid KA, Gilbert TM, Willerslev E, 
Orlando L. Improving the performance of True Single Molecule Sequencing for 
ancient DNA. BMC Genomics 2012; 13:177. 
24. Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I, Causey M, 
Colonell J, Dimeo J, Efcavitch JW, Giladi E, Gill J, Healy J, Jarosz M, Lapen D, 
Moulton K, Quake SR, Steinmann K, Thayer E, Tyurina A, Ward R, Weiss H, Xie Z. 
Single-molecule DNA sequencing of a viral genome. Science 2008; 320:106-9. 
25. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, Leamon JH, 
Johnson K, Milgrew MJ, Edwards M, Hoon J, Simons JF, Marran D, Myers JW, 
Davidson JF, Branting A, Nobile JR, Puc BP, Light D, Clark TA, Huber M, 
Branciforte JT, Stoner IB, Cawley SE, Lyons M, Fu Y, Homer N, Sedova M, Miao X, 
Reed B, Sabina J, Feierstein E, Schorn M, Alanjary M, Dimalanta E, Dressman D, 
Kasinskas R, Sokolsky T, Fidanza JA, Namsaraev E, McKernan KJ, Williams A, Roth 
GT, Bustillo J. An integrated semiconductor device enabling non-optical genome 
sequencing. Nature 2011; 475:348-52. 
26. Littink KW, Koenekoop RK, van den Born LI, Collin RWJ, Moruz L, Veltman JA, 
Roosing S, Zonneveld MN, Omar A, Darvish M, Lopez I, Kroes HY, van Genderen 
MM, Hoyng CB, Rohrschneider K, van Schooneveld MJ, Cremers FPM, den Hollander 
AI. Homozygosity mapping in patients with cone-rod dystrophy: novel mutations and 
clinical characterizations. Invest Ophthalmol Vis Sci 2010; 51:5943-51. 
27. Collin RWJ, van den Born LI, Klevering BJ, de Castro-Miro M, Littink KW, Arimadyo 
K, Azam M, Yazar V, Zonneveld MN, Paun CC, Siemiatkowska AM, Strom TM, 
Hehir-Kwa JY, Kroes HY, de Faber JT, van Schooneveld MJ, Heckenlively JR, Hoyng 
CB, den Hollander AI, Cremers FPM. High-resolution homozygosity mapping is a 
Chapter  8 
 
216 
 
powerful tool to detect novel mutations causative of autosomal recessive RP in the 
Dutch population. Invest Ophthalmol Vis Sci 2011; 52:2227-39. 
28. Bloch-Zupan A, Jamet X, Etard C, Laugel V, Muller J, Geoffroy V, Strauss JP, 
Pelletier V, Marion V, Poch O, Strahle U, Stoetzel C, Dollfus H. Homozygosity 
mapping and candidate prioritization identify mutations, missed by whole-exome 
sequencing, in SMOC2, causing major dental developmental defects. Am J Hum Genet 
2011; 89:773-81. 
29. Liu MM, Tuo J, Chan CC. Gene therapy for ocular diseases. Br J Ophthalmol 2011; 
95:604-12. 
30. Sundaram V, Moore AT, Ali RR, Bainbridge JW. Retinal dystrophies and gene 
therapy. Eur J Pediatr 2012; 171:757-65. 
31. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, 
Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying GS, 
Ziviello C, Acerra C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A. 
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years 
after vector administration. Mol Ther 2010; 18:643-50. 
32. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, 
Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, 
Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene 
therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 
358:2231-9. 
33. Bennett J, Maguire AM. Gene therapy for ocular disease. Mol Ther 2000; 1:501-5. 
34. Bessant DA, Ali RR, Bhattacharya SS. Molecular genetics and prospects for therapy of 
the inherited retinal dystrophies. Curr Opin Genet Dev 2001; 11:307-16. 
35. Bennett J, Tanabe T, Sun D, Zeng Y, Kjeldbye H, Gouras P, Maguire AM. 
Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat 
Med 1996; 2:649-54. 
36. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling 
SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J. Gene 
therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 
28:92-5. 
37. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka 
NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG. 
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene 
Chapter  8 
 
217
 
transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 
12:1072-82. 
38. Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, Zelenaia O, Mingozzi F, 
Hui D, Chung D, Rex TS, Wei Z, Qu G, Zhou S, Zeiss C, Arruda VR, Acland GM, 
Dell'Osso LF, High KA, Maguire AM, Bennett J. Reversal of blindness in animal 
models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. 
Mol Ther 2008; 16:458-65. 
39. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, Bennicelli J, Banfi S, 
Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone 
E, Sun J, Jacobs J, Dell'osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, 
Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, Wellman McDonnell J, 
Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's 
congenital amaurosis. N Engl J Med 2008; 358:2240-8. 
40. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, 
Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan 
JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, 
Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, 
McDonnell JW, Leroy BP, Simonelli F, Bennett J. Age-dependent effects of RPE65 
gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 
2009; 374:1597-605. 
41. van der Spuy J, Chapple JP, Clark BJ, Luthert PJ, Sethi CS, Cheetham ME. The Leber 
congenital amaurosis gene product AIPL1 is localized exclusively in rod 
photoreceptors of the adult human retina. Hum Mol Genet 2002; 11:823-31. 
42. Tan MH, Smith AJ, Pawlyk B, Xu X, Liu X, Bainbridge JB, Basche M, McIntosh J, 
Tran HV, Nathwani A, Li T, Ali RR. Gene therapy for retinitis pigmentosa and Leber 
congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of 
partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol 
Genet 2009; 18:2099-114. 
43. Sun X, Pawlyk B, Xu X, Liu X, Bulgakov OV, Adamian M, Sandberg MA, Khani SC, 
Tan MH, Smith AJ, Ali RR, Li T. Gene therapy with a promoter targeting both rods 
and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther 2009. 
44. Farrar GJ, Kenna PF, Humphries P. On the genetics of retinitis pigmentosa and on 
mutation-independent approaches to therapeutic intervention. EMBO J 2002; 21:857-
64. 
Chapter  8 
 
218 
 
45. Shintani K, Shechtman DL, Gurwood AS. Review and update: current treatment trends 
for patients with retinitis pigmentosa. Optometry 2009; 80:384-401. 
46. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, 
Willett W. A randomized trial of vitamin A and vitamin E supplementation for retinitis 
pigmentosa. Arch Ophthalmol 1993; 111:761-72. 
47. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, 
Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Further 
evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving 
vitamin A treatment: subgroup analyses. Arch Ophthalmol 2004; 122:1306-14. 
48. Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000; 40:93-111. 
49. Sahni JN, Angi M, Irigoyen C, Semeraro F, Romano MR, Parmeggiani F. Therapeutic 
challenges to retinitis pigmentosa: from neuroprotection to gene therapy. Curr 
Genomics 2011; 12:276-84. 
50. Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, 
Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini 
M, Yau KW, Sowden JC, Ali RR. Restoration of vision after transplantation of 
photoreceptors. Nature 2012; 485:99-103. 
51. Kim DH, Kim JA, Choi JS, Joo CK. Activation of caspase-3 during degeneration of the 
outer nuclear layer in the rd mouse retina. Ophthalmic Res 2002; 34:150-7. 
52. Liu C, Li Y, Peng M, Laties AM, Wen R. Activation of caspase-3 in the retina of 
transgenic rats with the rhodopsin mutation s334ter during photoreceptor degeneration. 
J Neurosci 1999; 19:4778-85. 
53. Davidson FF, Steller H. Blocking apoptosis prevents blindness in Drosophila retinal 
degeneration mutants. Nature 1998; 391:587-91. 
54. Concha NO, Abdel-Meguid SS. Controlling apoptosis by inhibition of caspases. Curr 
Med Chem 2002; 9:713-26. 
55. Lipinski DM, Singh MS, MacLaren RE. Assessment of cone survival in response to 
CNTF, GDNF, and VEGF165b in a novel ex vivo model of end-stage retinitis 
pigmentosa. Invest Ophthalmol Vis Sci 2011; 52:7340-6. 
56. Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res 2012; 31:136-
51. 
57. LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung CH, 
Steinberg RH. Protection of mouse photoreceptors by survival factors in retinal 
degenerations. Invest Ophthalmol Vis Sci 1998; 39:592-602. 
Chapter  8 
 
219
 
58. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. 
Expert Opin Biol Ther 2006; 6:717-26. 
59. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, Brown DM, Jaffe 
GJ, Tao W, Williams GA. Ciliary neurotrophic factor delivered by encapsulated cell 
intraocular implants for treatment of geographic atrophy in age-related macular 
degeneration. Proc Natl Acad Sci U S A 2011; 108:6241-5. 
60. Tao W, Wen R, Goddard MB, Sherman SD, O'Rourke PJ, Stabila PF, Bell WJ, Dean 
BJ, Kauper KA, Budz VA, Tsiaras WG, Acland GM, Pearce-Kelling S, Laties AM, 
Aguirre GD. Encapsulated cell-based delivery of CNTF reduces photoreceptor 
degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 
2002; 43:3292-8. 
61. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. 
Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of 
CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 
2006; 103:3896-901. 
62. Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic potential of splice-switching 
oligonucleotides. Oligonucleotides 2009; 19:1-13. 
63. Wood M, Yin H, McClorey G. Modulating the expression of disease genes with RNA-
based therapy. PLoS Genet 2007; 3:e109. 
64. Bittles AH, Black ML. Evolution in health and medicine Sackler colloquium: 
Consanguinity, human evolution, and complex diseases. Proc Natl Acad Sci USA 
2010; 107 Suppl 1:1779-86. 
65. Hussain R, Bittles AH. The prevalence and demographic characteristics of 
consanguineous marriages in Pakistan. J Biosoc Sci 1998; 30:261-75. 
66. Nirmalan PK, Krishnaiah S, Nutheti R, Shamanna BR, Rao GN, Thomas R. 
Consanguinity and eye diseases with a potential genetic etiology. Data from a 
prevalence study in Andhra Pradesh, India. Ophthalmic Epidemiol 2006; 13:7-13.
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
Summary
Summary 
 
222 
 
SUMMARY 
Inherited retinal dystrophies (RD) are a significant cause of blindness worldwide. In RD 
the photoreceptors and retinal pigment epithelium primarily degenerate. Clinically, RD is 
classified according to the subtype of photoreceptors that are primarily involved and the 
age at which the degeneration first occurs. Retinitis pigmentosa (RP) represents the most 
common form of RD that primarily involves rod photoreceptor degeneration and initially is 
characterized by night vision problems. Genetically, RP is very heterogeneous as >60 
genes have been implicated in different inherited forms of RP. The autosomal recessive 
(ar) inheritance pattern is predominant for RP and accounts for more than 50% of the 
cases. ArRP shows the largest genetic heterogeneity as mutations in 39 genes are known to 
cause arRP, together explaining the disease in about 80% of the cases. The current thesis 
study aimed to identify the genetic defects in consanguineous Pakistani RD families, which 
in most cases are affected by arRP. 
Chapter 1 provides an overview of the retinal structure, function and physiology and how 
it correlates with disease pathology. Clinical and genetic characteristics of retinal 
dystrophies are briefly described. Gene identification strategies are also discussed and the 
choice of homozygosity based mapping for the Pakistani cohort is justified.   
Chapter 2A describes microsatellite marker analysis of the arRP genes previously 
implicated in two unrelated families, which revealed homozygosity of a region on 
chromosome 3 spanning RHO. Sequence analysis of the coding exons of RHO in the 
proband of these families identified a known mutation p.(Glu150Lys) in homozygous state 
in both families. The mutation alters the glycosylation of opsin and impairs the trafficking 
of the protein to the photoreceptor outer segment. Comparison of the haplotype of the 
original Indian pedigree, in which the mutation was first described, with the Pakistani 
families, suggested a common ancestry for this mutation.  
Genetic analysis in two large consanguineous arRP families, is described in chapter 2B. 
High-density single nucleotide polymorphism (SNP) microarray analysis indicated an 
overlapping homozygous genomic region that encompassed TULP1, a gene previously 
implicated in arRP and LCA. Sequence analysis identified homozygous missense variants, 
p.(Thr380Ala) and p.(Arg482Gln), in the respective families. Both variants are considered 
likely pathogenic as they affect the functional tubby-like domain of the protein and the 
mutated amino acids are highly conserved. In addition, the variants segregate with the 
disease in the respective families and were not found in population-matched controls. 
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Chapter 2C reports on four arRP families, in which high-density SNP microarray analyses 
were performed for multiple affected members. Analysis of genotype data in the these 
families, revealed large homozygous regions that harbor several genes previously reported 
to be associated with inherited retinal diseases. Sanger sequencing identified protein-
truncating mutations in three different families, i.e., in ABCA4 p.(Gln2220*), AIPL1 
p.(Trp278*) and CERKL p.(Arg283*). In the fourth family, a missense mutation 
p.(Arg544Trp) was found in PDE6A, which is predicted to destabilize the protein structure 
and thus hinder the normal enzymatic function. 
Chapter 3 describes a three-generation pedigree with four affected individuals which were 
genotyped using Illumina 6K arrays. Analysis of the genotyping data using homozygosity-
based linkage mapping revealed a 25-Mb homozygous region on chromosome 6, 
encompassing the arRP-associated gene EYS. Sanger sequencing of all coding exons of 
EYS in the proband reveled a novel missense variant p.(Asp2767Tyr). A homozygous 
region encompassing the EYS gene was also found in an Indonesian family, and upon 
sequence analysis another novel missense variant p.(Asp3028Tyr) was identified. Both 
variants segregate in the respective families and affect homologous amino acid residues in 
the laminin A G-like domains of EYS. 
Chapter 4 describes the molecular genetic analysis of a consanguineous arRP family in 
which a large number of homozygous genomic regions were identified by homozygosity 
mapping. After exclusion of the most obvious autosomal recessive retinal disease 
associated genes in the homozygous regions, the DNA of an affected proband was 
analyzed using a next generation sequencing (NGS) platform. All the exons of the genome 
(i.e. the exome) were selectively enriched and sequenced. All variants within the 
homozygous regions were selected, and then prioritized based on nucleotide conservation. 
The highest ranked variant was present in the largest homozygous region and resided in 
SNRNP200, a gene previously found to be mutated in autosomal dominant RP (adRP). The 
variant (c.3269G>A; p.(Arg1090Gln)) affects the same residue as a known adRP 
associated variant (c.3269G>T; p.(Arg1090Leu)) that was described in a large Chinese 
family. In vitro studies demonstrate that the p.(Arg1090Leu) variant impairs splicing; 
hence we believe that the mutation identified in the Pakistani arRP family represents a 
hypomorphic variant that explains the phenotype in the Pakistani family. U4/U6 unwinding 
assays are warranted to confirm our hypothesis. 
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Chapter 5 describes the results of linkage analysis using SNP microarray data of multiple 
affected individuals from two arRP families. This analysis identified an overlapping 
homozygous region that was shared between all affected individuals of both families. 
Sequence analysis of CLRN1, a gene previously found to be mutated in Usher syndrome 
type III and residing in the overlapping homozygous region, revealed two novel missense 
mutations p.(Pro31Leu) and p.(Leu154Trp). Both mutations alter highly conserved amino 
acid residues in the transmembrane domains of clarin-1, and were predicted to alter its 
topology. Subcellular localization experiments indicated that the mutant proteins are 
retained inside the endoplasmic reticulum, whereas the wild-type protein is transported to 
the membrane. As mutations in CLRN1 are known to cause Usher syndrome type III, 
characterized by arRP and hearing impairment, patients were re-examined clinically. 
Hearing loss was ruled out in both families, thus providing a novel genotype-phenotype 
correlation for CLRN1. 
Chapter 6 describes two unrelated consanguineous families with fundus albipunctatus, in 
which homozygosity mapping suggested the involvement of RDH5. Sanger sequencing of 
RDH5 gene in the probands revealed a frameshift p.(Val305Hisfs*29) and a missense 
p.(Met253Arg) variant. Both novel variants segregates with the disease in the respective 
families and were interpreted to be causative.  
Finally in chapter 7, we recapitulate our homozygosity mapping approach and the 
subsequent sequence analysis results in Pakistani RD families. In 32 of 41 (78%) families 
of our Pakistani RD cohort, sequence variants were identified that very likely explain the 
retinal phenotypes. In more than ninety percent of solved cases the mutations were found 
in known RD genes, residing in the first or second largest homozygous region. A 
comparison of all Pakistani RD-associated gene defects with those described in other 
populations indicated that 90% are population-specific. Based on this inventory, we 
propose a sequencing-based pre-screening genetic test for genetically unsolved cases, in 
which 14 different amplicons capture up to 50% of the mutations. In addition, nine 
potential novel arRP loci were described. 
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The knowledge obtained regarding the molecular pathogenesis of retinal disease in this 
patient cohort will undoubtedly pave the way for better patient management and treatment 
strategies. The molecular genetic data of our RD families has significantly contributed to 
the clinical and genetic information on inherited retinal diseases. As many persons were 
identified with specific genetic defects for which novel treatments have been designed, we 
aim to participate in clinical trials to halt the progression of disease. While therapies are 
being developed, attention should be paid to methods to slow down the progression of the 
disease to create a larger time window for treatment options to be implemented. On the 
short term, the results described in this thesis will be used to support proper genetic 
counseling of the affected families.  
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SAMENVATTING 
Erfelijke retina dystrofieën (RD) zijn wereldwijd een belangrijke oorzaak van blindheid. 
Bij RD degenereren met name de fotoreceptoren en het retinal pigment epitheel. Klinisch 
gezien worden RD geclassificeerd op basis van het type fotoreceptor dat hoofdzakelijk 
betrokken is bij het ziektebeeld, en op welke leeftijd de eerste tekenen van degeneratie 
worden waargenomen. Retinitis pigmentosa (RP) is  de meest voorkomende vorm van RD, 
waarbij voornamelijk de staaf fotoreceptoren degenereren, en wordt in eerste instantie 
gekenmerkt door problemen van het nachtzien. Genetisch gezien is RP erg heterogeen; 
inmiddels zijn er >60 genen betrokken bij verschillende erfelijke vormen van RP. Bij meer 
dan 50% van de RP gevallen wordt een autosomaal recessief overervingspatroon gezien. 
Van mutaties in 39 genen is bekend dat deze arRP kunnen veroorzaken, en arRP is 
daarmee de genetisch meest heterogene groep. Deze genen verklaren tezamen ongeveer 
80% van de arRP gevallen. Het doel van het onderzoek in dit proefschrift is het 
identificeren van genetische defecten in consanguine Pakistaanse RD families, met name 
met arRP.  
Hoofdstuk 1 geeft een overzicht van de structuur, functie en fysiologie van de retina en 
hoe dit in verband kan worden gebracht met de pathologie. Klinische en genetische 
kenmerken van retinale dystrofieën worden kort beschreven. Tevens worden 
genidentificatie strategieën besproken, en wordt de keuze voor ‘homozygosity-based 
mapping’ in het Pakistaanse cohort toegelicht.  
Hoofdstuk 2a beschrijft de microsatelliet marker analyse van bekende arRP genen in twee 
niet-verwante families, waarin een homozygoot gebied werd gevonden op chromosoom 3 
rondom het RHO gen. Sequentie analyse van de coderende exonen van het RHO gen in de 
probanden van deze families onthulde een bekende homozygote mutatie p.(Glu150Lys) in 
beide families. Deze mutatie verandert de glycosylering van het opsine eiwit waardoor 
mogelijk het transport van het eiwit naar de buitensegmenten van de fotoreceptoren wordt 
beperkt. Het vergelijken van de haplotypes van de originele Indiase familie, waarin de 
mutatie oorspronkelijk werd beschreven, met de Pakistaanse families, suggereert een 
gemeenschappelijke voorouder.  
In hoofdstuk 2B worden de genetische bevindingen in 2 grote consanguïne families 
beschreven. Single nucleotide polymorfisme (SNP) microarray analyses onthulde een 
homozygote regio die TULP1 bevat, een gen dat eerder geassocieerd is met arRP. Met 
sequentie analyse werden homozygote missense varianten, p.(Thr380Ala) en 
p.(Arg482Gln), aangetoond in deze families. Beide varianten zijn waarschijnlijk 
Samenvatting 
 
227
 
pathogeen, aangezien ze zich bevinden in het tubby-like domein, en de gemuteerde 
aminozuren sterk geconserveerd zijn. Daarnaast segregeren de varianten in de betrokken 
families, en zijn ze niet gevonden in een controle populatie. 
In hoofdstuk 2C worden vier families beschreven, waarbij SNP microarray analyses 
werden uitgevoerd bij meerdere familieleden. Analyse van de genotype data toonde grote 
homozygote gebieden aan die bekende RD genen bevatten. Met Sanger sequencing werden 
in drie families nonsense mutaties gevonden in ABCA4 p.(Gln2220*), AIPL1 p.(Trp278*) 
en CERKL p.(Arg283*). In de vierde familie werd een missense mutatie in PDE6A 
p.(Arg544Trp) gevonden, waarvan voorspeld wordt dat deze de stabilisatie van de 
eiwitstructuur aantast en daarmee de normale enzymatische activiteit belemmert. 
Hoofdstuk 3 beschrijft een familie met vier aangedane personen, die gegenotypeerd 
werden met Illumina 6K arrays. Analyse van de genotype data onthulde een 25-Mb 
homozygote regio op chromosoom 6 dat het arRP gen EYS bevat. Sanger sequencing van 
alle coderende exonen toonde een onbekende missense variant p.(Asp2767Tyr) aan. In een 
Indonesische familie werd ook een homozygote regio gevonden dat het EYS gen bevat, en 
met sequentie analyse werd ook in deze familie een onbekende missense variant 
p.(Asp3028Tyr) gevonden. Beide varianten segregeren in de betrokken families en 
veranderen homologe aminozuren in de laminin A G-like domeinen van EYS. 
Hoofdstuk 4 beschrijft de moleculair genetische analyse van een consanguine arRP 
familie waarbij een groot aantal homozygote gebieden werden ontdekt middels 
homozygotie mapping. Na het uitsluiten van de meest logische kandidaatgenen in de 
homozygote gebieden, werd het DNA van een aangedane proband geanalyseerd met 
behulp van next generation sequencing (NGS). Alle exonen van het genoom (het exoom) 
werden selectief verrijkt en gesequenced. Alle varianten binnen de homozygote gebieden 
werden geselecteerd, en vervolgens gesorteerd op basis van nucleotide conservering. De 
meest geconserveerde variant werd gevonden in het grootste homozygote gebied en 
bevond zich in SNRNP200, een gen dat autosomaal dominante RP (adRP) kan 
veroorzaken. Deze variant (c.3269G>A; p.(Arg1090Gln)) treft hetzelfde nucleotide als een 
bekende adRP variant (c.3269G>T; p.(Arg1090Leu)) die eerder beschreven is in een 
Chinese familie. In vitro studies lieten zien dat de Arg1090Leu variant resulteert in 
abnormale splicing. Daarom is het aannemelijk dat de mutatie in de Pakistaanse arRP 
familie een hypomorfe mutatie betreft, die de aandoening in de familie verklaart. Om dit te 
bewijzen zullen U4/U6 splicings assays uitgevoerd moeten worden. 
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Hoofdstuk 5 beschrijft de resultaten van koppelingsstudies middels SNP microarray 
analyses in meerdere aangedane individuen van twee arRP families. In deze families werd 
een homozygoot gebied gevonden dat voorkomt bij alle aangedane individuen. Sequentie 
analyse van CLRN1, een gen dat Usher syndroom type III kan veroorzaken, en gelegen is 
in het gedeelde homozygote gebied, toonde twee nieuwe missense mutaties p.(Pro31Leu) 
en p.(Leu154Trp) aan. Beide mutaties veranderen geconserveerde aminozuren in het 
transmembraan domein van clarin-1. Subcellulaire lokalisatie experimenten toonden aan 
dat de gemuteerde eiwitten achterblijven in het endoplasmatisch reticulum, terwijl het 
wild-type eiwit wordt getransporteerd naar het celmembraan. Omdat mutaties in CLRN1 
eerder geassocieerd zijn met Usher syndroom type III, gekarakteriseerd door RP en 
slechthorendheid, werd de gehoorfunctie in deze patiënten opnieuw beoordeeld. In beide 
families werd slechthorendheid volledig uitgesloten, waardoor een nieuwe genotype-
fenotype correlatie is aangetoond voor CLRN1. 
Hoofdstuk 6 beschrijft twee niet-verwante consanguine families met fundus albipunctatus 
waarbij homozygotie mapping wees op een oorzakelijke rol van RDH5. Sanger sequencing 
van RDH5 in de probanden leverde een frameshift p.(Val305Hisfs*29) en een missense 
p.(Met253Arg) variant op. Beide nieuwe varianten segregeren met de ziekte in beide 
families en werden als oorzakelijk geïnterpreteerd. 
In hoofdstuk 7 wordt een samenvatting gegeven van de homozygotie mapping en de 
daarop volgende sequentie analyse data. In 32 van de 41 (78%) Pakistaanse RD families 
werden varianten geïdentificeerd die zeer waarschijnlijk de oorzaak zijn voor het retina 
fenotype. In meer dan 90% van de opgeloste gevallen zijn mutaties gevonden in bekende 
RD genen in de twee grootste homozygote gebieden. Vergelijking van alle Pakistaanse RD 
geassocieerde gendefecten met die beschreven in andere populaties geeft aan dat 90% 
populatie-specifiek zijn. Gebaseerd op deze gegevens adviseren we voor nieuwe 
onopgeloste patiënten en families een voorscreening, waarbij sequentie analyse van 14 
amplicons 50% van de mutaties kan detecteren. Daarnaast werden er nog 9 potentieel 
nieuwe arRP loci beschreven. 
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De kennis verkregen tijdens dit promotie onderzoek zal naar verwachting resulteren in een 
betere behandeling van patiënten. De moleculair genetische data van onze RD families 
hebben een bijgedrage geleverd aan de klinische en genetische informatie over erfelijke 
ziektes van de retina. Aangezien er voor specifieke gendefecten nieuwe behandelingen zijn 
ontwikkeld, willen wij patiënten de mogelijkheid bieden om deel te nemen aan klinische 
trials om de progressie van de ziekte tegen te gaan. Omdat het ontwikkelen van nieuwe 
therapieën tijd kost, moet er aandacht besteed worden aan methoden die de progressie van 
de ziekte kunnen vertragen totdat er een geschikte behandeling beschikbaar is. Op korte 
termijn zullen de resultaten beschreven in dit proefschrift gebruikt worden voor beter 
erfelijkheidsadvies voor aangedane families. 
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GDNF glial cell derived neurotrophic factor 
GDP guanosine diphosphate 
GTP guanosine triphosphate 
GUCY2D guanylate cyclase 2D 
hBBR2 homolog of yeast Brr2 
hg19 human genome version 19 
HOPE have your protein explained 
Hz hertz 
IMPG2 inter photoreceptor matrix proteoglycan 2  
IS inner segment 
ISCEV international society for clinical electrophysiology of vision 
JBTS Joubert syndrome 
LAMA1 laminin alpha 1 
LCA Leber congenital amaurosis 
LE left eye 
LG laminin G 
LOD logarithm of odds 
LP light perception 
LRAT lecithin retinol acyltransferase 
Mb megabases 
MERTK mer tyrosine kinase proto-oncogene 
mFRP monomeric red fluorescent protein 
MIM Mendelian inheritance in man 
MKS Meckel-Gruber syndrome 
mM millimolar 
mRNA messenger ribonucleic acid 
mV millivolts 
NGS next generation sequencing 
nm nanometer 
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OMIM online Mendelian inheritance in man 
OCT optical coherence tomography 
OS outer segment 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PDE phosphodiesterase 
PDE6A phosphodiesterase 6A 
PDI protein disulphide isomerase 
PolyPhen polymorphism phenotyping 
PPRPE preserved para-arteriolar RPE 
rAAV recombinant adeno-associated virus 
RBP serum retinol binding protein 
RD retinal dystrophy 
RDH5 retinol dehydrogenase 5 
RE right eye 
RFLP restriction fragment length polymorphism 
RHO rhodopsin 
RLBP1 retinaldehyde binding protein 1 
ROH regions of homozygosity 
RP retinitis pigmentosa 
RPA retinitis punctata albescens 
RPE retinal pigment epithelium 
RPE65 retinal pigment epithelium-specific protein, 65-KD 
SD-OCT spectral-domain optical coherence tomography 
SER smooth endoplasmic reticulum 
SIFT sorting intolerant from tolerant 
SLS Senior Løken syndrome 
SNP single nucleotide polymorphism 
snRNP small nuclear ribonucleoprotein 
SNRNP200 small nuclear ribonucleoprotein, 200-KD 
SPATA7 spermatogenesis associated protein 7 
STGD Stargardt disease  
TULP1 tubby like protein 1 
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USH2 Usher syndrome type II 
USH3 Usher syndrome type III 
UV ultraviolet 
VA visual acuity 
VEGF vascular endothelial growth factor 
VF visual field 
WES whole exome sequencing 
WGS whole genome sequencing 
xl X-linked 
μM micromolar 
χ2 chi-square 
3D three dimensional 
